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ABSTRACT
The Baculovirus Expression System has been used to express the 
mammalian glucose transporter isoform GLUT 1. The full-length protein was 
expressed to a level of ~ 200 pmol/mg membrane protein, and was found to 
exhibit a lower apparent molecular weight (-50 kDa) than the native transporter 
derived from human erythrocyte membranes. Photolabelling studies using 
transporter side-specific ligands demonstrated that the expressed protein binds 
the bismannose compound 2-7V-4-(l-azi-2,2,2-trifluoroethyl)benzoyl-l,3-bis- 
(D-mannos-4-yloxyl)-2-propylamine (ATB-BMPA) and cytochalasin B at its 
exofacial and endofacial binding sites respectively.
Constructs of GLUT 1 which produce either the N-terminal (amino acids 
1 - 272) or C-terminal (amino acids 254 - 492) halves of the transporter are 
expressed at levels in the plasma membrane which are similar to that of the 
full-length GLUT 1, but do not bind either ATB-BMPA or cytochalasin B. A 
dual infection approach has been used to demonstrate that when Sf9 cells are 
simultaneously infected with recombinant baculoviruses encoding both the C- 
and the N-terminal halves of GLUT 1, then the ligand labelling is restored. 
Immunoprecipitation using specific antibodies demonstrates that the labelling is 
associated only with the C-terminal half. This suggests that labelling of this 
domain is dependent on the presence of the N-terminal half of the molecule. 
This supports the bilobular model of the three-dimensional structure of the 
GLUT 1 protein, in which separate C- and N-domain halves pack together to 
produce a ligand-binding conformation.
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1.1 FACILITATED GLUCOSE TRANSPORT
Glucose is a major source of metabolic energy, and its movement 
across the plasma membrane of cells is central to the requirements of many 
organisms. Virtually all mammalian cells have a system of facilitated transport 
of glucose, allowing the movement of glucose down its chemical gradient, 
either into or out of cells. The transport is stereospecific, and in mammals is 
mediated by a family of distinct but related transmembrane transport proteins 
(Bell et al, 1990).
That a family of transporters exists, rather than a single universal 
isotype, reflects the variations in glucose requirements, and the homeostatic 
roles of different cell types.
To date, at least six genotypically distinct transport isotypes, each 
characterised by unique tissue distribution, regulation, and kinetic properties 
have been cloned and identified in mammalian tissue. The family members are 
closely related in terms of primary, and proposed secondary structure within 
the membrane. Such similarities are not limited to mammalian transporters, 
with significant amino acid sequence homology and proposed two- dimensional 
structural similarities also found in the sugar transport systems of protozoa, 
algae, yeast and prokaryotes (Baldwin, 1993 provides a comprehensive reveiw 
of sequence homologies between prokaryotic and eukaryotic hexose 
transporters)
The particular mechanism used by cells for the uptake or release of 
glucose is reflected by specific needs, related to the environmental glucose 
concentrations. That most mammalian cells utilise the facilitated diffusion 
systems which will be described in this thesis, is reflective of fairly reliable 
glucose concentrations. For example, red blood cells (RBC) are normally 
permanently bathed in ~5mM glucose. Hence there is little requirement for 
transport of glucose against its concentration gradient.
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1.1.2 THE MAMMALIAN GLUCOSE TRANSPORTER FAMILY
1.1.2.1 GLUT 1
The most extensively studied mammalian glucose transporter is that 
present in human erythrocytes. To date, it is the only one to have been purified 
(Baldwin et al 1982; Baldwin and Lienhard, 1989), and this has allowed partial 
amino acid sequencing, and the generation of specific antibodies (eg. Davies et 
al, 1987), which has enabled the isolation of a cDNA clone (Mueckler, 1985; 
Bimbaum et al 1986). The gene encoding this protein has also been isolated 
(Fukumoto et al 1988; Williams and Bimbaum 1988). Although this 
transporter is abundant in erythrocytes, comprising up to 5% of the membrane 
protein; it is not exclusive to these cells; GLUT 1 mRNA is found in almost all 
human tissue (Flier et al, 1987b; Kahn and Flier, 1990). GLUT 1 is present in 
the highest levels in the brain, and abundantly found in blood barrier tissues, 
especially the blood-brain barrier, the placenta, the retina, and the kidneys. 
Significant levels of GLUT 1 protein are also present in insulin sensitive 
skeletal and cardiac muscles, and in fat cells. The near ubiquitous tissue 
distribution of GLUT 1, and presence of other isoforms of transporter in the 
same tissues in many cases, has led to the suggestion that GLUT 1 is the 
"basal" glucose transporter of many cells (Thorens et al, 1990).
Since the cloning and sequencing of the human erythrocyte glucose 
transporter, analogous sequences have been determined for rat, mouse, rabbit, 
chicken, and pig . Each of them are highly homologous to each other, and to 
human GLUT 1, at the amino acid level. For example, the rat sequence has 
98% homology with the human, and the rabbit sequence 97%. Such a high 
degree of homology suggests that all parts of the molecule are functionally 
important.
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GLUT 1 mRNA and protein are also found in highly elevated levels in 
transformed mammalian cell lines in culture. Although this observation has 
been made for very many cell lines (Warburg, 1923; Flier et al, 1987; Hiraki et 
al, 1989; Bimbaum et al, 1987; Merrall et al, 1993), particularly high levels are 
found in the Hep G2 cell line (Mueckler et al, 1985). Consequently GLUT 1 is 
often referred to as the Hep G2-type glucose transporter, named according to 
this source. The observation that GLUT 1 expression levels are elevated when 
cells are transformed to culture lines has led to the suggestion that many, if  not 
all, circulating growth factors (as are abundantly present in cell culture media), 
as well as the depravation of glucose, can stimulate GLUT 1 expression (Weber 
et al, 1984; Rollins et al, 1988; Hiraki et al, 1988; Kahn and Flier, 1990;
Haspel et al, 1986; Ortiz et al, 1992). It has been shown that an increase in 
glucose uptake accompanies normal cellular proliferation (Weber et al, 1984). 
Under normal cicumstances, glucose uptake will return to the resting level 
following this. A number of tumour states also demonstrate elevated GLUT 1 
expression (Yamamoto et al, 1990).
The kinetics of GLUT 1 have been found to be asymmetric (Walmsley 
1988; Lowe and Walmsley, 1986.). The asymmetry has been suggested to be 
due to a high proportion of carriers having an inward-facing conformation, as 
occurs at low temperatures (Lowe and Walmsley, 1986). However, the ratio 
of inward- facing to outward- facing transporters has been found to be roughly 
the same at physiological temperatures. Although there is only a 2.5 fold 
difference in affinities for glucose between the inward and outward- facing 
conformations, the asymmetry is conferred by the net efflux of glucose 
being about ten times higher than the net influx. That both influx and efflux 
K^’s are significantly lower than the equilibrium exchange is very important 
in transporter function, and is discussed in section 1.1.4.
These observations, together with the known tissue distribution of 
GLUT 1, have led to the proposal that the salient property of this isotype is that
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it can function efficiently as a unidirectional transporter under low external 
glucose conditions, where intracellular glucose demand is high (Gould and 
Holman, 1993).
1.1.2.2 GLUT 2
On the basis of very low levels of GLUT 1 mRNA detectable in the 
liver, and the observation of very different glucose transport kinetics in 
hepatocytes, it was proposed that a genotypically distinct glucose transporter 
was functioning in the liver (Elliot and Craik, 1982; and Axelrod and Pilch, 
1983). On the basis of this, the search for another glucose transporter was 
made specifically in liver cells. "GLUT 2" was cloned by Fukumoto and co­
workers, and by Thorens and co-workers, in 1988; by using the GLUT 1 cDNA 
to probe gene libraries from hepatocytes. The new transporter was found to 
have 55% sequence homology with GLUT 1; but hydropathy plots, used to 
predict secondary structure, show the two to be virtually identical, suggesting a 
close similarity in general molecular structure.
As well as being expressed at high levels in the liver, it is also found in 
very high levels in the P-cells of the pancreas, where it is thought to be 
involved in the glucose stimulated release of insulin (Orci et al, 1989; Thorens 
et al. 1990.). GLUT 2 is also expressed in the basal (blood system) side of the 
small intestinal epithelium; acting in conjunction with a glucose/Na+ symporter 
which actively transports glucose into the cells from the apical (digestive tract) 
side; the GLUT 2 acting to rapidly export glucose from its side of the cells to 
the blood. The expression of this transporter in kidney epithelia is thought to 
perform a similar function. This isoform therefore plays an important overall 
part in blood glucose homeostasis. The markedly different role of GLUT 2 to 
that of GLUT 1 is reflected in its different kinetic profile. GLUT 2 shows 
symmetrical transport (Craik and Elliot, 1979), and has a high for the 
glucose analogue 3-O-methyl-glucose (~42mM) (Gould et al, 1991); which
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means that, under physiological glucose concentrations, glucose flux is 
proportional to glucose concentration, and there is therefore no transporter 
saturation, which would be rate limiting. A high transport capacity, and no 
effective rate limitation provide appropriate characteristics for a transporter 
expressed in the situations occupied by GLUT 2.
1.1.2.3 GLUT 3
The GLUT 3 glucose transporter was isolated using a similar approach 
to that used in the discovery of GLUT 2; by the screening of a foetal muscle 
library (Kayano et al, 1988). Its expression is at high levels only in the brain, 
nerves and heart; and it may act in conjunction with GLUT 1 to meet the high 
glucose demands of these tissues (Gould et al, 1991; and Shepherd et al, 1992). 
GLUT 3 is also found in muscle, fat, liver, kidney and placenta, at very low 
levels. Since its general role seems to be primarily as glucose transporter to 
high- glucose demanding tissues, its presence in these tissues is thought to be 
limited to specific localised areas of cell types having such glucose demand 
(Gould and Holman, 1993).
The kinetics of this transporter are such that tissues expressing it will, 
in conditions of low glucose concentration, receive glucose in preference to 
tissues expressing other isoforms. GLUT 3 shows a low Km for exchange flux 
for 3-O-methyl-glucose (~10mM) (Gould et al, 1991). Since GLUT 1 is the 
primary isoform present in the blood/brain and blood/nerve barriers, and it 
exhibits a higher Km for equilibrium exchange than GLUT 3; under normal 
conditions it seems that the presence of GLUT 3 acts as a backup system. 
However, in times of hypoglycaemia, or increased glucose demand, the low 
Km of GLUT 3 for hexoses allows the successful uptake of glucose from low 
blood glucose concentrations (Gould et al, 1991). GLUT 3 has also been 




GLUT 4 (originally cloned by five independent laboratories 
simultaneously, James et al, 1989; Bimbaum, 1989; Charron et al, 1989; 
Kaestner et al, 1989 and Fukumoto et al, 1989) is expressed exclusively in 
insulin-responsive tissues (adipocytes, skeletal and cardiac muscle).
Stimulation of these cells with insulin can produce up to a 30-fold increase in 
the rate of glucose transport in some tissues (Ploug et al, 1987). The control of 
this transporter is also by circulating glucose levels. In insulin-deficient, 
glucose starved states, adipocyte levels of immunologically detectable GLUT 4 
at the cell surface, are found to become reduced ( Berger et al, 1989).
The insulin-induced increase in glucose transport by GLUT 4 is 
brought about in two principal ways. Firstly, the action of insulin is to 
apparently increase the Vmax of the transporter, whilst barely altering the 
value (Dohm et al, 1988; Palfreyman et al, 1992; Keller et al, 1989), though 
how a proportion of this is accomplished is, as yet, unclear. Unlike GLUT 1, 
the kinetic properties of GLUT 4 are symmetrical, with Km values of 2 to 5 
mM (Thorens et al 1988; Fukumoto et al, 1988). The most salient property of 
this transporter, however, is its localisation in intracellular vesicles under 
normal, non-insulin stimulated conditions. The second action of insulin then, is 
to bring about the translocation of these transporters to the cell surface, which 
leads to much of the observed increase in Vmax. The low of this transporter 
would then ensure a maximal operation rate, for the rapid removal of glucose 
from the blood into the cells. In an insulin stimulated state, glucose transport is 
not rate-limiting to metabolism (Dohm et al, 1988). GLUT 4 sequences have 
also been determined in rat and mouse, to reveal a high degree of homology to 
one another and to human ( rat to human GLUT 4 homology 95%).
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1.1.2.5 GLUT 5
The GLUT 5 protein has recently been isolated (Kayano et al, 1990), 
and had been found to be a high affinity fructose transporter, expressed to high 
levels in the small intestine, testes, spermatozoa, muscle, brain, and adipose 
tissue. Where GLUT 2 is localised on the basolateral border of the cells of the 
small intestine epithelium, and the unrelated glucose/Na+ symporter is localised 
at the apical border of the same cells; GLUT 5 also appears to be specifically 
located on the apical (digestive tract side) border (Davidson et al, 1992).
Where the glucose transport functions are carried out by the symporter and 
GLUT 2; GLUT 5, having a high affinity for fructose, and only a limited 
affinity for glucose, is considered to be responsible for the uptake of dietary 
fructose (Burant et al, 1992). GLUT 5's role as a fructose transporter and not a 
glucose transporter would explain its distribution in tissues well supplied with 
the other transport isoforms. Despite this obvious specificity difference, GLUT 
5 shares significant sequence homology with the other family members.
1.1.2.6 GLUT 6
GLUT 6, a glucose transporter-like sequence, named according to 
chronological convention, was identified, and mRNA detected in all tissues 
investigated (Kayano et al, 1990). However, analysis of the sequence found 
that, despite having a high degree of homology with GLUT 3 (79.6%); the 
cDNA reveals multiple stop codons and frame shifts. The high degree of 
identity with GLUT 3 suggests that the glucose transporter-like region of the 
GLUT 6 pseudogene arose as a result of a viral reverse transcription event, 
causing the insertion of a GLUT 3 mRNA transcript into the non-coding region 
of a ubiquitiously expressed gene (Kayano et al, 1990). Time, and no 
requirement for a protein product, have allowed extensive mutation; and it is 
very unlikely to produce a functional transport protein.
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1.1.2.7 GLUT 7
This most recently isolated member of the transporter family shares 
68% sequence identity with GLUT 2. It is believed that GLUT 7 is responsible 
for the intracellular transport of glucose in liver cells, across the endoplasmic 
reticulum (ER.) membrane, into the cytosol (Waddel et al, 1992). In the liver, 
glucose is produced by gluconeogenesis and the degradation of glycogen, for 
export into the blood. The final step in both processes is the removal of a 
phosphate from glucose-6-phosphate, by glucose-6-phosphatase. This 
multicomponent enzyme resides in the ER, and the synthesised glucose is 
initially confined to the lumen of the ER; hence the role as the intracellular 
glucose transporter.
The very close sequence similarities of GLUT 7 to GLUT 2 (100% in 
places) may be significant in the origin of GLUT 7. An absence of base drift in 
the third position of many of the codons suggests that GLUT 7 is either a 
complex splice variant of GLUT 2 ( a simple variant would have the 100% 
identity regions corresponding to intron-exon junctions, which is not the case), 
or has an evolutionary origin in GLUT 2. There is one area of significant 
difference between GLUT 7 and GLUT 2: a unique six amino acid sequence at 
the C-terminus of GLUT 7. This sequence motif (KKMKND) is a consensus 
sequence for the retention of membrane-spanning proteins in the ER.
1.1.2.8 Non-M am m alian  sugar Transporters
Many non-mammalian glucose-transporter- type proteins have been 
identified. From sequence homologies, it is clear that the general 12- 
membrane-spanning-domain structure is found, in some form, in 
representatives of most types of organism. However, there can be some 
important functional differences between these transporters and the general 
GLUT 1- based model. Substrate specificity is varied. Although many have a
12
high affinity for D-glucose, some are more specifically fructose transporters 
(such as GLUT 5), or lactose (e.g. the LAC P transporter of Kluyveromyces 
Lactis, Chang and Dickson, 1988), D-galactose (eg. the GAL 2 of 
Saccharomyces cerevisiae, which also has a high affinity for glucose - 
Szkutnicka et al, 1989), or maltose (eg. MAL 6T of Saccharomyces cerivisiae, 
Hong and Marmur, 1986). Some transport pentoses, such as L-arabinose (e.g. 
the Ara E of Escherichia coli, Maiden et al, 1988). Some members of this 
transporter family are transporters of a non-sugar substrate; the six-membered 
ring compound quinate (such as the QUTD gene for quinate permease, 
allowing Aspergillus nidulans to exist on quinate as a sole carbon source, 
Hawkins et al, 1988).
Although homologous to the mammalian model transporter in 
sequence, structure, and substrate specificity, a number of transporters, 
particularly in prokaryotes, have a different mechanism of function. For 
example, the Gal P gene of E. coli encodes a transporter which does not 
function by passive diffusion, but by active transport of glucose against its 
concentration gradient. This is achieved by the simultaneous transport of a 
single proton, per glucose molecule. This is therefore a glucose/H+ symporter. 
This is reflective of the difference in environmental glucose availability of an 
organism such as E. coli, compared to mammalian cells. Where a mammalian 
cell w ill usually be bathed in a good concentration of glucose (~5mM in blood), 
glucose concentration can be very variable for a bacterium, possibly very low - 
hence the the development of this particular adaptation.
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1.1.3 GLUCOSE TRANSPORTER STRUCTURE
1.1.3.1 General Structure
The family of mammalian glucose transporters, and many other hexose 
transporters, share a common basic molecular structure. Most, like GLUT 1 
(from which the basic structure was derived, from HepG2 cell glutl, Mueckler 
et al, 1985) are about 500 amino acids long, with mobilities of between 45 and 
55 kDa on SDS-PAGE.
The principal structural similarity between the members of the glucose 
transporter superfamily is that there are twelve predicted membrane spanning 
regions of a-helix, with both termini in the cytoplasm (this has been confirmed 
by the use of antibodies made to peptides directed towards areas of the N  and C 
termini, and the finding that they cannot recognise these areas when only the 
external surface of the cell is available for binding, (Davies et al, 1987, 1989). 
There is a large loop between the first and second transmembrane domains 
(TM1 and TM2), and a large cytoplasmic loop between helixes 6 and 7. The 
remaining helix connecting loops are relatively short. This basic structure is 
depicted in figure 1.1. It is based on GLUT 1, and shows regions and residues 
that are highly conserved throughout the transporter superfamily.
Structurally the most significant area of difference between members 
of the family is that of overall length. The primary areas of variation are the 
amino terminal tail (varying from 10 residues in mammalian GLUT 2, to more 
than 90 residues in a yeast transporter), and the extracellular loop region 
between helices 1 and 2 (from 19 to 66 amino acids, 33 in GLUT 1). Apart 
from these differences, the overall structure varies only moderately between 
different transporters, with some areas of very high conservation, particularly 
between the mammalian isoforms.
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Figure 1.1 Schematic representation of the proposed two-dimensional structure of human GLUTl. 
Proposed sites of ligand binding are shown.
The large central loop, and the very short nature of the remaining a- 
helix connecting loops may be indicative of a bilobar tertiary structure. The 
length and sequence of many of the connecting loops, especially at the 
cytoplasmic surface, are highly conserved, at seven to 15 residues, and are 
generally shorter at the cytoplasmic surface. This suggests a very close packing 
of the six helixes of each domain, rather than a single bundle of twelve helixes. 
The slightly shorter loops on the cytoplasmic surface suggest a closer 
association of the helixes at this side of the molecule. A structure of this 
nature has been observed in the twelve -membrane- spanning domain protein of 
E.coli, lactose permease, by low resolution electron microscopy ( Li and Tooth, 
1987). A molecular model of the two domain packing is illustrated in figure 1.2 
(from Hodgson et al, 1992, with permission from Dr. G.D. Holman)
The probability of the glucose transporter structure existing as two six- 
helix lobes raises the suggestion that the structure may be the evolutionary 
result of the duplication of a gene encoding a protein which spans the 
membrane with six helixes. The repetition of two conserved motifs in the two 
halves of the molecule also supports this view. The GRR(K) motif is found 
between TM2 and TM3 in the N-terminal half, and between TM8 and TM9 in 
the C-terminal domain (Henderson, 1991) . The motif EXXXXXXR  is found 
between helixes 4 and 5 of the N-terminal domain, and again in the loop 
connecting helixes 10 and 11. That these features are seen in the sequences of 
yeast and bacterial transporters suggests that if  gene duplication is the case, it 
must have occurred early on in the evolution of the gene. However, these 
sequences may only serve to indicate the maintenance of conformational 
stability. Structural features such a b-tums have been suggested as an 
explanation for the GRR motif, since this has also been found in unrelated 
multi-membrane spanning proteins (Maiden et al 1987, Henderson 1991).
They may be involved in salt-bridging between the helixes. Nevertheless, this 
need not be contrary to the suggestion of an ancestral gene duplication.
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Figure 1.2 Molecular model of the three-dimensional structure of GLUT1. 
Reproduced with permission from G.D.Holman, based on molecular modelling 
work of Hodgson et al, 1992.
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Analysis of GLUT 1 by infra- red spectroscopy suggests that more 
than 80% of the structure is a-helical (Chin et al, 1986; and Alvarez et al,
1987), and that most of this structure resides within the lipid bilayer, although 
the highly hydrophilic central loop region between TM6 and TM7 is predicted 
to contain a large portion of a-helix located cytoplasmically (Henderson 1991). 
Despite this, 80% of the residues have been found to be accessible to 
deuterium exchange, suggesting that most of the molecule is accessible to water 
(Gould and Bell, 1990). This is consistent with the existence of a pore formed 
by the transmembrane regions, through which glucose can travel. Other 
structural features also support the hypothesis of a glucose pore. Molecular 
modelling suggests that most of the highly conserved residues of the helical 
portions, are on the faces of the helixes predicted to be towards the centre of 
the protein, away from the membrane lipid. The amphipathic and highly 
conserved nature of TM7 has been proposed to be evidence for the formation of 
a transmembrane channel (Mueckler et al, 1985). Molecular modelling shows 
that adjacent to the highly conserved region of TM7 is a series of conserved 
threonine and asparagine residues in TM8, which are also considered to form 
part of the hydrogen bonding channel concerned with the movement of glucose.
The GLUT 1 glucose transporter is a glycoprotein, glycosylated at a 
single point of the molecule, which was found by the use of proteolytic 
cleavage and a series of antibodies, to be located on the extracellular domain on 
the loop between TM 1 and TM  2 (Cairns et al, 1987, Flier and Kahn, 1990). 
The glycosylation is heterogeneous, hence the broadness of the band on SDS- 
PAGE. The carbohydrate represents about 15% of the weight of the 
transporter ( Sogin and Hinckle, 1978). The glycosylation site has been found 
to be Asn 45 (Mueckler et al, 1985). Endoglycosidase F treatment of detergent 
solubilised purified transporters results in a very sharp band of Mj. 46,000 Da 
on electrophoresis, which represents a virtually deglycosylated form (Lienhard
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et al, 1984); though treatment with endoglycosidases in concert shows that the 
mature protein has a core polypeptide of Mr 38,000 on electrophoresis (Haspel 
et al, 1985). The structure of the asparagine-linked sugar chain of GLUT 1 
from human erythrocytes has been fully determined (Endo et al, 1990). Both 
high- mannose type and complex trimmed, and trimmed and decorated sugar 
chains are found in the molecule. Studies of GLUT 1 expressed in a mutant 
form of CHO cells, deficient in N-acetylglucosaminyltransferase 1 activity 
show that altered asparagine- linked glycosylation can effect the biogenesis of 
the transporters, but does not affect glucose uptake (Haspel et al, 1988). It has 
been suggested that the alterations may cause changes in targetting, or disturb 
the formation of a functionally appropriate conformation, rather than a more 
obvious effect on transport activity (Asano et al, 1993)
1.1.3.2 Two Glucose Binding Sites.
Other areas of good sequence conservation are those that have been 
implicated in the binding of glucose. It is generally accepted that there are two 
discrete glucose binding sites, an intracellular and an extracellular. Each has 
specific ligands, which are not recognised by the other, and these are useful 
tools in labelling the binding sites, and even locating transporter molecules. 
These are discussed in more detail in chapter 5. The specific nature of such 
ligands permits their use in determining ligand recognition, in conjunction with 
mutagenesis studies.
In the C-terminal half, a conserved sequence, PESPRFL, located 
between TM6 and TM7 may serve a role in substrate recognition (Henderson, 
1990). Close to this, in helix 7, is a twelve residue motif that is conserved in 
all the mammalian isoforms, and largely conserved in other superfamily 
members, which is thought to be concerned with both substrate binding, and 
pore formation. I f  the first glutamine of this motif (Gin -282) is mutated to a 
leucine (in GLUT 1), the binding of the ligand ATB-BMPA (a bis-mannose
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derivative), specific to the external glucose binding site does not occur, and the 
rate of glucose transport is reduced by half (Hashiramoto et al, 1992). Also 
close to this sequence is a three residue motif, QLS, that is conserved in GLUT 
1, GLUT 3 and GLUT 4 (as well as transporters from other species), having 
high affinity for D-glucose, but is not found in GLUT 2, GLUT 5, or other 
superfamily members having higher affinities for D-fructose than for D- 
glucose. Since the principal difference between D-glucopyranose and D- 
fructofuranose is the anomeric position, at C l for D-glucopyranose, and C2 for 
D-fructofuranose; this motif is probably involved in the binding of the C l 
position of D-glucopyranose, conferring specificity for this.
1.1.4 GLUCOSE TRANSPORTER FUNCTION
The accepted sequence of events for the transport of glucose across a 
membrane by a facilitative glucose transporter is as follows. A glucose 
molecule, presented to the transporter in the appropriate orientation, is 
recognised by and bound to the glucose binding site on that side of the 
membrane. This binding causes a conformational change in the transporter 
such that the glucose is passed to the opposite side of the molecule, and 
released. The orientation of the glucose remains the same throughout, and must 
present the opposite-side binding site in the reverse orientation to bind. The 
nature of the conformational change during transport is such that only one 
binding site is available for ligand binding at a time. The conformational 
change involved in transport results in the opposite-side site becoming available 
for binding. This is known as the alternating conformer model of glucose 
transport, and all aspects of it have been experimentally demonstrated.
1.1.4.1 TWO SEPARATE GLUCOSE BINDING SITES
Studies using the side-specific ligands to label the transporter have 
been used to suggest some structural separation of the internal and external
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binding sites. The extracellular-side specific bis-mannose labelling site has 
been mapped to TM9 (Holman and Rees, 1987), and TM8 (Davies et al, 1991). 
The cytoplasmic-side specific ligand, cytochalasin B, a fungal metabolite, has 
been shown to bind an area between TM10 and TM 11 ( Holman and Rees,
1987; Davies et al, 1991; and Cairns et al, 1987). Both sites, to note, are 
resident of the C-terminal half of the transporter.
Cytochalasin B (Tavema and Langdon, 1973; Lin and Spudich, 1974) 
specifically binds to the cytoplasmic glucose binding site. It inhibits glucose 
transport when presented at the cytoplasmic side of the membrane, in 
competition with glucose. It’s inhibition of glucose influx is non-competitive 
when present at the internal side. This is evidence for the alternating 
conformer model, suggesting that when cytochalasin B is bound, the transporter 
is locked into the cytoplasmic-site orientation
ATB-BMPA irreversibly labels the protein from the external glucose 
binding site, inhibiting transport by locking the transporter in the extracellular- 
facing conformation.
Forskolin is also a potent inhibitor of glucose transport, and a tritiated 
form is used as a photoaffinity reagent for the glucose transporters of 
erythrocytes (Shanahan et al, 1987; Wadzinski et al, 1988). Binding is 
cytochalasin B inhibitable, by binding the cytoplasmic-side hexose binding site.
Site-directed mutagenesis has been used to determine specific features 
involved in transport. The truncation of 37 amino acids (o f 42) o f the C- 
terminal tail results in a transporter with a low affinity for extracellular ligands 
(E.g. ATB-BMPA), and no transport activity, in GLUT 1 expressed in CHO 
cells (Oka et al, 1990). A loss of ATB-BMPA labelling is also produced by the 
mutation of the highly conserved Gln-282 of the binding site (TM 7), though 
this also causes a 50% reduction of internal-side specific ligand binding 
(Hashiramoto et al, 1992).
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Single residue mutations near to the proposed binding sites for both the 
internal and external ligands have shown that loss of labelling of only one of 
the ligands results. Such studies have also demonstrated varying effects on 
transport efficiency (Garcia et al, 1992; Oka et al, 1990, amongst others).
1.1.4.2 Co nfo r m atio nal Changes
A conserved triple proline motif (GPGPIP) in TM10 is considered to 
be a point of considerable flexibility, and as such is believed to be central to the 
conformational changes between the external and internal-facing transporter 
forms (Gould and Bell, 1990). Molecular modelling and dynamic studies have 
supported this, placing particular emphasis on the last two proline residues (Pro 
383 and Pro 385)(Hodgson et al, 1992; unpublished). Cytochalasin B (a 
competitive intracellular glucose transport and binding inhibitor) is thought to 
bind to this region, which is therefore important in the binding site, and the 
prevention of state change on inhibitor binding (Holman and Rees, 1987). That 
the removal of the C-terminal domain results in an inward-facing -locked state 
is indicative that this domain may also be important in the switching 
mechanism from one form to the other (Oka et al, 1990).
Much of the kinetic data for the GLUT 1 glucose transporter is also 
indicative of a conformational change between two conditions. This is based 
on the observation that sugar exchange across the membrane is faster than 
either sugar uptake, or the movement of glucose out of a cell (Widdas, 1980). 
That is, the return of a transporter to the original conformation is much slower 
(and therefore rate-limiting ) without substrate presence, than the substrate 
binding-induced change which occurs upon glucose exchange.
Further evidence for conformational change is that the inactivation of 
the transporter by the labelling of a modifying agent FDNB is faster in the 
presence of substrate (sugar). That is, FDNB (l-fluoro-2,4-dinitrobenzene) 
inactivates GLUT 1 sugar transport in RBC. This inactivation is faster in the
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presence of D-glucose, mannose, or 2-deoxy-D-glucose (transported sugars) 
(Krupka, 1971). The presence of a non-transported sugar, maltose, protects the 
molecule from FDNB labelling. FDNB specifically binds to the cytoplasm- 
facing conformation of the transporter. This has been demonstrated by the fact 
that C l, C2 and C3 alkyl substituted glucose analogues enhance FDNB 
labelling; but C4 or C6 alkyl substitutes either reduce labelling, or have little 
effect. (Barnett et al, 1975). That is, when transportable substrate is present 
outside the cell, the transporter rapidly changes conformation to the 
intracellular-facing form, on binding and transportation from the outside. This 
makes sites available to FDNB labelling. When no substrate is available for 
influx, or only inside-specific derivatives are available, the rate of 
conformational change towards the inside of the cell is much slower, and so 
therefore is FDNB labelling.
1.1.4.3 Glucose Or ien tatio n
The use of glucose analogues derivatised at different positions of the 
molecule has shown that the movement of glucose through the transporter is 
orientation dependent, and provides an insight into the specificity of the two 
sites for different areas of the molecule, and therefore the specificity of 
different molecules as competitive transport inhibitors. When glucose is 
derivatised at the C 1 position (e.g. n-propyl-p-D-glucopyranose) it is a good 
competitive inhibitor o f glucose transport when present on the cytoplasmic 
side, but inhibits only poorly from the extracellular environment. The model of 
glucose transport shown in figure 1.3 depicts glucose binding to the internal 
binding site (part b). From this, it is clear that a Cl-derivatised molecule could 
not bind well to this conformation, because of steric hindrance, but could bind 
the inside-facing conformation. It is also clear that steric interference would 
prevent such a molecule from being transported. Sugars derivatised at the C6 
position (e.g. 6-O-propyl-D-galactose, 6-O-propyl-D-glucose, and 6-O-pentyl-
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Figure 1.3 The two state carrier model for the human erythrocyte glucose 
transporter. Glucose can bind to either the inward or outward conformation.
Iiysidt
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D-glucose) are found to be good inhibitors of glucose influx, and bind only 
poorly to the internal site (Barnett et al, 1973, 1975 ).
The model shown in figure 1.3, and the model of Barnett et al 1975 
shows the model of transport based on derivatised sugar molecule studies. This 
shows that the glucose molecule approaches the extracellular binding site with 
the C l end towards the binding site. The binding, by hydrogen bonding and 
dissociation of water from the bonding residues causes a conformational 
change, such that the glucose moves through an essentially hydrophobic 
channel, and the transporter molecule closes around the C4/C6 end of the 
glucose, and opens at the C l end, such that the cytoplasmic binding site is now 
open, and the periplasmic site is closed (Barnett et al, 1975). The glucose 
molecule is released, and the internal site receptive to a glucose molecule from 
the intracellular environment. On leaving the cell, the glucose molecule must 
present the C4/C6 end to bind the internal binding site.
The alternating conformation model explains the specificity of 
cytochalasin B as an inhibitor of glucose efflux, and shows why it is not 
transported and therefore prevents the conformational change to the outside- 
facing state (Tavema and Langdon, 1973 and Lin and Spudich, 1974). This 
also demonstrates the similar function of ATB-BMPA as a specific inhibitor of 
glucose influx.
Not all kinetic data that has been collected for GLUT 1 have supported 
the alternating conformer model of transporter function. Carruthers and 
Helgerson (1991) have presented results which demonstrate the simultaneous 
existence of two binding sites within the transporter. They used maltose 
(which inhibits glucose uptake by binding at or close to the sugar influx site) 
with cytochalasin B (which inhibits glucose uptake non-competitively by 
binding at or close to the glucose efflux site). They found that one, when 
present in the uptake media, increases the Ki(app) for inhibition of the other, in a
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maimer that was consistent with simultaneous binding of both inhibitors. 
However, although these data demonstrate the simultaneous existence of 
binding sites for cytochalasin B and maltose, it does not prove that these sites 
represent the glucose binding sites. It has been suggested that the cytochalasin 
B site and the sugar efflux (internal) binding sites may be either overlapping, or 
mutually exclusive (Krupka, 1971; Barnett et al 1975).
1.1.5 THE FUNCTIONAL UNIT OF GLUCOSE TRANSPORT.
There may be a simpler explanation for the apparent dichotomy 
between the alternating conformer model o f glucose transport, and the evidence 
for the simultaneous existence of both internal and external glucose binding 
sites; the functional unit.
Before the gene had been cloned, and the protein purified, the size of 
the glucose transporter of human erythrocytes had been determined. Using 
analysis by SDS-PAGE, various sources had indicated at least five different 
protein sizes for the glucose transporter (Batt et al, 1976; Lienhard et al, 1977; 
Tavema and Langdon, 1973; and Jung and Carlson, 1975). Cuppoletti and 
Jung (1981) used freezing, and increasing radiation dose in the form of an 
electron beam, to inactivate the flux of D-glucose by the transporter (without 
significant increase in the flux of normally impermeant sugars). Target size 
analysis was used to determine the size of the glucose transporter in situ to be 
185 kDa. Jung et al (1980) had previously reported the cytochalasin B binding 
protein to be 200 kDa (also by radiation inactivation and target size analysis), 
though at the time it was unclear whether this represented the transporter, or a 
functionally associated protein. Cuppoletti and Jung (1981) found both to be 
the transporter protein. Their data, together with SDS-PAGE analyses, 
suggested that the D-glucose transporter of erythrocytes was multimeric. This 
was consistent with kinetic data which had pointed towards the same 
conclusion (Lieb and Stein, 1971).
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Further characterisation of the GLUT 1 protein in situ by radiation 
inactivation analysis indicated an apparent Mr of 124 kDa (Jarvis et al, 1986). 
Other reports have indicated molecular weights of 220 kDa (Jung et al, 1980; 
Cuppoletti et al, 1981). These figures are very close to the predicted sizes of 
dimers and tetramers of a 55 kDa protein.
Hebert and Carruthers (1991) determined the size of purified GLUT i 
by cholate solubilisation, size-exclusion chromatography, and sucrose gradient 
ultracentrifugation. They found the transport system to exist as 104 and 226 
kDa species. This was considered to be consistent with previous findings, as 
evidence for the formation of both dimers, and tetramers. This was tested by 
the expression of chimeric transporter proteins in CHO cells endogenously 
expressing GLUT 1. The chimera was GLUT 1 protein, with the 29 C-terminal 
residues replaced by the 30 C-terminal residues of GLUT 4, identifiable by 
specific anti-GLUT 4 antibodies. Immunoprecipitation with the anti-GLUT 4 
antibody was found to also precipitate the native GLUT 1 protein of the CHO 
cells (where no such co-precipitation is found in cells endogenously expressing 
both GLUT 1 and GLUT 4 together), thus indicating a homooligomeric 
structure formation.
Hebert and Carruthers (1991) proposed a model for the functional 
arrangement of these oligomeric structures. A simplified representation of this 
model is shown in figure 1.4. Briefly, they propose a dimer to have four 
possible states, in respect of its four binding sites (part a). Hence the 
possibility of internal and external glucose binding sites being simultaneously 
available or occupied, within a transporter unit. Both monomeric parts of a 
dimer are proposed to be catalytically active, and to function independently of 
each other. However, this independence is thought to be lost in the formation 
of a tetramer - a dimer of dimers. Within this structure, a dimer is thought to 
function as a unit. That is, each dimer now only has two possible states (shown 








Figure 1.4 Schematic representation of the proposed functional arrangement 
of GLUT 1 glucose transporter monomers, based on Hebert and Carruthers, 
1991.
28
antiparallel to their partners, such that one influx and one efflux site is available 
per dimer. The transport of one glucose molecule by one monomer, causes a 
simultaneous but antiparallel conformational change in the other. In this 
arrangement, a tetramer always presents two influx and two efflux sites, 
irrespective of substrate presence, movement or direction.
1.1.6 CONTROL OF GLUCOSE TRANSPORTER FUNCTION
As has been mentioned in section 1.1.2.1, GLUT 1 appears to be 
regulated by circulating growth factors, hormones, and other mitogens, by 
inducing increases in transport activity, cell surface localisation, transcription 
rate, and increasing the stability of mRNA(Rollins et al, 1988; Hiraki et al,
1988). It has also been shown that reduced blood glucose levels also stimulate 
GLUT 1 activity ( Kahn and Flier 1990; and Haspel et al,1986.), or affect 
expression indirectly by inhibiting its lysosomal degradation (Ortiz et al, 1992). 
Such influences apparently being the primary regulators o f GLUT1 function, it 
is clear from studies of insulin- responsive tissues, that GLUT1 is also 
regulatable by insulin.
GLUT 4, the principle insulin-regulatable transporter isoform, is 
regulated by intra-cellular redistribution, as well as the more direct effects of 
insulin of increasing the carrier's capacity for glucose. That is, under non­
insulin stimulated conditions, the GLUT 4 molecules of adipose and skeletal 
muscle tissue are located intracellularly, membrane bound in microsomes 
(Cushman and Wardzala, 1980). Insulin induces a redistribution of the GLUT 
4 so that many molecules are present on the cell surface. Despite GLUT 4 
being the predominant glucose transporter in insulin- sensitive tissue, insulin 
has also been found to cause an increase in the cell- surface appearance of 
GLUT 1, in a similar way (GLUT 1 cell surface localisation found to be 
increased by three to five- fold, where the redistribution of GLUT 4 accounts 
for a 15 to 20 fold increase for this isotype) (Holman et al, 1990; Clark et al,
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1991). The increase in GLUT 1 cell surface availability is probably largely due 
to the fact that GLUT 1 is maintained at the cell surface in the absence of 
insulin, where GLUT 4 is virtually absent from the surface under the same 
conditions (Yang and Holman, 1993). This is considered to be due to a unique 
targeting property of GLUT 4, to the intracellular location. Levels of GLUT 1 
mRNA are also maintained during glucose deprivation and during re-feeding, 
where GLUT 4 mRNA decreases in starvation, and rapidly increases in 
response to re-feeding ( Sivitz et al, 1989), which also explains the difference 
in the magnitude of insulin and glucose -regulation between these two isotypes.
Insulin has been found to have no effect on either GLUT 1 function or 
distribution in non- insulin responsive tissues, where GLUT 4 is not present 
(e.g. brain, erythrocytes, Hep G2 cells). Although the mechanisms involved are 
not known, it is clear that GLUT 1 can be regulated by insulin, but only under 
certain, not- yet- determined conditions. Expression of GLUT 1 in CHO cells 
has illustrated this (Harrison et al, 1990). It was found that insulin caused an 
increase in 2-deoxy-D-glucose uptake in some cells expressing GLUT 1 (no 
increase was found in non- transfected cells). However, this increase was only 
found in cells expressing fairly low quantities of GLUT 1 protein. No increase 
was found in cells expressing high levels. It was suggested by the authors that 
the increase was not due to translocation of GLUT 1 to the cell surface. The 
principal conclusion from this work of Harrison et al would seem to be that it is 
specific insulin - responsive cellular processes that are important in insulin 
response, rather than the particular transporter isotype involved. That is, in the 
environment of CHO cells, the GLUT 1 protein, not usually responsive to 
insulin, can be made to respond to insulin, given the appropriate conditions, in 
this environment.
During the synthesis and membrane insertion of a glucose transporter, 
there is no proteolytic cleavage at any point (Maiden et al, 1987). GLUT 1
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lacks a cleavable amino terminal signal sequence (Mueckler et al, 1985). 
Mueckler and Lodish (1986) have proposed that glucose transporters have 
instead, at least two distinct signal sequences within the protein sequence.
They proposed the involvement of a "signal recognition particle" (SRP), an 
RNA component, in the targeting and membrane insertion of the transporter 
protein. It is proposed that such sequences, and the SRPs are responsible for 
the co-translational insertion of the appropriate local areas of the molecule into 
the membrane.
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1.2 EXPRESSION OF GLUCOSE TRANSPORTERS IN A
NON-NATIVE ENVIRONMENT
The use of alternative cellular environments for the expression of 
glucose transporters is important for a number of reasons. Firstly, if  an isoform 
is isolated and expressed in a non- native environment, assuming the glucose 
transporter and transport profiles of that system have been investigated, then 
studies conducted can be carried out, with proper controls, on that one isoform 
in isolation. Mutations can be made, or the transporter protein or gene 
otherwise manipulated in a controlled way, and the results studied in the light 
of a background of the same cell type expressing either none of that transporter 
isotype, or the un-manipulated version. The expression of each isotype in 
isolation in this way has been important in the determination of kinetic 
parameters, and substrate specificities of the different transporters. The use of 
an expression system may allow simplified purification techniques, or the 
expression of higher levels of die protein than is available in any cell type 
naturally. Glucose transporters have been expressed in a number of different 
systems, and to different ends. Each system has its advantages and 
disadvantages, and the aims of the expression must be carefully bom in mind in 
the selection of the most suitable system.
1.2.1 BACTERIAL SYSTEMS
The GLUT 1 glucose transporter, cloned from HepG2 cells, has been 
expressed in bacterial cells (Sarkar et al, 1988; Thorens et al, 1988). A mutant 
strain of E.coli, defective in glucose transport, was used. The transporter gene 
was expressed on a bacterial plasmid, and studies were made of cells 
harbouring the plasmid, against the mutant cells without the plasmid. Cells 
with the plasmid were shown to take up both D-glucose and 2-deoxy-D- 
glucose, where no such activity was found in the non- transformed cells. The
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transport was found to be stereospecific (that is, 2-deoxy-D-glucose transport 
was inhibited by D-glucose, but not by L-glucose). In accordance with the 
normal profile of GLUT 1, transport was also found to be inhibited by 
cytochalasin B. The use o f antibodies against specific areas of the GLUT 1 
molecule, and the use of whole cells against permeabilised cells in cytochalasin 
B inhibition of 2-deoxyglucose transport, demonstrated that the transporter was 
membrane inserted, and correctly orientated. However, the limitation of 
bacterial systems are based on their inability to process eukaryotic proteins as 
they would be in a eukaryotic system. The transporter was shown to be 
functional, but in the absence of appropriate post- translational modification to 
the protein, bacterially- expressed glucose transporters would not be suitable 
for any structural analyses. The protein expressed in this way, when analysed 
by SDS-PAGE was found to have an apparent Mr of 34 kDa. In a native 
eukaryotic environment, the same protein has an Mj. of -55 kDa. The 
deglycosylated form of the protein in a eukaryotic environment is -38  kDa. 
(Mueckler et al, 1985). Therefore the use of prokaryotic expression systems is 
valuable, but not without significant limitations.
1.2.2 CULTURED M AM M ALIAN CELL SYSTEMS
The two principal eukaryotic systems which have been used for the 
expression of the GLUT family of glucose transporters are the mammalian cell 
line CHO (Chinese Hamster Ovaries), and the use of oocytes from Xenopus 
laevis.
In 1988, CHO cells were utilised to investigate the effects of altered 
glycosylation on the function of GLUT1 (Haspel et al, 1988). They expressed 
GLUT1 in wildtype (W T) CHO cells, and compared this expression to GLUT1 
expressed in mutant CHO cells, deficient in N-Acetylglucosaminyltransferase I 
activity. Where GLUT1 expressed in W T CHOs was found to have an 
apparent Mr of -55 kDa, expressed in the mutant CHO cells, this was -  40
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kDa. The use of endoglycosidases and glycosylation inhibitors revealed a core 
protein of Mr 38 kDa (as native in erythrocytes) as the unglycosylated form of 
GLUT1 in both types of cells. This study was important in highlighting the use 
of this expression system to express modified forms of glucose transporters.
Harrison et al (1990) expressed GLUT1 in CHO cells in order to 
examine the action of insulin on the cell surface disposition of GLUT1. 
Expression of a long-term nature such as the CHO cell system is unpredictable, 
and as such, much work is involved in the production of CHO cell clones 
expressing the desired protein. The level of expression, per clone, is 
unpredictable, and not manipulable once expression is achieved. During the 
transfection protocol, very many cells must be used, and only a very limited 
number take up any DNA at all. In this way, if  a transfection is a success, then 
often a substantial number of clones w ill be the result, each expressing it's own 
level of the foreign protein ( the DNA must be stably integrated into the host 
cell genome, and there is no way of controlling the localisation of this 
integration). In this way, Harrison et al (1988) studied a number of CHO 
clones expressing GLUT1. They found that untransfected CHO cell native 
glucose transporters are responsive to insulin, showing a 40% increase in 
tritiated 2-deoxy-D-glucose uptake. Clones expressing only low levels of 
GLUT1 were also found to be responsive to insulin by a 40% increase in 
transport (since the presence of the GLUT1 increases the basal 2-deoxy-D- 
glucose uptake, this represents GLUT1 insulin responsiveness). However, in 
clones expressing more GLUT1, and therefore showing larger increases in 
basal transport rates (upto seven fold); the insulin responsiveness o f the cells 
became lower. This work demonstrated that the action of insulin on the 
GLUT1 in the CHO cells was not by a translocation system. This work 
demonstrates the comparative value of the use of a stable expression system, 
when several clones can be examined.
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The CHO cell system has also been used to study mutated forms of 
glucose transporter protein. Oka et al (1990) produced a form of GLUT1 
truncated at the C-terminus by 37 amino acids (the C-terminal tail usually 
comprises 42). They studied glucose transport and ligand binding profiles of 
this mutant, in comparison to the same profiles of W T GLUT1. Such 
comparisons led to the conclusion that the C-terminal tail of GLUT1 is 
important in the conformational change required to alternate between the 
inward and outward facing forms of the transporter. That is, the mutant form 
was not able to transport glucose, and showed very limited binding of the 
external side-specific ligand ATB-BMPA (where the W T had shown good 
binding). Binding of cytochalasin B at the cytoplasmic side was at a level 
equivalent to that of the W T clone, and was glucose displaceable. That is, this 
work demonstrated that the truncation of the C-terminus resulted in a 
transporter which was located in the membrane, but apparently locked into an 
inward facing conformation.
Although these studies illustrate the merits of a stable transfection 
expression system, such a system is difficult to utilise, and expression levels 
cannot be manipulated, and are often low. For glucose transporter expression, 
transport studies must be conducted against a background of glucose transport 
from the native transporters of the cells. Although the native transporters are 
immunologically distinct from the expressed transporters, their function as 
transporters can, at best, be subtracted from observed transport values.
GLUT1, GLUT2, GLUT3 and GLUT4 at least, have now been 
successfully expressed in oocytes from Xenopus (Gould et al, 1989; Keller et 
al, 1989; Vera and Rosen, 1989; and Gould et al, 1991, amongst others). 
Perhaps the principal advantage that the oocyte system has over a stably- 
transfected cell line, is that the level of expression of the foreign protein can be 
directly manipulated. Expression is achieved by the in vitro production of
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mRNA encoding the foreign protein, from a constructed plasmid. The mRNA 
is directly microinjected into the cell. The level of expression of the protein is 
directly dependent on the amount of mRNA injected.
Expression of cDNAs encoding GLUT1 and GLUT4 in oocytes 
confirmed that the cDNA actually encoded glucose transporters (Keller et al,
1989). Oocyte expression of glucose transporters has yielded much 
information about substrate specificities of the various isoforms (Gould et al, 
1991); and comparative kinetic analyses of hexose transport by the different 
isoforms have been possible.
Oocytes have the advantage of being eukaryotic, and therefore 
posttranslational modification of expressed proteins can reasonably be expected 
to be true to the native forms. Oocytes do normally transport glucose, although 
endogenous transport activity is low. Although the oocyte glucose transport 
system is both kinetically and immunologically different to the mammalian 
glucose transporters (GLUT1 and GLUT2 studied, Vera and Rosen, 1989), the 
transport is stereospecific, and has been found to be inhibitable by cytochalasin 
B. The transport of glucose by uninjected oocytes has also been shown to be 
stimulated by both insulin, and insulin-like growth factor.
It is from this observation, and other work examining the expression of 
different glucose transporter isoforms in cells usually either responsive or 
unresponsive to insulin, which allowed the conclusion that the insulin response 
of increased glucose transport is a function of the cell in which the glucose 
transporters are functioning, and not a function of the isotype present.
The oocyte system is an easily manipulable transient eukaryotic 
expression system. It's use for the study of transport kinetics, substrate 
specificities and inhibition studies of the different glucose transporter isoforms 
has been, and w ill probably continue to be an important contribution to the 
study of glucose transporters. However, on answering the question of the 
three-dimensional structure of glucose transporters, the oocyte system is not
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useful. Although expression levels are fully adequate for study, the expression 
of transporters in this way is not suitable for the production of the quantities of 
protein that would be required for three dimensional analysis.
Section 1.3 describes the baculovirus expression system, which, as a 
large-scale expression system, is likely to find its own place in the range of 
expression systems that have been used in the expression of glucose 
transporters.
The differences between the various systems that have been used for 
the expression of glucose transporters provide them all with a useful function. 
Where some are suitable for transport kinetic studies, others are more useful for 
the comparative analysis of various parameters of the transporter isoforms. Yet 
others w ill be useful in the large-scale production of transporters, which w ill 
become important in the elucidation of the three dimensional structure of the 
mammalian glucose transporter.
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1.3 THE BACULOVIRUS EXPRESSION SYSTEM
Baculoviruses have been isolated only from invertebrates, with most 
found in insects. Baculovirus infections have been reported in over 600 
species, ranging from Lepidoptera (butterflies and moths) to Coleoptera 
(beetles). Infection causes death, and early studies of baculoviruses were from 
a biological control perspective. Baculoviruses were first reported for the use 
of the expression of a foreign protein by Smith et al in 1983, expressing b- 
interferon.
The two principle advantages of the exploitation of the baculovirus as 
the basis of an expression system are that it is completely safe to workers, on 
the basis of its host range, and the fact that controlled infection permits the 
removal, or replacement of a gene encoding a highly expressed protein, without 
detriment to the infection. Other advantages of the system are that there is no 
practical lim it on the size of the foreign DNA that can be introduced (a 
baculovirus genome is between 88 and 200 kbp, and the nucleocapsid expands 
to accommodate the DNA present). There are available strong gene promoters, 
allowing the expression of foreign proteins in large quantities. Since insect 
cells are eukaryotic, post translational processing (with the exception of 
glycosylation) o f mammalian or other eukaryotic proteins, is usually as would 
occur in the normal environment of the protein.
Although a number of baculoviruses, and a range of host cells have 
been used as a tissue culture- based expression system, the Autographa 
califomica multiple nuclear polyhedrosis virus (AcMNPV): Spodoptera 
frugiperda (Sf) cell- line combination has so far been the most popular and 
efficient. The cell lines most commonly used are S£21, from the IPLB-S£21- 
AE cell line, derived of ovarian tissue, or the Sf9 line, a clonal expansion of 
Sf21 (Vaughn et al, 1977, Summers and Smith, 1987). The use of tissue 
culture as opposed to the use of insects is in itself an advantage of this system,
38
in that specialist equipment and insect rearing techniques are not required 
(although the baculovirus expression system can be used in whole insects).
1.3.1 BACULOVIRUS LIFE CYCLE
A description of the natural life cycle of the baculovirus in the insect 
host is the best way to illustrate many of the features that make this 
combination successful as an expression system. Figure 1.5 illustrates the main 
features of the life cycle of AcMNPV in a fall army worm caterpillar 
(Spodoptera frugiperda ).
The first cells of a new host to be infected are those of the mid gut.
The virus DNA genome rapidly replicates in the nucleus of the cell, and virus 
nucleocapsids are produced within eight hours of the infection. By 12 hours 
post infection (h.p.i.), virus nucleocapsids bud out of the nucleus, and 
subsequently bud through the plasma membrane, acquiring a lipid envelope 
(which, as part of the infection cycle already contains viral proteins). These 
mature particles infect other cells nearby. This represents one turn of the 
primary cycle of a two cycle system. In this way, almost all of the cells of the 
insect become infected. In a tissue culture system, this represents the infection 
of a whole dish, flask or suspension culture of cells.
Returning to the progress in the original cell: after having released a 
number of mature virus particles, the production continues. Whole mature 
viruses, with lipid envelopes are produced within the nucleus. After about 18 
h.p.i., polyhedrin, encoded by the virus, is produced in the nucleus. This is a 
tough, crystalline protein, into which the new virus particles become 
embedded, to form viral occlusions, "polyhedra". This protein, and an 
associated protein, plO, is produced in very large quantities, and very many 
polyhedra are formed in the nucleus, which swells to almost fill the cell before 
it finally lyses. Very soon all of the cells of the host lyse, and the insect 
becomes a soup of polyhedra, virus and debris. In a natural environment, the
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Figure 1.5 The baculovirus lifecycle. Schematic representation of the bi- 
phasic lifecycle of the AcMNPV baculovirus in a Spodoptera frugiperda cell 
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debris is quickly washed away. The polyhedrin protects the virus particles 
from any environmental impact, (including degradation by bacteria in soil, and 
the passage through the intestines of birds ) and they remain viable. A second 
potential host caterpillar feeding in the area ingests polyhedra. The resistant 
nature of the polyhedrin ensures that the polyhedra do not become solubilised 
until they reach the high pH of the midgut. The cells are infected by adsorptive 
endocytosis of released virus particles, thus completing one turn of the 
secondary cycle. Since polyhedron-embedded virus particles are not infective 
in tissue culture, and the infection of a tissue culture flask of cells is carried out 
by the experimenter, this secondary cycle is not necessary in a tissue culture 
system. (Summers and Smith 1987; and King and Possee, 1992)
1.3.2 THE BASIS OF AN EXPRESSION SYSTEM
In 1983 , Smith et al demonstrated the dispensable nature of 
polyhedrin to the production of mature virus particles, even late in the 
infection, by making deletions in the coding sequence of the gene. Viable virus 
was still found to be formed throughout the cycle.
The polyhedrin gene promoter was the first and is the most widely used 
in the expression of foreign proteins. It is also the strongest promoter, and so 
the first choice if  high levels of expression are desirable. The plO promoter is 
also used for the expression of proteins to a high level. Although these two 
"very late" gene promoters are the most commonly used to express foreign 
genes using baculovirus, promoters of other genes can also be used. Figure 1.6 
is a non-scale illustration of the four principal phases of the highly ordered 
expression of baculovirus genes, and outlines the timing and approximate 






Figure 1.6 Phases of baculovirus protein expression during an infection. 
(Not drawn to scale - approximate comparison of expression levels of protein 
from the four principal phases of baculovirus gene expression only).
Non polyhedrin/plO promoters are not used for large- scale expressions, but 
earlier promoters are useful if  expression level is relatively unimportant but a 
high degree of post-translational modification to the foreign protein is 
necessary. Also, the baculovirus system can be used for the production of cell 
lines for longer-term expression of foreign protein. This thesis is concerned 
only with the polyhedrin gene promoter, and others w ill not be discussed 
further.
1.3.3 EXPRESSION OF FOREIGN PROTEINS
In the wildtype AcMNPV, polyhedrin is optimally produced in Sf9 
cells, to represent 50% of the total cell protein content (500 to 1200 mg/L). In 
theory then, the replacement of the polyhedrin gene with a foreign gene, under
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the same promoter, might be expected to achieve similar levels. However, 
although high levels are usually achieved, levels matching those of polyhedrin 
are rare. Examples of proteins that have been produced to high levels include 
the expression of LCMV N protein (lymphocytic choriomeningitis virus 
nucleoprotein) to represent approximetely 50% of the total cellular protein 
(Matsuura et al, 1987); the LCM V-N (lymphocytic choriomeningitis virus N  
protein),expressed to around 3 jig/mg whole insect protein (Emery and Bishop, 
1987), and human p-interferon expressed to 1 Optg/106cells ( Smith et al 1983b) 
However, a yield of lmg/L is more realistic for many proteins. Unfortunately, 
beyond using transfer vectors which have been designed to include the features 
important for maximal protein expression, there is presently no reliable way to 
predict the level of synthesis that w ill be achieved by a recombinant protein, 
except the very general guide that the greater the post- translational 
modification that is required, the lower the expression may be, with membrane- 
associated glycoproteins usually becoming expressed to the lower end of this 
range. However, it has been suggested that expression levels may be improved 
upon by slight sequence modifications to the foreign gene, to optimise the 
codon usage to match the usage of insect cells (Cameron et al, 1989).
A number o f other factors have also been shown to effect the final 
yield of a foreign protein. Licari and Bailey (1991) expressed p-galactosidase 
as a fusion protein, as a model to study such factors. The effects of the 
multiplicity of infection (moi) used to infect cells, were found to depend very 
much on the growth phase of the cells at the time of infection. That is, if  cells 
were infected in the early phase of exponential growth, the final yields were 
found to be relatively independent of the moi used (using a range of 0 to 100 
pfu/cell). However, if  infection was deferred until late in the exponential phase 
of growth, a logarithmic relationship was found between moi and final foreign 
protein yield. Licari and Bailey (1991) also studied the effects of protein 
degradation. It was found that up to about 24 hpi (about the time the
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expression of many foreign proteins begins to be detected) the rate of protein 
degradation was found to be of the same order of magnitude as the rate of 
synthesis. This may be a reason why foreign proteins are rarely detectable 
much earlier than this, since with the use of an extremely sensitive method of 
detection, foreign protein expressed in Sf9 cells has been detected as early as 
one hour post infection (hpi) (Karp et al, 1992). But, as synthesis increases 
rapidly up to around 96 hpi, the rate of degradation actually slows down, until 
its effects become insignificant to the net production of protein.
1.3.3.1 POST- TRANSLATIONAL MODIFICATION
Protein processing of virtually every type has now been successfully 
demonstrated of proteins expressed in insect cells. These include 
glycosylation, fatty acid acylation (myristillation and palmitoylation), nuclear 
transport, disulphide bond formation, C-terminal adaptation, phosphorylation, 
proteolytic cleavage of precursor proteins and signal sequences, and the 
formation of complex tertiary and quaternary structures. A number of post- 
transcriptional processes have also been demonstrated in insect cells, including 
polyadenylation and 5' capping of mRNAs. However, the recognition and 
appropriate splicing out of introns have so far only been hinted at (Jeang et al, 
1987). Since glycosylation, and possibly the formation of tertiary structure, are 
the only types of processing with which the work described in this thesis is 
directly involved, examples of the other types of processing w ill not be 
discussed. A number of comprehensive reviews of this subject are available ( 
King and Possee, (1992); Licari and Bailey (1991); Bishop and Possee (1990) 
and Possee et al (1990)).
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Glycosylation
A large number of glycoproteins have been expressed using the 
baculovirus expression system. From these, two general rules have been 
determined. The protein, as most proteins expressed in this way, is usually 
found to be biologically active, often to the same level as the native protein in 
its normal host cell; and the glycosylation is usually present, in the appropriate 
location(s) on the protein (Cameron et al, 1989), but is of a different nature to 
the native protein.
Butters and Hughes (1981) studied the membranes from an established 
mosquito cell line, both N-linked and simple O-linked glycosylation was 
found. The N-linked oligosaccharides found were of the high mannose type.
In mammalian cells, high mannose oligosaccharides are the starting point of N - 
linked glycans. However, in mammalian cells, these structures are extensively 
trimmed, and then "decorated" - modified to form complex branching structures 
by the addition of sialic acid, fucose, galactose and glucosamine-galactose 
residues. Butters and Hughes concluded that insect cells lack the relevant 
enzymes for such modification, and therefore are unable to modify the core 
oligosaccharide structures. That is, the oligosaccharides of insect glycoproteins 
are essentially the same as mammalian intermediate oligosaccharides.
Endo-H (endo-p-A-acetyl-D-ghicosaminidase H) specifically removes 
immature high mannose type oligosaccharides. Most mammalian glycoproteins 
are therefore endo H- resistant. The demonstration that insect cell 
glycoproteins, and mammalian glycoproteins expressed in insect cells, are 
Endo- H sensitive (as determined by a reduction of apparent M r on SDS-PAGE 
analysis) shows that the oligosaccharides are the high mannose type, as the 
same, or corresponding proteins in mammalian cells are usually endo H 
resistant (Hseih and Robbins, 1984). It has been shown, however, that insect 
cells are capable of trimming the core oligo-mannose structure, though this
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study did not find evidence o f modification following trimming (Kuroda et al,
1990). Lucklow and Summers (1988) also concluded that insect cells were 
capable of both high mannose and "hybrid" type carbohydrates, and simple O- 
linked chains.
In 1989, however, the established generally held rules about the nature 
of glycosylation in insect cells were refuted. Jarvis and Summers used human 
plasminogen activator as a model for the study of the insect/baculovirus 
glycosylation pathway. Their studies demonstrated that at least some of the N - 
linked glycans were endo H resistant. Davidson et al (1990) studied human 
plasminogen, and found 40% of the N-linked oligosaccharides to be of the 
complex- type. This indicates the presence of one or all of the trimmed 
oligosaccharide modifying enzymes previously thought to be only found in 
mammalian cells.
Having established what, in the way o f glycosylation, insect cells are 
capable of, however, does not appear to allow any predictions as to the state of 
glycosylation that w ill be achieved by a glycoprotein expressed in insect cells.
Germann et al (1990) expressing the human multidrug transporter, a 
membrane associated glycoprotein, in insect cells, found that the apparent 
on SDS-PAGE analysis corresponded to the size of the non-glycosylated form 
of the normal counterpart. Despite this however, biological activity, as 
determined by specific photolabelling ( drug resistance not being measurable 
because of the lytic nature of the viral infection), was measured, but found to 
be much lower than for the protein expressed in a normal host cell. 
Vissavajjhala and Ross (1990) expressed the extracellular domain of human 
nerve growth factor (expression of the extracellular domain only of a usually 
membrane anchored protein allows secretion of the protein, allowing simplified 
purification procedures.). They also found an apparent lack of glycosylation, 
or very reduced glycosylation compared to the normal protein.
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In contrast, for perhaps the majority of insect cell expressed 
glycoproteins, reduced glycosylation has been observed and, where studied, 
been found to be endo H sensitive - the high mannose type. For example, 
Greenfield et al (1988) expressing the EGF (epidermal growth factor) receptor, 
and Paul et al (1990), expressing the human insulin receptor, both observed a 
significant difference in apparent molecular weight between the proteins in 
their normal host cell environment, and their expression in insect cells. When 
studied further, the carbohydrate chains of these glycoproteins were found to be 
endo H sensitive, and therefore concluded to be of the high mannose type.
Both proteins were reported to be fully biologically active. Similar molecular 
weight differences have been observed in many other glycoproteins, including 
the glycosylphosphatidylinositol- linked complement inhibiting protein (Davies 
et al, 1993), the human transferrin receptor (Domingo and Trowbridge, 1988), 
and the human P2-adrenergic receptor (Reilander et al, 1991). A ll of these 
proteins have also been demonstrated to be biologically functional. Chen et al 
(1991) used the baculovirus system to express the p-subunit of human 
choriogonadotrophin. O f the molecular weight o f this protein, in its native 
environment, 33% is carbohydrate. In this environment, the protein has two 
complex-type N-linked carbohydrate chains, and four O-linked chains. When 
expressed in insect cells, although the extent of the glycosylation was much 
reduced, it appeared that both N - and O- glycosylation sites had been 
recognised by the insect enzymes, and the localisation of all of the 
carbohydrate chains was apparently correct. The N-linked chains were found 
to be the high mannose type. Again, the carbohydrate difference did not effect 
either the immunogenicity or the biological activity of the protein, which was 
comparable to the activity of the native protein.
A limited number of glycoproteins that have been expressed in insect 
cells, have shown evidence of limited processing of the oligosaccharides. The 
human insulin receptor is a disulphide- linked heterotetramer of a  and P
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subunits, the biosynthesis of which is complex, and involves the synthesis and 
processing of a single polypeptide- chain precursor, to the subunits. Sissom 
and Ellis (1989) used the baculovirus system to express a soluble secreted 
extracellular binding domain of the insulin receptor. The precursor protein was 
detected in the cytoplasm of the insect cells. The apparent Mj. was found to be 
consistent with a reduced level of glycosylation (which occurs at a number of 
sites). Treatment of the precursor protein with endo H demonstrated that all of 
the oligosaccharide chains were of the high mannose type. However, on 
processing and secretion of the precursor protein to the mature secreted form, 
some endo H resistance was detected. The level of resistance was consistent 
with the trimming of some, but not all, of the oligosaccharide chains. Further 
analysis confirmed that the trimmed oligosaccharides were not further 
processed to mature complex forms. Again, biological activity was comparable 
to both the normal insulin receptor, and the truncated secreted version 
expressed in mammalian cells.
It seems, from studies o f many insect cell expressed glycoproteins, that 
in general, biological activity is dependent on the presence of glycosylation per 
se, and not on the type of oligosaccharide chains present. However, predictions 
of the glycosylation state and functional characteristics of any given 
glycoprotein are still not possible.
1.3.4 BACULOVIRUS TRANSFER VECTORS
Due to the size of the AcMNPV genome, 130 kbp, direct manipulation 
for cloning purposes is practically impossible. This necessitates the use of 
transfer vectors, encoding appropriate areas of the AcMNPV genome for later 
re- introduction into it by recombination. Transfer vectors are based on 
bacterial plasmids, containing enough of the plasmid to enable the cloning of 
the required gene sequence to be carried out in E.coli. using standard
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Figure 1.7 Generalised arrangement of the major components of a 
polyhedrin-based baculovirus transfer vector.
The other key elements in a transfer vector are (in the case of a 
polyhedrin- based system) the polyhedrin gene promoter, and transcription 
termination signals - set at either side of the cloning site for the foreign gene. 
The precise requirements of the sequence 5' upstream to polyhedrin for the 
expression of a foreign gene have been fully elucidated (Smith et al, 1983b; 
Matsuura et al, 1987; Possee and Howard, 1987; Possee et al, 1991) so that 
optimal expression is available from vectors produced. Flanking these (see 
figures 1.7 and 1.8 ) are areas of DNA corresponding to the areas normally 
flanking the polyhedrin gene in the AcMNPV genome. These elements are 
taken form an AcMNPV genome as a fragment. The polyhedrin gene is on a 
contiguous sequence of DNA, in the middle of a 7.3 kbp Eco R1 restriction 
fragment (Summers and Smith, 1987; Bishop and Possee, 1990). This excised 
fragment, modified to remove the polyhedrin coding sequence ( Smith et al,
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Figure 1.8 Schematic representation of the general components in the 
construction of a baculovirus transfer vector, co-transfection with AcMNPV 
genome, and homologous recombination events allowing the replacement of the 
polyhedrin gene with the foreign gene.
1983a; Pennock et al, 1984; Matsuura et al, 1987) has been used as the basis 
for many transfer vectors.
1.3.5 PRODUCTION OF RECOMBINANT BACULOVIRUSES
Figure 1.8 illustrates the principles involved in the production of a 
recombinant baculovirus, encoding a foreign gene in die place of polyhedrin.
A transfer construct, containing the foreign gene, is co- introduced into an 
insect cell with whole baculovirus genome DNA (methods of co- transfection 
and preparation of viral genomic DNA w ill be discussed shortly). Homologous 
recombination in two areas, between the corresponding polyhedrin flanking 
regions (flanking polyhedrin in the genome and the foreign gene in the transfer 
construct) results in the replacement of the polyhedrin gene with the foreign 
gene. This DNA is then incorporated into a virus, infection with which w ill 
result in the corresponding production of the foreign gene product. The entire 
progeny of viruses, or sample of, must then be screened, in order to identify the 
recombinant viruses against a background of polyhedrin- encoding viruses.
In practice, however, these simple principles have been found to be 
fraught with problems. Principally, the number o f recombinant viruses 
following a co- transfection with infectious AcMNPV DNA is usually expected 
to be at a rate of less than 1%; and the recognition o f infected cells ( in a plaque 
assay) that are not producing polyhedrin generally requires a lot of time and 
patience, and an experienced eye.
In recent years however, there have been a number of principal 
advances in the production of recombinant baculoviruses, which have resulted 
in the simplification of the procedure, which in turn has resulted in a reduction 
in the time and frustration involved. Most of the advances described have been 
exploited during the work described in this thesis.
The first of these (in procedure order) is the use of linearised genome 
DNA. In yeast and mammalian cells, DNA containing double-stranded breaks
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are known to be highly recombinogenic (Bollag et al, 1989), and the 
exploitation of this has become a routine method for recombination of 
homologous DNA sequences in such systems. This observation was tested in 
insect cells. Kitts et al (1990) compared infectivity and recombination 
frequencies of circular and linearised forms of AcMNPV. This was made 
possible by the introduction of a unique restriction site into the DNA (Matsuura 
et al, 1987). When introduced into Sf cells with a five-fold excess of plasmid 
DNA, linearised AcMNPV DNA was found to have only 1/150th of the 
infectivity of circular DNA co-transfected in a parallel experiment. Although 
recombination itself was only found to be ten to 12- fold higher for linear 
molecules than circular; the reduction in infectivity results in a reduction in the 
background o f non-recombinant viruses. Therefore, whereas with circular virus 
DNA recombinant usually represent < 1% of the total progeny, for linearised 
virus DNA, recombinant viruses represent 16 to 39% (Matsuura et al, 1987; 
King and Possee, 1992).
This advance has meant that fewer progeny viruses need to be screened 
in order to identify recombinants, as well as having an improved number of 
recombinants to find.
A significant advance in the improvement of the baculovirus 
expression system can, co-incidentally, also incorporate the first. The single 
unique restriction site, Mst 11 (also called Bsu 361 and Sau 1) was found to 
exist within the coding region of the E.coli (3-galactosidase (lacZ) gene. This 
gene, when introduced into the AcMNPV genome (for example, to replace the 
polyhedrin gene o f the wildtype virus) can be used to give a blue colouration to 
cells infected with that virus, in the presence of X-gal (Pennock et al, 1984; 
Possee and Howard, 1987).
In a co-transfection, an ordinary transfer vector construction is used, 
and the AcMNPV. lacZ DNA is used in place of the normal parental wildtype 
(for example, as used by Pennock et al, 1984 and Possee and Howard 1987). In
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non-recombinant viruses, the "wildtype" retains the blue phenotype, which can 
be easily detected in a plaque assay. In a recombinant virus, the lacZ gene is 
displaced by the foreign gene, and the blue phenotype therefore removed. 
Recombinant virus plaques can be easily detected as white (non blue). Using 
this approach, 40 to 80% of the white plaques in a first round plaque assay can 
be expected to contain the appropriate foreign gene (King and Possee, 1992).
I f  the AcMNPV./acZ DNA is linearised prior to co-transfection, then the 
advantages of improved proportions of recombinants to non- recombinants, and 
the ease of recombinant identification, are simultaneously conferred.
Since it has been reported that some workers experience problems in 
identifying white plaques against a background of parental- type blue plaques, 
the lacZ gene has also been utilised in another way. For example, in transfer 
vectors using the polyhedrin gene promoter for the expression of a single 
foreign gene; the p 10 promoter has been used for the expression of the lacZ 
gene (i.e. a dual expression vector), which thus acts as a "reporter". Used with 
a normal wildtype AcMNPV (or AcMNPV. SC), recombinant plaques now 
appear as blue, against a background of polyhedrin containing "white" plaques 
(Vialard et al, 1989). The main disadvantage of this approach is that infected 
cells w ill continue to co-express P-galactosidase as well as the protein of 
interest.
A third significant improvement to the baculovirus system is the 
introduction of improved methods of co- transfection. Traditionally, co­
transfection was carried out using calcium phosphate co-precipitation. This 
technique involves precipitation of both genome DNA and transfer vector DNA  
to an exactly appropriate size for entry into the cells, involving a very careful 
balancing o f pH ( Smith et al, 1983). This technique, though widely used, was 
not very efficient, and the results were not reproducible. Two other methods 
are now commonly used for the introduction of DNA into insect cells.
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Electroporation involves the temporary formation of pores in the 
surface of the cells by subjecting them to high voltages. This has been found 
to be much more efficient than calcium phosphate co- precipitation, and highly 
reliable and reproducible. For co- transfection of wildtype AcNPV and a 
transfer plasmid carrying a lacZ gene; electroporation has been found to 
produce upto 100 times more recombinant viruses than are produced using 
calcium phosphate co- precipitation. Single transfection of AcNPV has been 
shown to be upto 1000 times more efficient using this method (Mann and King, 
1990). The principle disadvantage of this system is that expensive highly 
specialised equipment is required, which can be restrictive for its use.
Cationic lipid - mediated co- transfection is now probably the method 
of choice when using the baculovirus expression system. The reagent involved 
is the cationic lipid A[l,l-(2,3-dioleyloxyl)propoyl]-A,V,V,- 
trimethylammonium chloride, and it is readily commercially available from a 
number of sources. Virus litres obtained using this method have been found to 
be at least 20- fold higher than those obtained using the calcium phosphate 
precipitation method. The percentage of recombinant viruses produced using 
circular AcMNPV is five to 50 times higher using this method than using 
calcium phosphate precipitation (Greobe et al, 1990). This method is cheaper 
and easier to set up in a laboratory than an electroporation system, and is much 
more efficient and more reliable than the calcium phosphate system.
A feature of the baculovirus system which is becoming widely 
exploited is the ability to simultaneously express two ore more recombinant 
proteins in the same cells, thus allowing the analysis of interactions forming 
between the expressed proteins. The formation of complexes between the 
SV40 large T antigen and human p53 proteins (O’Reilly and M iller, 1988), and 
the complex of two influenza virus polymerase proteins (St Angelo et al, 1987), 
as described in section 7.3.1. The use of transfer vectors capable of encoding 
more than one foreign gene is useful to this end. In such a vector for example,
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both "very late” phase expression promoters (polyhedrin and plO) can be used, 
or two copies of the polyhedrin promoter may be included. As is mentioned 
previously in this section, a vector carrying a LacZ reporter gene encoded by 
the plO promoter, and the foreign gene under the control of the polyhedrin gene 
is available as a colour selection system for the identification of foreign 
protein-expressing cells.
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1.4 EXPRESSION OF GLUCOSE TRANSPORTERS IN
INSECT CELLS
Since the onset of this project in 1989, the baculovirus expression 
system has been successfully used to express the GLUT 4 glucose transporter 
(Woon et al, 1991), and the full- length GLUT 1 glucose transporter (Y i et al, 
1992). Because of the obvious intimate relevance of both of these studies to 
the work described in this thesis, greater reference is made to both in the 
Discussion (Chapter 7).
Although glucose transporters of mammals, and to a certain extent of 
bacteria and yeast, have been well characterised (see section 1.1.2), the glucose 
transport systems of insects have not. Wang and Wang (1993) have 
characterised the glucose transport system of Kc cells of Drosophila 
melanogaster, an established insect cell line. They demonstrated 
stereospecificity of transport, and an apparently unique substrate specificity; 
having greatest affinity for D- glucose, and lower, but equally efficient 
transport of both D-fructose, and D-galactose. Transport studies revealed that 
the Drosophila glucose transporter is inhibited by cytochalasin B. The 
inhibition level was found to be similar to that demonstrated by GLUT 2 (a 
of 4mM; GLUT 2 for cytochalasin B is 1 to 2 mM), which is an order of 
magnitude higher than for GLUT 1 (K^  of 0. Im M ). Since inhibition by 
phloridzin, an inhibitor of transport in sodium/glucose symporters but not in the 
GLUT family, is almost negligible; the inhibition profile of the Drosophila Kc 
cell glucose transporter is more similar to those of the GLUT family. However, 
rat cDNA glucose transporter probes showed no cross- hybridisation with 
Drosophila RNA, demonstrating that, despite functional similarities, there is 
apparently no sequence homology between the glucose transporters o f the 
Drosophila Kc cells and the mammalian facilitated glucose transporter family.
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1.5 AIMS OF THE PROJECT
1.5.1 EXPRESSION OF FULL LENGTH GLUT 1 PROTEIN.
At the onset of this project, no glucose transporter isoform had been 
expressed in insect cells using the baculovirus expression system.
Although the primary structures of the mammalian facultative glucose 
transporter family have been elucidated, and the two dimensional topology has 
been mapped, little is really known about the three dimensional structures of 
these molecules. The two principal reasons for this are firstly that they are very 
closely membrane associated proteins, presenting problems with the 
purification of structurally and functionally intact molecules. Secondly, no 
tissues express any isoform in sufficient abundance to realistically allow the 
purification of sufficient quantities of protein for three dimensional structure 
determination.
The baculovirus expression system is known to be a large scale 
expression system, and has been found to be capable of the production, using 
reasonable resources, of milligram quantities of some proteins (see section
1.3.3). It was on this basis that the baculovirus system was chosen for the 
expression of the erythrocyte type glucose transporter, GLUT 1. Although 
purification of any expressed protein would be beyond the scope of this project, 
the principal aims of the expression of GLUT 1 in this way were to determine 
whether indeed it could be expressed to a high level, and to determine whether 
the protein would be biologically functional within the insect cells. That is, if  
the protein could be expressed to high levels, if  no functionality could be 
shown, it would not be a suitable substrate for further research. Biological 
function would provide an indication that the expressed protein had adopted a 
functionally appropriate conformation within the host insect cells.
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1.5.2 INDEPENDENT EXPRESSION OF THE TWO HALVES OF THE
GLUT 1 PROTEIN.
GLUT 1 was the first of the mammalian family of glucose transporters 
to be identified, and as such is probably the best characterised to date. Its mode 
of action, functional structural unit, substrate specificity, and the localisation of 
the glucose binding sites to as close as a few amino acid residues, have all been 
well investigated (see sections 1.1.3 to 1.1.5). Most work on the sites of 
glucose binding and transport have indicated that the two ligand binding sites 
(one internal and one external), and possibly also the transmembrane channel 
all reside within the realms of the C-terminal half of the molecule ( figure 1.1 
depicts the proposed two dimensional topology of the GLUT 1 molecule, and 
shows the proposed ligand binding sites. Section 1.1.4 describes some of the 
work providing evidence for this). Based on this, and on the basis that the full 
length transporter would be found to be functional, it was proposed that 
expressed alone, the C-terminal half of the protein would be functional. 
Evidence that at least one signal sequence for membrane insertion exists on the 
C-terminal one third of the protein ( Mueckler and Lodish, 1986) suggest that 
membrane localisation may be achieved if  the insect cells recognise the signal 
sequence. To mirror this, it would be expected that the N-terminal half 
similarly expressed would not be shown to be functional, but, having also at 
least one signal recognition site (Mueckler and Lodish, 1986), would be 
expected to be inserted into the membrane.
The dual expression of both "proteins" in the same cells was based on 
results obtained from functional analyses of the individually expressed half 
"proteins", particularly the C-terminal half. The rationale for this work is 







Tryptone and yeast extract were from Oxoid Ltd., London, UK.
Agar was from Difco Labs, Detroit, Michigan, USA.
Redistilled phenol was from Rathbum Chemicals Ltd., Walkerbum, UK. 
N,N,N',N'-tetramethylethylene diamine (TEMED), sodium dodecyl sulphate 
(SDS), 2-mercaptoethanol, ammonium persulphate, and acrylamide 
were from BDH Ltd., Poole, UK.
Caesium chloride was from Rose Chemicals, London, UK.
Deoxy-nucleotide triphosphates were from Pharmacia, Upsala, Sweden. 
Polyallomer quick seal ultracentrifiige tubes were from Beckman Instruments 
Inc., Palo Alto, USA.
5-bromo-4-chloro-3-indolyl-P-D-thiogalactoside (X-gal), and isopropyl-p-D- 
thiogalactosidase (IPTG) were from Northumbria Biochemicals Ltd, 
Cramlington, UK.
Agarose, and Low melting point agarose were from Sigma, Poole, UK.
X-ray film  was from Fuji Photo Film Co. Ltd., Japan.
[y-32P ]  ATP was from ICN, ICN Flow, Richmansworth, Herts, UK. 
2-Deoxy-D[2,63H] glucose (52Ci/mmol), and [U -14C] sucrose (aqueous 
solution at 23GBq/mmol, 125I-protein A, (0.1 jj.C i/m l), [2(n)-3H]-Cytochalasin 
B, and Cytochalasin E were from Amersham International PLC, Aylesbury,
UK.
ATB-[-2-3H]-BMPA photoprobe (activity 10 Ci/mmol) was made at the 
University of Bath, by Dr G D Holman, using the method as described by Clark 
and Holman, 1990.
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Molecular weight markers and prestained molecular weight markers for SDS 
PAGE were from Bio-Rad Laboratories, 3300 Regatta Boulevard, 
Richmond, CA 94804 
Nonaethylene glycol dodecyl ether (Thesit) was from Boehringer Mannheim. 
Protein A sepharose was from Sigma.
ECL Western blotting kit, Amersham, Upsala, Sweden.
A ll other chemicals were from Sigma, Poole, UK; BDH, Poole, UK; and 
Fisons, Loughborough, UK.
Laboratory grade solvents were from BDH and Fisons.
2.1.2 ENZYMES. VECTORS AND PLASMIDS.
Restriction enzymes, T4 DNA ligase, X DNA for restriction digestion for Use as 
DNA standard markers on agarose gel electrophoresis, and T4 
polynucleotide kinase were from Northumbria Biochemicals, 
Cramlington, Northumberland, UK.
Restriction enzymes also from Pharmacia LKB Biotechnology, Central Milton 
Keynes, UK.
Taq DNA Polymerase (Amplitaq) was from Perkin Elmer Cetus, Valterstetten, 
Germany.
Gene Clean DNA purification kit was from BIO 101, from Stratech Scientific 
Ltd., 61-63 Dudley St., Luton, LU2 ONP 
pT7blue vector kit was from Novogen, AMS Biotechnology UK Ltd, 5, 
Thomey Park, Witney, Oxon, 0X 8 7GE. 




"anti C-terminal antibody" used throughout for the detection of Glut 1 
protein was a rabbit antiserum raised against a synthetic peptide corresponding 
to residues 480 to 492 at the C-terminal tail of the molecule. This antiserum 
was kindly provided by Dr. Avril Clark (Bath University, Bath)
"anti N-terminal antibody" used throughout for the detection of Glut 1 
protien, particularly the N-terminal half, was a rabbit antiserum raised against a 
synthetic peptide to residues 240 to 255 of the central loop region of the glut 1 
molecule (see figure 1.1, section 1.3). This antiserum was kindly provided by 
Dr. Stephen Baldwin (Leeds University, Leeds).
2.1.4 CDNA
The cDNA used for the production of all o f the glut 1 constructs was 
a rabbit glut 1 cDNA. This was a kindly provided by Dr. Yoshitomo Oka 
(Tokyo, Japan).
2.1.5 TISSUE CULTURE AND SPECIAL EQUIPMENT
Unless otherwise stated, all tissue culture disposables, media, and supplements 
were obtained from Gibco (Life Technologies Ltd. Cowley M ill 
Trading Estate, Longbridge Way, Uxbridge, U K .) Flow, (IC N  Flow, 102 
Witmer Road, Morsham, P.A, USA 19044 228), and Nunc Inc., 2000 North 
Arora Road, Naperville, Illinois, 60566.
Techne biological stirrer Spinner culture flasks were from Fisons.
Electrophoretic transfer unit used was the Multiphor I I  Nova Blot unit from 
Pharmacia LKB Biotechnology.
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The photolabelling reactions were carried out using a Rayonett RPR-100 
photoreactor containing RPR-3000 lamps.
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2.2 METHODS
2.2.1 MOLECULAR BIOLOGY METHODS
2.2.1.1 GROWTH AND MAINTENANCE OF BACTERIA
The E.Coli strain TG I : (Sup E hsd A5 thi A (lac - pro AB ) F  (fra 
D36 pro AB+ lac Iq lac Z A M 15)) was used throughout.
E.Coli cultures were grown in YT broth (lOg yeast extract, lOg yeast 
tryptone, and 5g sodium chloride per litre), and sub-cultured monthly on 
minimal agar plates ( 15g bacto agar, 10.5g K^HPO^ 4.5g KH2P04, lg  
(NH4)2S04, 0.5g sodium citrate, 0.2g MgS04.7H20 , 2g glucose, and 5jng 
thiamine HC1; per litre).
2.2.1.2 RESTRICTION DIGESTION OF DNA
Restriction digest reactions were usually carried out using 
manufacturers' supplied buffers, recommended reaction temperatures and 
incubation times (normally 37°C for 60 to 90 minutes). Restriction digestions 
carried out in preparation for a ligation reaction were carried out at 37°C 
(unless otherwise stated for a particular enzyme) overnight. Single, or 
concomitant double digestion reactions were stopped by the addition of EDTA 
to a final concentration of 20mM. The first enzyme o f sequential digestions 
(dictated by different buffer requirements ) was inactivated by heating to 85°C 
for 20 minutes.
Digestions for DNA analysis were not processed further before 
visualisation by agarose gel electrophoresis.
Digests in preparation for ligation reactions were either gel purified 
and cleaned by "Gene Clean" to isolate the required fragment; or extracted by 
phenolxhloroform , and precipitated with ethanol, to remove contaminating
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fragments before use. Such processed fragments were analysed by 
electrophoresis to determine the success of the digestion and the purification , 
before use in a ligation reaction.
2.2.1 .3  PHENOL: CHLOROFORM EXTRACTION OF DNA
An equal volume of phenol (pre-equilibrated to <pH 8) was added to 
the DNA solution, vortexed, and the two layers separated by centrifugation 
(6000rpm, 2 minutes). The (upper) aqueous layer was removed to a fresh 
tube. An equal volume of pre-equilibrated phenol:chloroform (1:1 ; pH 7.4) 
was added to the tube, and the extraction procedure repeated (vortexing, 
centrifugation, removal of aqueous phase to a clean tube). An equal volume of 
chloroform was then added to the aqueous phase, and the extraction procedure 
repeated again.
2 .2 .1 4  DNA PRECIPITATION USING ETHANOL
Unless otherwise stated, three volumes of absolute ethanol ( at -20° 
C), and 0.1 volume 3M sodium acetate (pH 4.0) were added to the DNA  
solution, and mixed thoroughly. This was incubated for 2 to 16 hours at -20°C, 
and centrifuged (22 OOOg for 30 minutes ) to collect the precipitated DNA. The 
DNA pellet was then washed in 70% ethanol, dried under vacuum in a Savant 
Speed Vac, and resuspended in ddH20  (double distilled water), unless 
otherwise stated.
2 .2 .1 .5  OLIGONUCLEOTIDE PREPARATION
Oligonucleotides were synthesised by the phosphoamidite method, on 
an Applied Biosystems 381 A DNA synthesiser. The completed 
oligonucleotide was removed from the synthesis column by slowly drawing 
through 1ml concentrated ammonia solution. This solution was then heated to 
55°C for six hours, and the oligonucleotide dried down under vacuum, using a
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Savant Speed Vac. The dry oligonucleotide was ethanol precipitated (section 
2.2.1.4), and dissolved in 1ml double distilled water (ddH20).
The yield of the synthesis was determined by a spectrophotometric scan of a 
diluted solution, from 350nm to 240nm. The concentration was calculated 
from the 260nm peak, assuming that 1.0 O.D ml corresponds to 37jig/ml DNA.
2 .2 .1 .6  OLIGONUCLEOTIDE QUALITY TESTING
The oligonucleotide quality was tested by radiolabelling with [y-32P]- 
ATP using polynucleotide kinase, and sizing of the radio-labelled material 
using polyacrylamide gel electrophoresis. The reaction was carried out on 0.2 
pmoles of oligonucleotide, using 0.15 pmoles gamma labelled 32P- ATP, and 
two units of polynucleotide kinase; at 37°C for 30 minutes. A 0.3mm thick 
20% polyacrylamide gel was prepared, the samples loaded, and run for 2 hours 
at 800 V. The gel was then visualised by autoradiography.
2 .2 .1 .7  POLYMERASE CHAIN REACTION
The PCR oligonucleotides, prepared as above (2.2.1.5) were designed 
in pairs to areas of glutl cDNA flanking the area targeted for amplification.
This included slight mismatches in order to introduce unique restriction 
recognition sites into the ends of the amplified fragments. The reaction mixture 
contained lpg template DNA (rabbit glutl cDNA); 0.2pM of each 
oligonucleotide primer; 1.5mM MgCl2; 50mM KC1; 10tnM Tris-HCl pH 8.3; 
and 50pM of each dATP, dCTP, dGTP, and used 0.5 U Taq DNA polymerase 
(Amplitaq).
The reaction mixture (lOOpl) was overlaid with mineral oil, and 
amplified for 30 cycles (60 seconds melting at 95°C; 60 seconds annealing at 
55°C; and 90 seconds extension at 72°C) in a Perkin Elmer Cetus DNA 
Thermal Cycler.
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2.2.1.8 AGAROSE GEL ELECTROPHORESIS
DNA was electrophoresed in 1% agarose gels, with lx  Tris-borate 
buffer ( 90mM Tris, 83mM boric acid, Im M  disodium EDTA, pH 8.3), unless 
otherwise stated. Samples were loaded in loading dye (15% w/v Ficol 400, 
0.25% w/v bromophenol blue, 0.25% w/v xylene cyanol), and electrophoresed 
at 50 V/cm (50mA). Bands were visualised using lpg/ml ethidium bromide 
and an ultraviolet transilluminator.
2 .2 .1 .9  GEL PURIFICATION OF DNA FRAGMENTS
DNA for gel purification was subjected to appropriate restriction 
digestion, before being run on an agarose gel (using 1% low melting point 
agarose; and lx  Tris Acetate buffer (0.04M Tris-acetate; 0.001M EDTA; pH 
8.0)). The gel was run until the appropriate band, visualised against molecular 
weight markers, using UV. light, was near to the end of the gel. The 
appropriate band was closely excised using a razor blade, to a microcentrifuge 
tube.
The agarose pieces containing the required DNA was then either 
heated to 55°C (until the agarose had melted) and subjected to a full 
phenolrchloroform extraction followed by an overnight ethanol precipitation, or 
purified using the ’’Gene Clean” kit. The manufacturers’ protocol was 
followed, which briefly involves the addition of three volumes of Nal ,and 
heating to 50°C until the agarose had melted. lOpl of the provided glass milk 
was added to the tube, mixed, and incubated at room temperature for five 
minutes. The mixture was then centrifuged briefly and the pellet washed three 
times according to the protocol. The DNA was finally dissolved at 50°C in 
ddH20  and removed from the glass milk, after centrifugation, to a clean tube. 
The purity of the fragment was determined by analysing 1 pi of the DNA 
solution on a 1% agarose gel.
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2.2.1.10 PRODUCTION OF "BLUNT" ENDED DNA FRAGMENTS
Purified DNA (1 to 2pg)(see section 2.2.1.9) was added to a 
microcentrifiige tube of mixed dNTPs at 2mM each, and 5 to 10 U of DNA  
Polymerase I Klenow fragment, in a volume of 50pl, including lx  buffer 
(supplied with enzyme), and incubated at 37°C for 30 minutes. The reaction 
was stopped by the addition of EDTA to a final 20mM. The DNA was then 
purified as described in section 2.2.1.9 before use in ligation reactions.
2.2.1.11 LIGATION OF DNA
The insert and vector DNA (molar ratio 1:2) were incubated in 25mM 
Tris-HCl (pH 7.5), lOmM DTT, and 4mM ATP, with 0.1 U of T4 DNA ligase 
for "sticky" ended ligations or 1 U for blunt ended fragments, for four hours at 
room temperature (sticky ends) or at 16°C overnight (blunt ended reactions). 
The reaction was stopped by the addition of EDTA to a final concentration of 
20mM.
2.2.1.12 COMPETENT CELLS
lm l of a 10ml overnight culture o f TG I cells in YT broth was 
inoculated into 100ml of YT broth, and grown at 37°C with vigorous shaking, 
until the culture reached an OD. of 0.4 (measured at 600nm) indicating log 
phase growth. The cells were cooled on ice, and pelleted at 3000rpm for 5 
minutes at 4°C. The cells were then resuspended in 40 ml ice cold 50mM 
CaCl2, and incubated on ice for 20 minutes. The cells were re-pelleted, as 
before, and resuspended in 4ml cold CaCl2. The competent cells were stored 
on ice for at least one horn* before use.
2.2.1.13 TRANSFORMATION REACTIONS
The ligation reaction was diluted with 200jil ddH20 , mixed with 
0.3ml of competent TG I cells in a chilled microcentrifuge tube, and incubated 
on ice for 45 minutes. The reaction mixture was then subject to a 1 minute 
’heat shock' incubation at 50°C, followed by rapid cooling on ice. 1ml of YT 
broth was added and the mixture incubated at 37°C for 60 to 90 minutes. 140 pi 
(1/1 Oth reaction mixture) aliquots were plated onto YT agar plates (1.5% agar, 
containing 100pg/ml ampicillin ). Where appropriate (e.g. for cloning and 
subcloning into pUC 18) colour selection was used ( 30pl of 2% X-gal (5- 
bromo-4-chloro-3-indolyl-p-D-galactosidase) and lO jil of 0.1M IPTG ( 
isopropyl-p-D-thiogalactoside) being added to the plates, with the cells.) The 
plates were then incubated at 37°C overnight.
2.2.1.14 SMALL SCALE PLASMID DNA PREPARATION
A single colony was transferred into 3mls YT broth, containing lOOp 
g/ml ampicillin, and grown overnight at 37°C with vigorous shaking. 1.5ml of 
the culture was transferred to a microcentrifuge tube, and pelleted by 
centrifugation at 12000g for 30 seconds, at 4°C. The pellet was resuspended in 
lOOpl ice cold TGE buffer ( 25mM Tris-HCl, pH 8 ; lOmM EDTA, pH 8; 
50mM glucose ) by vortexing. 200pl freshly prepared 0.2M NaOH; 1% SDS 
was added to the tube, and mixed gently. 150pl ice cold potassium acetate 
(5M ; pH 4.8 ) was added, and gently but thoroughly vortexed. The mixture 
was centrifuged for two minutes at 12000g, and the supernatant transferred to a 
clean tube, where it was subject to a phenolxhloroform extraction (section
2.2.1.3). This was then precipitated with two volumes of ethanol at room 
temperature. The DNA was pelleted (5 minutes at 12000g), rinsed with 70% 
ethanol, and dried under vacuum. The dry DNA was resuspended in 40pl TE 
buffer ( lOOmM Tris-HCl, pH 8; Im M  EDTA), containing 20pg/ml DNAse-
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free pancreatic RNAse. This method follows that given in Sambrooke et al 
1989.
2.2 .1 .15 LARGE SCALE PLASMID PREPARATION
A 10ml overnight culture of TG I cells containing the appropriate 
plasmid was used to inoculate a 500ml culture in YT broth, containing IOOji 
g/ml ampicillin. This culture was grown overnight at 37°C with vigorous 
shaking. The cells were pelleted by centrifugation (5000rpm, 10 minutes, at 4° 
C), and resuspended in 100ml TE buffer ( lOmM Tris pH 7.5, Im M  EDTA). 
The cells were re-pelleted (5000rpm, 10 minutes) and resuspended in 25ml of 
TGE buffer ( lOmM Tris pH 7.5, Im M  EDTA, 50mM glucose). 50ml of fresh 
0.2M NaOH, 1% SDS was added, and the tubes incubated on ice for 15 
minutes. 25ml 3M potassium acetate pH 4.8 were added, and the incubation 
continued for a further 30 minutes. The mixture was centrifuged, as before 
(5000rpm, 10 minutes), and the supernatant was filtered through muslin. 70ml 
2-propanol was added to the supernatant, and the mixture centrifuged as before. 
The pellet was air dried briefly, and resuspended in 7.5ml TE buffer. 8.5g 
CsCl was dissolved into i t , and 0.8ml lOmg/ml ethidium bromide was added. 
The solution was transferred to quick seal ultracentrifuge tubes, balanced, and 
sealed. The preparation was centrifuged in a VTi65 rotor, at 40 OOOrpm for 14 
to 20 hours, at 15°C, using a Beckman ultracentrifuge (model L5-65).
The plasmid bands were removed from the sealed tube using a 19G 
needle, and 1ml syringe. The DNA was extracted with isoamyl alcohol, until 
all traces of ethidium bromide were removed. The resulting solution was 
dialysed against TE buffer to remove CsCl, overnight, with three changes of 
buffer. The DNA was ethanol precipitated (section 2.2.1.4), and the pellet 
dissolved in 1ml ddH20 . The DNA concentration and purity were determined 
spectroscopically, at 260 and 280nm.
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2.2.2 BACULOVIRUS METHODS
Many of the methods described in section 2.2.2 follow those of King 
and Possee 1992.
2.2.2.1 ROUTINE SUB - CULTURE OF Sf9 CELLS
Stocks of Sf9 cells, of passage numbers 20 to 70 were routinely sub­
cultured in 25cm2 tissue culture flasks. The monolayer was examined using a 
reverse-phase microscope to ensure that the cells appeared to be healthy (well 
rounded cells with smooth, even edges, adhering loosely to the plastic), and not 
contaminated with fungus or bacteria, or infected with baculovirus (cells 
infected with baculovirus have a distinctly crenellated, uneven circumference, 
and distorted appearance). The medium was removed, and the cells were 
removed from the plastic by gently squirting fresh T C I00 (5% FCS) medium 
over the growing surface. One tenth of that volume was then removed to a new 
flask, containing 4.5ml of fresh TC100 (5% FCS) medium, and incubated at 28 
°C until the monolayer was confluent. Sub-culturing was usually required 
every five to seven days.
Cells required for experimental work were taken from these stocks as 
required. If  many cells were to be required, an appropriate number of 75cm2 
flasks would be used, where cells would be passaged once, to boost cell 
numbers before use. Very large numbers of cells were generated by using a 
suspension culture.
2 .2 .2 .2  SPINNER CULTURE OF Sf9 CELLS
Cells were not routinely cultured in suspension ("Spinner") culture, 
but such a culture was set up as required, particularly for the production of 
virus stocks.
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To initiate a Spinner culture, cells and medium (T C I00/5% FC S), to 
a total volume of 50ml were added to a sterile 250ml round, flat-bottomed glass 
flask containing a sterile magnetic stirring bar. The cells, from a monolayer 
culture, were added at a density of 5 x 105 cells/ml. The culture was incubated 
at 28°C, with the flask suspended slightly above a magnetic stirrer, and the 
culture was stirred at a constant 50 to 70 rpm.
The cell density was monitored daily (by removal of a small sample 
and counting the cells using a haemocytometer). On reaching 2 to 3 x 
106cells/ml, the culture was 'passaged'. That is, excess cells were removed, and 
fresh medium added to give a density of 1 to 2 x 105cells/ml. The culture was 
thus passaged at least once before cells were taken for experimental work, or 
increased to a larger volume; to allow the cells to adapt to spinner conditions.
If  a larger number of cells were required, cells from a 50ml spinner 
culture, and medium, were added to a 500ml "Techne" tissue culture flask, at 
an initial density of 1 to 2 x 105cells/ml. Cells were passaged, as before, or 
removed or used as required. A  volume of 250ml was found to be sufficient for 
all applications described in this thesis.
2.2.2.3 LONG TERM STORAGE OF Sf9 CELLS
Stocks of cells were held in liquid nitrogen. These were relatively 
low passage number cells (20 to 30), used to periodically replace the "running 
stocks" of cells as the passage number increased (60 to 70).
Cells to be frozen were microscopically analysed, using a reverse 
phase microscope, to determine whether their viability was 90% or more. Cells 
found to be of lower viability were not used for long term storage. Cells were 
removed from the monolayer by squirting with fresh ice cold TC100 (10%  
FCS) medium, and the density determined (counting a sample using a 
haemocytometer). The density was adjusted to 1 x 106 cells/ml. One tenth 
volume of tissue culture DMSO (sterile) was added, and 1ml aliquots were
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transferred to cryogenic vials, and chilled on ice. The vials were then placed in 
the vapour-phase of a liquid nitrogen container overnight. Vials were quickly 
transferred to the liquid nitrogen for storage.
To retrieve cells, a 25cm2 flask, containing 5ml T C I00 (10% FCS), 
was pre-warmed to 28°C. The vial was removed from storage, and thawed as 
rapidly as possible by holding the vial, without submersion, in a clean water 
bath at 37°C until only a sliver of ice remained. Ensuring sterility, the contents 
of the vial were transferred to the flask, and incubated at 28°C for four to five 
hours. After this time, the medium was replaced with fresh T C I00 (10% FCS). 
The medium was replaced again after a further 10 to 20 hours. On reaching 
confluence several days later, the culture was sub-cultured as normal, in T C I00 
(5% FCS).
2 .2 .2 .4  CO-TRANSFECTION OF VIRUS DNA AND TRANSFER VECTOR
lpg transfer vector DNA and 200ng linearised AcNPV:LacZ 
"wildtype" baculovirus purified genome DNA were very gently mixed in a 
microcentrifuge tube. A 2:1 Lipofectin reagent: sterile water mixture, to the 
same volume as the DNA mixture, was put into a sterile polystyrene universal 
bottle. The DNA mixture was carefully added to it, and incubated at room 
temperature for 15 minutes. A  35mm dish had been seeded with lx  106 cells 
the day before, and was washed twice with 1ml serum-free TC100. 1ml serum- 
free T C I00 was added to the cells. The DNA-Lipofectin mixture was then 
pipetted onto the cells, the dish swirled to mix, and incubated at 28°C 
overnight. 1ml T C I00 (5% FCS) was added to the dish. After 48 hours from 
the co-transfection, the medium (containing released virus particles) was 
"harvested" to a bijou bottle. 1ml TC100 (5% FCS), containing 15pi X-gal 
(2%w/v in dimethylformamide, stored at -20°C), was added to the cells. After 
24 hours, the dish was examined for blue colouration of cells and/or medium, 
to determine whether the co-transfection had been successful.
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2.2.2.5 RECOMBINANT VIRUS SCREENING BY PLAQUE ASSAY
Using serial dilutions (made in TC I 00/5% FCS) of the co­
transfection medium, in triplicate (from undiluted "neat", to 10-3 ), 35mm 
dishes o f cells (seeded at lxlO 6 cells/dish 18 horns earlier) were inoculated 
(lOOpl/dish). A negative control, using T C I00 (5% FCS) only was included. 
The dishes were incubated for 1 hour at room temperature. An overlay, 
(comprising in equal volumes, freshly autoclaved 2% w/v Sea Plaque agarose 
in water, and T C I00 (5% FCS)) was prepared. This was incubated at 37°C 
until required. The inocula removed, 2mls of overlay were carefully pipetted 
into each dish. When this had solidified, 1ml T C I00 (5% FCS) was added over 
the overlay and the dishes were incubated at 28°C in humidified conditions for 
five days.
To analyse the plaque assay, X-gal and neutral red stain were used in 
order to visualise all plaques. Recombinant plaques were colourless, whereas 
non-recombinant plaques produced a blue colour on incubation with X-gal.
The liquid medium was removed from the overlay, and replaced with 
lm l T C I00(5% FCS) containing 12pi X-gal (made up as described 3.2.4). This 
was incubated at 28°C for three hours, after which lm l neutral red stain (stock 
0.5% w/v in water, filter sterilised, diluted 1 in 20 with PBS before use) was 
added, and the incubation continued for a further two to three hours. The 
liquid stain was then removed, and the dishes drained and inverted, in the dark, 
for at least two hours (or overnight, if  plaques not clear).
Plaques were identified, and putative recombinants microscopically 
examined to ensure that there were no blue cells present. At least six, well 




The selected plaques were "picked" by removing a plug of agarose overlay 
from a plaque, containing virus particles, using a sterile glass Pasteur pipette, 
into a sterile bijou bottle containing 5ml medium (TC100/5% FCS). This was 
vortexed to disperse virus particles from the agarose plug into the medium. 
These "plaque-picks" were stored at 4°C.
Twelve 35mm dishes of cells (seeded at lx  106/dish one day earlier) 
were prepared for each plaque purification, plus two dishes as controls ( to be 
"inoculated" with medium alone). Serial dilutions were made of each plaque 
pick (including "neat", 101, 10 2, and 10*3, diluted in TC100/5% FCS), and 100 
fd of each used to inoculate dishes of cells (three dishes per dilution).
Following a five day incubation at 28°C (under humidified 
conditions) the dishes of cells were stained with X-gal and neutral red stain, as 
described in section 2.2.2.5. The plaques were inspected, to identify any 
contamination with "wildtype" virus (identified by any blue colouration of cells 
or overlay). W ell isolated white plaques were picked (one from each initial 
plaque pick assay set) to ensure a single phenotype; and subjected to another 
round of plaque assay if  contamination was detected or suspected.
2 2 2 .1  PRODUCTION OF SMALL VIRUS STOCKS
Because the titre of recombinant viruses was generally found to be 
very low by this stage (as determined by titration plaque assay, section 2.2.2.9), 
production of small "passage 1" and "passage 2" stocks was necessary before 
further analysis could be undertaken.
25cm2 tissue culture flasks were prepared one day before use, with 1 
x 106 cells/flask. The medium was removed, and the cells inoculated with 400 
j l i I  plaque-pick inoculum for one hour at room temperature. Once the inocula 
had been replaced by 4ml T C I00/5% FCS per flask, the flasks were incubated
75
at 28°C for up to seven days. Cells were inspected daily. I f  most of the cells 
showed signs of virus infection (ill-defined, highly crenellated edges, cells 
beginning to detach from the plastic) by three or four days post infection, the 
medium was harvested to a bijou bottle. Such infection indicates a sufficiently 
high titre for analysis of recombinant virus and/or product, and these stocks 
were not further passaged before analysis. I f  only a small proportion of the 
cells showed evidence of infection by this time, the medium was harvested at 
seven days post infection, and lm l of this used to inoculate a fresh flask of cells 
for the production of passage 2 virus for analysis.
2.2.2.9 TITRATION OF VIRUS STOCKS BY PLAQUE ASSAY
Determination of virus titre (plaque forming units, pfu per ml) was 
carried out by plaque assay, using the basic assay protocol as described in 
section 2.2.2.5, with minor modifications. The dilutions required to assay a 
virus stock would usually be serial 10-fold from 10~3 to 10-7, made in 
TC100/5% FCS, performed in duplicate, using lOOjul inoculum/dish. Assay 
dishes were only stained with neutral red stain, since the purity of the virus had 
been determined.
The stained cells were analysed, and the single dilution showing the 
maximum number of individual plaques it was possible to count, was used for 
the titre determination. An acceptable titre for a large "high titre" stock was 
considered to be >2 to 3 x 107.
2.2.2.10 PREPARATION OF (INFECTED) CELL LYSATES FOR ANALYSIS OF 
PROTEINS
One 35mm dish per putative recombinant virus, plus two dishes for 
control conditions (one for a "mock" infection, using medium alone, and one
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for infection with "wildtype" virus) were seeded with 1 x 106 cells each one 
day before use.
The medium was removed and each dish was incubated for one hour 
at room temperature with 200jnl of the appropriate inoculum. The inoculum 
was replaced with 1.5ml T C I00/5% FCS, and incubated under humidified 
conditions at 28°C, for the required time (for first analysis, usually 72 hours).
The cells were scraped into the medium using a large pipette tip, and 
transferred to a 1.5ml microcentrifuge tube. The cells were pelleted at low 
speed for one minute. The pellet was washed in PBS, and re-pelleted. All 
traces of PBS were removed, and the pellet resuspended in 50pl TE buffer. An 
equal volume of 2X PAG dye mix (10% SDS, 25% 2-mercaptoethanol, 50mM 
Tris-HCl, pH 6.8, 25% glycerol, a trace of bromophenol blue) was added, and 
boiled for 5 minutes. Samples not analysed immediately were stored at -20°C.
The lysates were then analysed by SDS-PAGE, and Western blotting, 
as described in sections 2.2.3.2 and 2.2.3.3.
After the initial analysis of recombinant virus proteins, all glucose transporter 
recombinant viruses were solubilised in the dye-buffer described in section 
2.2.3.2.
2.2.2.11 PREPARATION OF fflGH TITRE VIRUS STOCKS
On the positive identification of a true recombinant virus a large stock 
was made for use in all further experiments using that virus.
A 200ml Spinner culture was prepared (as described in section
2.2.2.2) and grown until the cell density reached 5 x 105/ml. The cells were 
inoculated at a low M OI (multiplicity of infection) (0.1 to 0.2 pfu/cell), using 
the least passaged virus stock available that would achieve this (as estimated by 
titrating plaque assay, section 2.2.2.9). Infection was carried out by adding the 
required amount of inoculum to the culture, and returning to stir at 28°C. 
Infected cultures were incubated for 5 to 6 days (samples microscopically
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analysed and counted using a haemocytometer daily, for determination of 
infection state). Supernatants containing the virus were harvested by 
centrifugation of the culture for five minutes at 10,000 rpm, and the removal of 
the supernatant from the cells. Supernatants were stored at 4°C. Two lml 
aliquots of each important virus passage were stored at -70°C.
2.2.3 PROTEIN ANALYSIS
2 .2 .3 .1  CELL MEMBRANE PREPARATION
Cells in 35mm dishes were seeded at a density of 1x10^ cells/dish, 
one day prior to infection. The medium was removed, and the cells incubated 
with the appropriate inoculum for one hour. The medium was replaced, and 
the infected cells were incubated at 28°C for the required time (usually 48 or 
72 hours).
The cells were scraped from the dishes, and pelleted gently in a 
microcentrifuge tube. The pellets were resuspended in PBS, and repelleted. 
This pellet was resuspended in 250pl ice cold TES buffer (lOmM Tris-HCl; 
5mM EDTA; 250mM sucrose; pH 7.2). Samples were stored on ice during the 
remaining procedure. Samples were homogenised, using 20 strokes of an 
electric Teflon homogeniser, transferred to a 3ml ultracentrifuge tube, and the 
volumes of each sample made up to 3ml by dilution and washing with ice cold 
TES buffer. Samples were spun at 100,000 g at 4°C, for 20 minutes, using a 
Beckman bench top micro-ultracentrifuge, and resuspended in lOOpl TES 
buffer.
The 100,000 gmax fraction was taken as being the total membrane 
material of the cells. Where stated in the text, centrifugation at 16,000 gmax 
was used. This was taken as being a plasma membrane fraction.
Membrane samples for labelling studies were preferably used 
immediately, or stored at -70°C overnight. Samples for use in SDS-PAGE and
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Western blotting only were stored in electrophoresis sample buffer (section 
2.23.2) at -20°C, until required.
2.2.3.2 SODIUM DODECYL SULPHATE POLYACRLAMIDE GEL ELECTROPHORESIS 
(SDS-PAGEl
Electrophoresis in the presence of SDS was performed using a 
method based on that of Laemmli (1970). Gels of 10, 12, or 15% 
polyacrylamide were used, made up using 0.248M Tris-HCl (pH 8.7) buffer, 
and polymerised by the addition of ammonium persulphate and N,N ,N ',N - 
tetramethylethylene diamine (TEMED). The slab gel was poured, and overlaid 
with water-saturated butanol, until the gel had set. The butanol was then 
removed, and the top of the gel rinsed with distilled water. A 4% 
polyacrylamide stacking gel was made, using 0.345% Tris HC1 (pH 6.8) buffer, 
and polymerised using ammonium persulphate and TEMED, as for the 
resolving gel, and a comb inserted to form the sample wells.
The protein samples were mixed with 6M urea sample buffer (10%  
SDS, 6M urea, 0.05% bromophenol blue ), and incubated at room temperature 
for 20 minutes prior to loading.
Standard molecular weight markers were made up according to 
manufacturers instructions (Pharmacia LKB), and boiled in sample buffer 
(12.5% v/v 0.5M Tris-HCl (pH 6.8); 20% v/v glycerol, 2% w/v SDS; 5% v/v |3- 
mercaptoethanol; and 0.00025% bromophenol blue) for five minutes before 
loading. Prestained markers were used when the gel was to be subjected to 
Western blotting. These were heated to 40°C for 10 minutes before loading, 
according to manufacturers’ instructions.
The gel was run at a constant current overnight (the current 
depending on the percentage polyacrylamide in the gel, and whether one or two 
gels were being run on the apparatus at the time. Usually 20 to 25 mA/gel).
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Following electrophoresis, initial protein analysis gels would usually 
be stained with Coomassie blue stain to determine whether the recombinant 
virus-expressed protein could be visualised in this way. Gels were stained for 
one hour at room temperature in Coomassie blue stain ( 0.25% Coomassie blue 
in 30% methanol, 10% acetic acid, 60% ddH20 ) and then destained in several 
changes of 30% methanol, 10% acetic acid, 60% ddH20 , also at room 
temperature, until the background was adequately destained.
2 .2 .3 .3  WESTERN BLOTTING OF PROTEINS FOLLOWING SDS-PAGE
A 3mm thick 10 or 12% SDS polyacrylamide gel was electrophoresed 
as described (section 2.2.3.2), removed from the glass plates, and trimmed 
using a razor blade.
3mm filter paper was cut to the size of the gel (12 pieces), as was one 
nitrocellulose sheet. Filter paper and nitrocellulose were pre-soaked in 
Western blotting buffer (48mM Tris-HCl; 39mM glycine; 0.375% w/v SDS, 
20% v/v pure grade methanol; pH 9.2).
The filter paper, nitrocellulose membrane and gel were carefully 
assembled onto a semi-dry western blotting apparatus. The cathode was 
attached, and the transfer carried out at a constant 0.85mA/cm2 (gel size), for 
an hour.
Protein transfer was briefly assessed by staining the membranes with 
Ponseau S stain (0.1% w/v Ponseau S; 3%w/v TCA) (if this was still unclear, 
the gel was stained with Coomassie stain, to assess the remaining protein). The 
Ponseau S was washed off with PBS-T buffer (PBS with 0.05% Tween-20 
{C12E9}); and the membrane incubated at room temperature, with gentle 
shaking, in blocking buffer (PBS-T with 5% casein), for one hour.
The membrane was washed briefly in PBS-T, then incubated with the 
detecting antibody, with shaking, for at least an hour at room temperature. The 
antibody was diluted to the required amount, in PBS-T with 1% casein. The
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membrane was rinsed briefly (PBS-T), followed by three ten minute PBS-T 
washes, with agitation. Incubation with the HRP (horse radish peroxidase)- 
labelled second antibody, diluted 1:2000 in PBS-T, was at room temperature, 
for at least an hour, with gentle shaking. The membrane was rinsed briefly, and 
then subjected to three ten minute washes, as before.
Immunoreactive proteins were detected using an ECL (enhanced 
chemiluminescence) Western blotting detection system, following the 
manufacturer’s protocol. Processed membranes were subjected to 
autoradiography, using "hyperfilm" X-ray film, for 15 seconds in the first 
instance, with the period being adjusted according to the appearance of the first 
developed autoradiograph.
2 .2 .3 .4  QUANTITATIVE IMMUN OBLOTTIN G
When some degree of quantitation was required from a Western blot, 
iodinated (125I) protein A was used as the detection method, and parts of the 
procedure varied from those used in the ECL- detection Western blots.
The SDS-PAGE and transfer methods were as described (section
2.2.3.3). The blocking incubation was carried out at 4°C overnight in PBS-T 
with 3% casein. Whilst the washing procedures and the first antibody dilutions 
remained the same, the blot was incubated with the first antibody for at least 
two hours at room temperature. 125I protein A [0.1 pCi/ml] in PBS-T, 1% 
casein replaced the second antibody, and the blot was incubated with this at 
room temperature for two hours, with gentle agitation. The washing following 
this step involved six washes of five minutes each, with PBS-T. The blot was 
then air dried, and wrapped in cling film. The blot was then subjected to 
autoradiography at -80°C, using intensification screens; overnight in the first 
instance, and adjusted according to this result to optimise the clarity of the 
result.
U
On attaining a suitable autoradiograph from the blot, this was used as 
a template, to determine the relative positions of the transferred detected 
protein species. The appropriate, identified areas of nitrocellulose were the cut 
out and the radioactivity of each section was measured using a gamma counter. 
Areas of the blot away from any immunoreactive product (for example, within 
a sample lane but lower down than the immunoreactive product detected in that 
lane), of an equivalent size to the sample pieces, were taken and counted.
These "background" control figures were subtracted from the experimental 
figures.
A series of known concentration standards (protein- depleted red 
blood cell membranes, prepared according to a method described by Gorga and 
Lienhard, 1981) were electrophoresed on the same gel as the experimental 
samples, and calculations of labelled protein concentration of each detected 
species were carried out directly on the basis of the measured standards’ 
radioactive content. "Background" samples were taken for the RBC standard 
samples, and these figures subtracted before calculations were made. 
Calculations were made on the basis of the glut 1 content of red blood cell 
membranes prepared in this way being 600 pmol/mg protein.
2.2.3.5 TIME COURSE OF PROTEIN EXPRESSION
Cells, seeded at lx l0^ cells/35mm dish one day in advance, were 
infected at a known constant M O I with the recombinant baculovirus under 
examination. Two dishes per time point were allowed. Dishes of both mock 
infected cells (medium only "inoculum"), and "wildtype" (AcNPViLacZ) virus 
of known M OI were also prepared.
Two dishes of recombinant virus-infected cells and one dish each of 
the control condition cells, were taken at each time point. (A visual microscopic 
analysis of the condition of the cells was made at this point). One dish of each 
condition, per time point was prepared as a cell lysate (see section 2.2.2.10,
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using 6M urea sample buffer). The remaining dish of cells was used to prepare 
membranes for analysis (see section 2.2.3.1). Each set of prepared samples 
was stored at -20°C until all time course samples had been collected.
Sets of samples were examined and taken at zero, six, 12, 18, 24, 36, 
42, 48, 60, 72, 96, and 120 hours post infection (hpi) .
Small samples of were retained for protein concentration estimation, 
before electrophoresis sample buffer was added.
Collected, prepared samples were subjected to SDS-PAGE. The 
control samples were stained using Coomassie blue. Recombinant vims 
infected samples were subsequently subjected to Western blotting using an 
appropriate antibody.
Samples were also subjected to quantitative immunoblotting (section
2.2.3.4), in order to determine the optimum expression of recombinant protein.
2 .2 .3 .6  IMMUNOPRECIPITATION OF SAMPLES
Protein A.sepharose (7mg per sample- a sample corresponding to one 
35mm dish of cells, or membranes from two such dishes) was swollen in cold 
5mM phosphate buffer, pH 7.2, by gentle mixing (by rotation) at 4°C for 15 
minutes. The protein A:sepharose was loosely pelleted at low speed in a 
microcentrifuge, and washed twice with cold phosphate buffer (with 
repelleting).
Anti-glut 1 antiserum, 80|il/sample, was added to the washed Protein 
A isepharose, and resuspended in phosphate buffer to a total microcentrifuge 
tube volume of 1.3ml. The mixture was allowed to coagulate by gentle mixing 
at 4°C for two hours.
The mixture was loosely pelleted and washed twice as before. An 
equal volume of resuspended mixture was added to each prepared sample ( in 
microcentrifuge tubes), and gently mixed at 4°C for two hours, to 
immunoprecipitate the sample.
83
The immunoprecipitate was gently pelleted (at low speed, in a 
microcentrifuge) and washed with lm l wash solution (0.2% thesit detergent 
(nonaethylene glycol dodecyl ether; C12E9), with mixed proteinase inhibitors; 
(antipain, aprotinin, pepstatin A and leupeptin, each at lpg/ml), in ice cold 
5mM phosphate buffer, pH7.2). This was done six times (if  an observable 
reduction of pellet volume was noted, this was reduced to four washes).
The final pellet was resuspended in 150jnl 6M urea sample buffer 
(10% SDS, 6M urea, 0.05% bromophenol blue), and gently mixed at 4°C for 
ten minutes. The sepharose was pelleted by microcentrifugation before the 
sample was loaded on an SDS-PAG for electrophoresis.
Immunoprecipitated samples were subjected to SDS-PAGE, as 
described in section 2.2.3.2; but using a 3mm thick gel, and a broad-tooth comb 
to ensure sufficient size to accommodate the whole sample.
2.2.3.7 CYTOCHALASIN B LABELLING
Cytochalasin B labelling experiments were carried out on either 
membrane preparations of infected cells (as prepared by the protocol in section 
2.2.3.1), or on whole cells. Cells, in 35mm culture dishes, were infected with 
the appropriate virus(es) for the required period. The medium was removed, 
and centrifuged at low speed, so that detached cells could be washed in PBS, 
re-centrifuged, and returned to the dish, after the monolayer had been washed 
twice with PBS buffer. The detached cells were returned to the dish in a 
minimal volume of PBS.
1.6pCi/ml3H-Cytochalasin B (sp. act. 19.6 Ci/mmol); 1CMM 
Cytochalasin E, and lOOmM D-glucose -where appropriate, were added to a 
microcentrifuge tube, in a total volume of 150pl (made up with PBS). The 
photosensitive cytochalasin B was added last, in the dark. The mixture was 
gently pipetted onto the monolayer, and irradiated with U V  light for 45 
seconds, at room temperature, lm l solubilisation buffer (2% thesit detergent,
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with mixed protease inhibitors (as used in section 2.2.3.6), in 5mM phosphate 
buffer pH 7.2) was added to each dish. The cell / solubilisation buffer mixture 
was transferred to a microcentrifuge tube and mixed, by gentle pipetting to 
solubilise the cell matter. The tubes were incubated for 20 minutes, then 
microcentrifuged at high speed at 4°C for 20 minutes. The supernatant was 
removed to a fresh tube, and immunoprecipitated (see section 2.2.3.6).
The samples were electrophoresed on 3mm thick 10 or 12% SDS- 
polyacrylamide gels.
The gels were lightly stained using Coomassie blue stain, and 
destained such that the positions of the sample lanes could be determined, and 
that the positions of the molecular weight standard protein markers could be 
seen.
Each sample lane was carefully isolated, using a razor blade, and 
accurately cut into 0.5mm slices (using carefully spaced razor blades set in a 
perspex block). Each slice was transferred to a scintillation vial, and incubated 
in an oven at 80°C until the slice was dry and hard. The positioning of the 
molecular weight standards was noted relative to the slicing of the experimental 
lanes. The dried sample slices were dissolved by a two hour incubation at 80° 
C, in 0.5ml of hydrogen peroxide, 5% ammonia. The vials were allowed to 
cool, and scintillation fluid was added, and the radioactivity of each sample 
was counted using a scintillation counter. The results were analysed 
graphically, relative to the molecular weight standards.
2.2.3.8 ATB-BMPA LABELLING
As for Cytochalasin B labelling, ATB-BMPA labelling was carried 
out on either membrane samples, or whole cells.
The cells were washed twice in PBS (or, if  membranes, membrane 
samples from two 35mm dishes were resuspended in PBS). The cells were 
incubated with lOOjuCi ATB-[-2-3H]-BMPA photolabel in a total volume of
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300pl PBS, in darkness, at 18°C. The cells were then irradiated ( in 35mm 
dishes) for 45 seconds in a Rayonett photochemical reactor, lml of Thesit 
detergent buffer per sample (2% C12E9 in 5 mM sodium phosphate pH 7.4, with 
mixed proteinase inhibitors as described in section 2.2.3.6) was used to 
solubilise the cells or membranes. From this point onwards the procedure used 
is as section 2.2.3.7. following cell solubilisation.
2 .2 .3 .9  PROTEIN ESTIMATION ASSAY
The BCA protein estimation assay was used. BSA standard protein 
concentrations of 0, 2, 4, 6, 8, and lOpg were prepared by diluting 2mg/ml 
stock BSA to lmg/ml using 0.2M NaOH. The standards were each made to 10 
pi volume using 0 .1M NaOH.
5pi of sample protein was made up to lOpl with 0.2M NaOH.
10ml of reagent A  (1% BCA-N02 detection reagent, 2%
Na2C03.H20  [11.5g (4.6%) NaC03. 10 H20 ], 0.16% Sodium tartrate, 0.4% 
Sodium hydroxide, and 0.95% NaHC03: Made upto pH 11.25 using 1M 
NaOH, and filtered through a 0.7pm filter (Millipore).) was mixed with 200pl 
of reagent B (4% CuS04, filtered through a 0.7pm filter ( Millipore)) to make 
reagent C.
200pl reagent C was added to each sample, including the standards, 
and incubated at 37°C for 30 minutes.
The absorbence was determined spectrophptometrically, using a 
microtitre plate reader, at 650nm. Sample protein concentrations were 
estimated using the standard protein samples. A ll samples were analysed in 
duplicate, and means of readings used in the estimations.
2.2.3.10 HEXOSE TRANSPORT ASSAYS
Cells were infected with virus (at high MOI, inoculated for one hour 
at room temperature) for the required period, in 75cm  ^flasks. 0.3pCi ^H-2-
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deoxy-D-glucose was made up to a lOOpM concentration with unlabelled 2- 
deoxy-D-glucose. If  inhibitor ( fructose, glucose, or both) was added, this was 
to a concentration of 0.3M.
Infected cells were PBS washed twice, and the cells of each condition 
were counted, in order to account for differences in cell death and growth etc. 
Samples were also retained for protein concentration estimation.
Transport was followed at 28°C for the required periods. Zero time, 
two minutes, and five minutes were the usual times, per condition. The assay 
was stopped by the addition of 3ml stop solution (lOmg/ml phloretin in PBS). 
The cells were pelleted at 20 OOOrpm for two minutes at 4°C. The supernatant 
was removed, and the cell pellets resuspended in a further 3ml stop solution. 
The cells were re-pelleted and solubilized in 500pl 10% TCA. The soluble 
material was transferred to a scintillation vial, scintillant was added, and 
samples were counted using a Packard 1500 scintillation counter.
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CHAPTER ?.
CONSTRUCTION AND PRODUCTION OF RECOMBINANT
VIRUSES
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A rabbit GLUT1 cDNA (Asano et al, 1988) was used as source DNA 
for all the experiments described in this thesis. Once produced and identified, 
the constructs were co-transfected into the Sf9 insect cells together with 
linearised baculovirus (AcMNPV) DNA for the production of recombinant 
baculoviruses, which were then identified by DNA and protein analysis.
3.1.1 PRODUCTION OF WHOLE GLUT1 BACULOVIRUS CONSTRUCT
A 2610 base pair fragment was isolated from pUC19:GLUTl, using 
Eco RI sites in the 5' and 3’ noncoding regions. This corresponded to base pairs 
-123 to 2487 (where base pairs 1 to 1600 represent the GLUT1 coding region), 
and incorporated 123 5' non-coding base pairs, and 888 base pairs of the 3' non­
coding region.
This was gel purified (by Gene Cleaning), and ligated into Eco RI 
digested (non-dephosphorylated) pVL 1392 baculovirus transfer vector. This 
was then used to transform competent E.coli. A  number of colonies were 
picked and small scale plasmid preparations were made. Each of these was 
digested with Eco RI, and three were found to contain a fragment of an 
appropriate size, when visualised by gel electrophoresis (see figure 3.1).
Further restriction analyses were carried out to confirm the identity of the 
band, and to determine it's orientation in the vector. Figure 3.2 represents a 
partial restriction map of the pVL:GLUTl construct, and figure 3.3 outlines the 
restriction analysis.
Since all of the three clones were positively identified as GLUT1 
DNA, and found to be correctly orientated, two were chosen to be amplified as 
large scale plasmid preparations.
3.1.2 PRODUCTION OF RECOMBINANT BACULOVIRUS E4.2
The transfer construct pVL:GLUTl was co-transfected into insect cells 
with linearised AcNPV DNA, and the resulting virus progeny was screened for
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1 2 3 4 5
Lane 1 Eco RI digested pVL1391:GLUTl clone
Lane 2 Eco RI digested pVL1391:GLUTl clone
Lane 3 Eco RI digested pVL1391:GLUTl clone
Lane 4 Eco RI digested pVL1392
Lane 5 pst 1 digested X  DNA
Figure 3.1 Agarose gel electrophoresis of Eco RI digested pVL1392:GLUTl 
clones 4, 5 and 6, identified from twelve minipreps (photograph not available) 
as positives. Identification of Eco RI fragments of -2610 base pairs, 
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Eco RI
4055 
Eco RIpvu II 5385
4661 pvu II
4893 Sma I5017 
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Figure 3.2 Construction of vector pVL1392:GLUTl from pVL1392, 
containing the GLUT1 Eco RI fragment from pUC19:GLUTl, inserted in the 
correct orientation. Limited restriction enzyme recognition sites, used for 
analysis and orientation determination, are shown (not drawn to scale).
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Figure 3.3 Agarose gel electrophoresis of restriction digestion of
pVL1392:GLUTl clones 4, 5 and 9, identified as putative positives, with 
restriction enzymes Eco RI, Bst Eli, pvu II and pst I. Single enzyme digestions 
to determine the orientation of the GLUT1 Eco RI fragment in each of the 
clones. See figure 3.2 for partial restriction maps. Listings of the digests 
performed are over the page. The restriction profiles of each of the three clones 
show that all correspond to the correct orientation.
Digests shown in figure 3.3
Lane 1 pst I digested X DNA.
Lane 2 pvu II digested pVL1392:GLUT 1 clone 9
Lane 3 pvu II digested pVL1392:GLUTl clone 5
Lane 4 pvu II digested pVL1392:GLUTl clone 4
Lane 5 Bst E li digested pVL1392:GLUTl clone 9
Lane 6 Bst E li digested pVL1392:GLUTl clone 5
Lane 7 Bst E li digested pVL1392:GLUTl clone 4
Lane 8 Eco RI digested pVL1392:GLUTl clone 9
Lane 9 Eco RI digested pVL1392:GLUTl clone 5
Lane 10 Eco RI digested pVL1392:GLUTl clone 4
Lane 11 Eco RI digested pVL1392
Lane 12 Eco RI fragment of GLUT1 from pUC19:GLUTl 
Lane 13 pst I digested X DNA
Lane 14 pst I  digested pVL1392:GLUTl clone 9
Lane 15 pst I digested pVL1392:GLUTl clone 5
Lane 16 pst I digested pVL1392:GLUTl clone 4
Lane 17 pst I digested pVL 13 92
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recombinants by plaque assay. Eight putative recombinants were picked, and 
subjected to a round of plaque purification (see section 2.3.6) to ensure there 
was no contamination of the recombinants with wildtype virus. Small passage 
2 stocks were made of four of the putative recombinant viruses, which were 
then subjected to a second round of plaque purification. Cells were then 
infected with these putative recombinants, and cell lysates made at 72 hpi 
(hours post infection), which were subjected to SDS-PAGE followed by 
Western blotting using the anti-C-terminal anti-peptide antibody. Figure 3.4 is 
a Western blot analysis of two putative recombinants. Clearly, virus E4.2 is 
expressing a protein of around 50kDa, which is highly immunoreactive with the 
anti-GLUTl antibody. The virus was subjected to a third round of purification 
plaque assay, and passaged again, until a titre of at least 1 x 107 pfu/ml had 
been achieved. Large stocks were made in 250ml Spinner culture. Virus titres 
were determined by plaque assay, for each passage, and are summarised in 
table 4.1 below. The final passage of E4.2 ,p3s ( "s” denoting spinner culture 
derivation) which was used in all subsequent experiments was found to have a 
titre of between 8.5 x 106 pfu/ml and 2.6 x 107 pfu/ml (estimates from two 
separate assays)
Virus passage number 
(monolayer or spinner culture 
derived, m or s.)
titre (pfu/mD
Om 2.00 x 103
2m 2.05 x 106
3m 6.50 x 106
3 s (first est.) 2.60 x 107
3s (second est.) 8.50 x 106
Table 4.1 Recombinant baculovirus E4.2 titres
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1 2 3 4 5 6 7 8
106 kDa 
<■80 kDa
^ 4 9 .5  kDa
<-32.5 kDa 
<-27.5 kDa
^  18.5 kDa
Figure 3.4 Western blot analysis of Sf9 cell lysates at 72 hpi. Lane 1; 
prestained markers; Lane 2 mock infected Sf9 cells; Lane 3, AcMNPV:LacZ 
infected cells; Lane 4 erythrocyte membranes; Lane 5 cells infected with 
putative recombinant virus E4.3; Lane 6 cells infected with putative 
recombinant E4.7; Lane 7 cells infected with putative recombinant E4.2. The 
blot was detected using the anti C-terminal anti-GLUTl antibody. Note that 
virus E4.2 has a strong immunoreactive band at around 50 kDa, in contrast to 
the strong immunoreactive band of ~ 55 to 65 of the erythrocytes.
3.2.1 CONSTRUCTION OF GLUT1 N-TERMINAL BACULOVIRUS.
The N-terminal "half' of the GLUT1 gene was isolated and amplified 
by PCR. Figure 3.5a represents the approximate positioning of the 
oligonucleotides used in the PCR reaction, in relation to the two-dimensional 
protein structure.
Oligonucleotide GT7 was made to the last 25 5' non-coding base pairs 
of the GLUT1 gene, modified to incorporate an Eco RI restriction enzyme 
recognition site (see figure 3.5b). The gene's own start codon was retained in 
the PCR product, and was not included in the oligonucleotide.
A complementary strand oligonucleotide, GT8 was designed to an area 
of the cDNA from base pairs 907 to 939; corresponding to part of the large 
cytoplasmic loop between transmembrane domains six and seven, as indicated 
on the protein structure representation in figure 3.5a. This construct was 
designed so that there would be an overlap of this construct with the C-terminal 
"half' construct of 11 amino acids at the central loop. This oligonucleotide was 
designed to incorporate a Bgl II site, and two stop codons (replacing those 
coding for Phe 263 and Ser 265), such that the last amino acid encoded is Ala 
267. Figure 3.5c outlines the design of GT8.
The PCR reaction products were analysed by agarose gel 
electrophoresis. A  clear band corresponding to an 810 bp product was found, 
corresponding to the expected size of GT78 (see figure 3.6). This was gel 
purified, and cloned into the plasmid pT7blue, on blunt ends (see sections \
2.2.10 and 2.2.11). Small scale plasmid preparations of the resulting clones 
were analysed by restriction digestion with Eco RI and Bgl II (still contained 
within the insert, since cloning into pT7blue retained the restriction sites 
encoded by the oligonucleotides), in order to identify the GT78 insert. Three 
clones contained inserts of the appropriate size. Samples of each were 








ACT GCC AGA ATT CCT AGC GCA GGG C
'-------- »-------------  y---------v------ —----------------
Eco R I site
3’ noncoding 3’ noncoding GLUT1 (GLUT1 original Met
GLUT 1 start codon immediately follows primer
3.5 b. Oligonucleotide GT7
GAT GGG CTA CAT CTA GGC AGG TCA GCG GAA GAG
stop stop
Bgl II site 
Complementary sequence to 




Complementary sequence to 
GLUT1 coding bases 926 to 907.
Figure 3.5 a. Cartoon representation of the two-dimensional structure of the 
GLUT1 protein, showing representations of the relative positioning of the PCR 
oligonucleotides GT7 and GT8. b. Sequence and design of oligonucleotide 
GT7. c. Sequence and design of oligonucleotide GT8.
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Lane 1 pst I digested X  DNA
Lanes 2 & 3 PCR products using GT7 and GT8
Figure 3.6 Agarose gel electrophoretic analysis of PCR products from 
GLUT1 cDNA template (pUC19:GLUTl) using oligonucleotides GT7 and 
GT8. PCR reaction involved 30 cycles as described in section 2.2.7.
analysed by agarose gel electrophoresis. Clone 9 was found to produce a clear 
product at the appropriate size (see figure 3.7). For further confirmation, this 
construct was subjected to restriction digestions. Figure 3.8 shows a limited 
restriction map of the construct, showing the enzymes used in the analysis. 
Figure 3.9 shows the agarose gel analysis of the digests, which positively 
identify clone 9 as containing the GT78 insert. A large scale plasmid 
preparation was carried out, and the clone designated pT7blue:GT78. The 
GT78 insert was removed by sequential overnight restriction digestion with Eco 
RI and Bgl II, and gel purified, including additional phenol:chloroform 
extraction and ethanol precipitation steps in the Gene Clean procedure, to 
ensure no vector contamination. Baculovirus transfer vector pVL1393 was also 
digested with these enzymes.
O f 96 colonies from the cloning procedure, 24 were picked, small scale 
preparations made, and subjected to digestion with the two restriction enzymes 
used in the cloning. Figure 3.10 shows the results of electrophoresis of 12 such 
digests, and illustrates that every clone contains an insert of the appropriate 
size. A single representative clone was selected for further analysis. Figure 
3.11 outlines the restriction digests carried out, and the confirmation of the 
identification of GT78. Figure 3.12 shows limited restriction site information 
for the plasmid pVL1393:GT78. A  large scale plasmid preparation was made, 
and designated pVL1393:GT78.
3.2.2 PRODUCTION OF RECOMBINANT BACULOVIRUS N1
Medium from the co-transfection of AcNPV DNA with 
pVL1393:GT78 transfer construct was screened by plaque assay. Six putative 
recombinant viruses were picked, and the remaining co-transfection medium 
retained. These were each subjected to a purification plaque assay, from which 
nine white plaques were taken, and subjected to another round of plaque assays 
to ensure their purity. These viruses were passaged to small stocks and three
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Lane 1 PCR using pT7blue:GT78 clone 10
Lane 2 PCR using pT7blue:GT78 clone 8
Lane 3 PCR using pT7blue:GT78 clone 9
\
Lane 4 pst I digested X  DNA
Figure 3.7 Agarose gel electrophoresis of PCR products, using putative 
pT7blue:GT78 cloned DNA as templates (ljrl of standard small scale DNA 
prep.), and using oligonucleotides GT7 and GT8 as primers (as described in 
section 2.2.7). Clone 9 is clearly identified as having a clear band 














Figure 3.8 Schematic representation of construct pT7blue:GT78, from the 
vector pT7blue, and the PCR product GT78. Restriction recognition sites used 







1 2 3 4 5
Bam HI and pst I double digest of pT7blue:GT78 clone 9 
Bam HI and BstEII double digest of pT7blue:GT78 clone9 
Eco RI and pst I double digest of pT7blue:GT78 clone 9 
Eco RI and Bgl II double digest of pT7blue:GT78 clone 9 
pst I digested X  DNA
Figure 3.9 Restriction digest analysis of pT7blue:GT78 clone 9. Digestion 
with Eco RI and Bgl II, Eco RI and pst I, Bam HI and Bst Eli, and Bam HI and 
pst I.
1 2 3  4 5 6 7 8 9 10 11 12 13 14 15
16 17 18 19 20 21 22 23 24 25 26 27
Figure 3.10 Agarose gel electrophoresis of restriction digestion of putative 
pVL1393:GT78 clones, with restriction enzymes Eco RI and Bgl II (enzymes 
used in the directional cloning of GT78 into the vector pVL1393). Lanes 1, 15 
and 27 represent A, DNA digested with pst I, as a molecular size marker. 12 
clones have been analysed. On the top row, from lane 2, undigested then 
double digested DNA has been loaded alternately, for each clone. On the 
bottom row, double digested then undigested DNA for each clone has been 
loaded from lane 17. Lane 16 represents the double digestion of one clone 
(corresponding undigested sample not shown). Every clone analysed was 
found to contain a fragment of the appropriate size (-810 base pairs).
1 2 3 4 5 6 7 8 9  10
1 2 3 4 5 6 7 8 9  10
Lane 1 pst I digested X  DNA
Lane 2 Eco RI & pvu II double digested pVL1393/ pVL1393:GT78
Lane 3 Sma I & Eco RI double digested pVL1393/ pVL1393:GT78
Lane 4 Bam HI & Bgl II double digested pVL1393/ pVL1393:GT78
Lane 5 Eco RI & Bgl II double digested pVL1393/ pVL1393:GT78
Lane 6 Sma I digested pVL1393/ pVL1393:GT78
Lane 7 pvu n  digested pVL1393/ pVL1393:GT78
Lane 8 Bam HI digested pVL1393/ pVL1393:GT78
Lane 9 Undigested pVL1393 or pVL1393:GT78.
Lane 10 pst I digested X  DNA
Figure 3.11 Agarose gel electrophoresis of restriction digest analysis of a 
pVL1393:GT78 clone, using restriction enzymes Bam HI, pvu II, Sma I, Eco RI 
and Bgl II, Bam HI and Bgl II, Sma I and Eco RI, and Eco RI and pvu II. The 
lower part of the gel represents the digests carried out on pVL1393 alone; and 













Sma I4376 pvu II
Figure 3.12 Schematic representation of construct pVL1393:GT78, from the 
vector pVL1393, and the GT78 Eco RI; Bgl 11 fragment from pT7blue:GT78. 
Restriction recognition sites used in analyses of the constructs are shown (not 
drawn to scale).
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were used to infect cells for Western blot analysis at 72 hpi, using the anti N- 
terminal anti peptide antiserum (see section 2.2.3). Figure 3.13 shows that Sf9 
cells infected with viruses N 1 and N 4.1 express an immunoreactive protein 
with an apparent molecular weight of 3 lkDa, which is within die predicted 
range for the protein from construct GT78. This protein is not present in mock 
infected cells, cells infected with the "wildtype" virus AcNPV:Lac Z, cells 
infected with virus E4.2, or cells infected with virus R12. None of the detected 
bands reacted with the anti C-terminal antibody.
Virus N 1 was passaged to p2, and a large passage 3 (p3) stock was 
produced in Spinner culture (p3s). The titre of this was 1.2 x 107, and this 
stock was used for all subsequent experiments involving the expressed N- 
terminal half of GLUT1.
The table below summarises the titres for each passage of virus N 1, 
monitored to gain a reasonable titre at as low a passage number as possible.
Virus passaee number
(monolayer or suspension culture derived)
titre (pfu/ml)
lm 1.05 x 106
2m 1.23 x 107
3s 1.20 x 107
Table 3.2 Recombinant baculovirus N 1 Titres
3.3.1 PRODUCTION OF C-TERMINAL HALF GLUT 1 BACULOVIRUS 
CONSTRUCT
The C-terminal half of GLUT1 was isolated by the PCR amplification 
of the corresponding area of the GLUT1 DNA. The PCR product was first
106
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Figure 3.13 Western blot analysis of Sf9 cells; mock infected (lane 1); 
infected with AcMNPV:LacZ virus (lane 2); recombinant baculovirus E4.2 
(full-length GLUT1) (lane 3); recombinant baculovirus R12 (C-terminal 
half)(lane 4); putative recombinant baculovirus N 1 (lane 5); putative 
recombinant baculovirus N 4.1 (lane 6). Lanes 1 to 6 detected using the anti-N- 
terminal half anti-GLUTl antibody. Lanes 7 to 11 represent the same samples 
as in lanes 2 to 6 (in the same order), but the anti-C-terminal GLUT1 antibody 
was used in the detection. All cell lysates were made at 72 hpi. Both putative 
recombinant baculoviruses N 1 and N 4.1 are shown to have an immunoreactive 
band of around 30 kDa Mr ,when using the anti-N-terminal half GLUT1 
antibody, which is appropriate to the size of the N-terminal "half " of GLUT1 
as designed. No immunoreactive product is detectable from infection with 
either of these viruses, when detecting with the anti-C-terminal anti-GLUTl 
antibody.
cloned into the plasmid pUC 18, and subsequently into the baculovirus transfer 
vector pVL941.
A 30 base oligonucleotide, GT2B was designed to be complementary 
to the 3' end of the GLUT1 coding sequence, as well as part of the 3' noncoding 
sequence, incorporating an Xba I restriction recognition site, and a translation 
stop codon (see figure 3 .14b).
GT5 is an oligonucleotide of 27 base pairs, corresponding to coding 
sequence in the central loop region of the GLUT1 protein (base pairs 883 to 
897), including a Bam H I site and translation start codon.(designed for 5’ to 3' 
amplification during PCR, as indicated by arrows in figure 3.14a). The design 
of GT5 is outlined in figure 3 .14c.
The oligonucleotides GT2B and GT5 were used in PCR reactions, 
following conditions outlined in section 2.2.7. 10% of the final reaction 
mixture was analysed by agarose gel electrophoresis. A  product, GT52, of the 
appropriate size (740 base pairs) was easily identifiable. Figure 3.15 shows 
GT52 against a fragment the size of the entire GLUT1 coding region (GT21). 
The 740bp band was excised, and purified by phenol, phenolxhloroform and 
chloroform extractions, and an overnight ethanol precipitation.
GT52 was digested overnight with Bam H I and cloned into pUC18 on 
the Bam H I cloning site. A clone containing an appropriately sized fragment 
was identified by small scale plasmid preparation from recombinant colonies, 
and restriction digestion with Bam H I. This clone was amplified by large scale 
plasmid preparation. A  sample of this DNA was digested with Bam H I for four 
hours and subjected to agarose gel electrophoresis. The GT52 fragment was 
gel purified (using the gene clean method), and further purified by ethanol 
precipitation.
This was finally cloned into pVL941 (a baculovirus transfer vector) on 
the Bam H I cloning site. Two clones containing a 740 base pair fragment were 
isolated and amplified as large scale DNA preparations. These clones,
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GT5
a. GLUT1
CTC GGA TCC A
Bam H I site
G GAG AAG AAG GTC ACC
Sequence corresponding to GLUT1 coding 
bases 883 to 987 
Translation start codon
b. Oligonucleotide GT5
GAG GCA GT G TCT AGA GCC TCA CAC TTG GGA
Xba I site 
Sequence complementary to 
3' noncoding GLUT1
V "




Figure 3.14 a. Simplified schematic representation of the proposed two- 
dimensional structure of the GLUT1 protein, showing the approximate relative 
positions of the oligonucleotides GT5 and GT2. b. Sequence and design of 
oligonucleotide GT5. c. Sequence and design of oligonucleotide GT2.
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Lane 1 pstl digested A DNA
Lane 2 GT52
Lane 3 GT21
Figure 3.15 Agarose gel electrophoresis of the PCR product from 
pUC19:GLUTl, using oligonucleotides GT2 and GT5 (PCR conditions given 
in section 2.2.7), shown against a PCR product representing the full-length 
coding region of glut 1 (1470 bp), GT21, and A, DNA digested with pst I, as a 
standard marker. A single band of -740 bp is clearly visible.
pVL941:GT52, 9 and 10, were subjected to restriction analysis, based on 
restriction sites known to exist in the C-terminal half of the original GLUT1 
cDNA. This analysis served as confirmation of the identity of the clones, as 
well as identification of whether the fragment was inserted into the vector in 
the correct orientation for expression. Figure 3.17 gives details of the digests 
carried out and figure 3.16 shows limited restriction maps of pVL 941 alone, 
and pVL941:GT52 with the GT52 insert correctly orientated for expression.
The digests confirmed the identity of both inserts as GT52, and showed 
pVL941:GT52 clone 9 to be in the correct orientation, and clone 10 to be 
incorrectly orientated.
3.3.2 PRODUCTION OF RECOMBINANT BACULOVIRUS R12
Following a similar procedure to those described in sections 3.1.2 and 
3.2.2, a number of putative AcNPV:GT52 recombinants were picked.
Following an arduous process which is discussed in section 3.4, virus R12 was 
finally isolated as expressing protein of -25  kDa that was highly 
immunoreactive with the anti C-terminal anti-peptide antibody. Figure 3.18 
illustrates protein species immunoreactive with this protein from mock infected 
Sf9 cells, erythrocytes, and Sf9 cells infected with a number of putative 
GLUT1 C-terminal half-expressing recombinant baculoviruses.
3m 6.00 x 105
4m 1.50 x 10«
5m 1.45 x 106
5s 1.25 x 107
Table 3.3 Recombinant baculovirus R12 titres
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Kpn I GT524752 
Bam HI
Figure 3.16 Schematic representations, showing limited restriction enzyme 
recognition positions of the baculovirus transfer vector pVL941 (top); and the 
construct pVL941 :GT52 (shown with the GT52 insert correctly orientated).
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1 2 3 4 5 6 7 8 9  10 11
Lane 1 pvu II digested pVL941:GT52 clone 10
Lane 2 pvu II digested pVL941:GT52 clone 9
Lane 3 pst I digested X  DNA
Lane 4 Bst Eli & Kpn I double digested pVL941:GT52 clone 10
Lane 5 Bst Eli & Kpn I double digested pVL941:GT52 clone 9
Lane 6 Bst Eli digested pVL941:GT52 clone 10
Lane 7 Bst Eli digested pVL941:GT52 clone 9
Lane 8 Hind m  digested X  DNA
Lane 9 Bam HI digested pVL941:GT52 clone 10
Lane 10 Bam HI digested pVL941:GT52 clone 9
Lane 11 Bam HI GT52 fragment excised from pUC18:GT52.
Figure 3.17 Agarose gel electrophoresis of restriction digests of 
pVL941:GT52 clones 9 and 10. The digests carried out are indicated above. 
The restriction digestion profiles of both clones positively identify them as 
pVL941:GT52. Digestion with pvu II, Bst Eli, and Bst Eli and Kpn I double 
digest show that only clone 9 is correctly orientated in the vector.









Figure 3.18 Western blot using the anti C-terminal anti-GLUTl antibody.
Sf9 cells were infected with either TC100 only (mock infection) (lane 1); 
AcMNPV:LacZ (lane 2); recombinant baculovirus R12 (lane 3); putative 
recombinant baculovirus R8 (lane 4); putative recombinant baculovirus R4 
(lane 5); or recombinant baculovirus R13 (lane 8)(each at passage 5); and 
lysates made at 72 hpi. Erythrocyte membranes (unclear) were run in lane 6. 
Other putative recombinant viruses were run in lanes 5 and 9. Viruses R12 and 
E13 clearly show immunoreactive protein species at around 25 kDa. Lanes 10 
and 11 more clearly demonstrate the immunoreactive profile of R12 infected 
cells, shown against RBC (lane 12)(separate Western blot). Equal quantities of 
total protein were loaded in all of the Sf9 cell lanes (for each gel). Molecular 
weight standards correspond to the blot showing lanes 10 to 12.
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3.4 DISCUSSION
The AcMNPV:GT52 construct was the first construct, chronologically, 
to be co-transfected into Sf9 cells. Initially, thirteen putative AcNPV:GT52 
recombinants were picked, and screened by immuno-dot-blot analysis, using 
the anti C-terminal anti peptide antiserum as detection. O f these, a number 
were used to infect cells which were then subjected to SDS-PAGE and Western 
blotting, as described. Virus R13 was chosen as producing good levels of 
expression of a 25 kDa GLUT1 antibody immunoreactive protein. However, 
despite passaging the virus in culture a number of times, the titre remained very 
low. The best titre attained (from the best estimate) was 3 x 106, at passage 5. 
Since the passage number is rather high (problems associated with spontaneous 
mutation and other genetic reorganisations are often associated with repeated 
passaging of viruses in culture), and the titre still low, this virus was finally 
abandoned in favour of another. R12 was screened later, and found to result in 
apparently improved levels of expression of the C-terminal half protein than 
R13.
Table 3.3 illustrates the problems of low titre that were experienced 
for virus R13. The titres measured for R12 were an improvement on this, and 
passaging to passage 5 (Spinner) produced a sufficiently high titre for further 
work, at 1.25 x 107.
1T5
Virus Passage number
(monolayer or spinner derived)
Estimated titre (pfu/ml)
R13 2s 245
R13 3m 3.00 x 102
R13 5m (1st est.) 3.00 x 106
R13 5m (2nd est) 1.00 x 104
R12 3m 6.00 x 105
R12 4m 1.50 x 106
R12 5m 1.45 x 106
R12 5s 1.25 x 107
Table 3.4 Comparison of titres of viruses R13 and R12
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CHAPTER4.
OPTIMISATION OF EXPRESSION AND QUANTITATION OF
PROTEIN PRODUCTS
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4.1 FULL LENGTH GLUT1 PROTEIN
Figure 3.4 (chapter 3) illustrates the positive identification of anti 
GLUT1 antibody reactive protein expressed by cells infected with the 
recombinant baculovirus E4.2. It is clear that the whole GLUT1 protein being 
expressed in this way shows a greater mobility than the GLUT1 protein 
expressed natively in human erythrocyte membranes. That is, where the native 
GLUT1 is seen as a smeary band with an Mj. of about 55 to 60 kDa, the E4.2 
protein, whilst also smeary, appears at a Mj. of about 50kDa.
4.1.1 QUANTITATION AND LOCALISATION OF GLUT1 PROTEIN 
EXPRESSION B YE4.2
In order to determine the level of GLUT1 expression being achieved in 
Sf9 cells by this vims, quantitative immunoblotting of an SDS-PAGE gel was 
carried out. This is shown in figure 4.1; and the calculated quantities of 
expression of whole GLUT1 protein by vims E4.2 are summarised below. 
Calculations were made on the basis of standard quantities of RBC of known 
concentration being processed with the experimental samples, based on 
600pmol GLUT 1/mg RBC membrane protein.
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Figure 4.1 Western blotting of a 12% SDS-PAGE of Sf9 cell lysates (lanes 5 
and 7), and membrane preparations (lanes 6 and 8) of cells infected with E4.2, 
taken at 48 hpi. (lanes 5 and 6 contain 5pg total protein, lanes 7 and 8, 20pg) 
Lanes 1 to 4 represent varying quantities of RBC membranes (est. 5, 10, 20 and 
30pg respectively). The blot was processed according to section 2.2.3.4.
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SAMPLE RBC membrane 
immunoreactive 
equivalent fue)
pmol elutl/m e protein
5 fig membranes 1.6 192
20pg membranes 3.4 102
mean membrane 147
5fig whole cell lysates 1.7 204
20pg whole cell lysates 3.3 99
mean cell lysate 151.5
Table 4.1 Quantification of E4.2 GLUT 1 protein
These figures indicate that the level of expression of GLUT1 protein in 
Sf9 cells infected with recombinant baculovirus E4.2 is approximately a quarter 
of the GLUT1 expressed natively in erythrocyte membranes. However, a 
number o f factors must be considered. Firstly, although background 
radioactivity was accounted for in the calculations, the physical size of the 
immunoreactive band is not fully taken into account in this procedure. That is, 
the molecular weight range over which the principal immunoreactive species is 
found in erythrocytes is significantly greater than the range over which the 
E4.2/Sf9 expressed GLUT1 protein is found. Therefore, the radioactivity of 
the immunoreactive species is measured over a wider area in the red blood cell 
lane of the blot. Even if  equivalent quantities of immunoreactive protein are 
present in each sample, physical constraints o f the nitrocellulose for the 
immobilisation of protein may create a maximal band intensity per unit area, 
and therefore protein that is more "spread out" may be more accurately 
measurable.
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The figures shown in table 4.1 suggest that a maximal loading of the 
nitrocellulose may be occurring, and that perhaps only lower band intensities 
should be used in the calculation of quantitation. That is, the figures calculated 
from an initial loading of 5mg of total protein (for both whole cell lysates, and 
membrane preparations) are very noticeably higher (at 192 pmol/mg and 204 
pmol/mg for membranes and whole cells) than those from a loading of 20mg 
total protein (102 and 99 pmols/ml for membrane samples and whole cell 
lysates respectively).
From this then, a mean of around 150 pmol GLUT1 molecules per mg 
total Sf9 membrane protein is calculated. However, considering the possibility 
of overloading the nitrocellulose with one immunoreactive species, this figure 
may actually be closer to 200 pmol/mg.
These quantification experiments were carried out more than a year 
after the production of the passage 3 s stock of virus E4.2. Some reduction in 
virus titre is to be expected on storage of baculovirus stocks. However, on the 
visual comparison of Western blotting of E4.2 samples when the stocks were 
new, and after a year or so of storage, suggests a very significant reduction of 
the titre of this virus. For example, figure 6.1 shows similar band intensities for 
E4.2 and the R12 monomer band. Figure 6.1 also apparently shows that the 
E4.2 GLUT1 band is of an approximately equivalent intensity (though without 
the same molecular weight distribution) to the erythrocyte equivalent band. 
Therefore, the level of expression of GLUT1 protein by Sf9 cells using the 
recombinant baculovirus E4.2 was apparently higher than the calculated 150 
pmol/mg, earlier in the project. In an even later quantitation experiment, the 
level of GLUT1 protein from E4.2 infected insect cells was calculated to be 
only 25 pmol/mg. This is a certain indication of deterioration of the virus.
Although there is no recognised reliable method currently available for 
the isolation of the cytoplasmic membrane fraction of insect cells, differential 
centrifugation to approximately separate cytoplasmic membranes from total
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cellular membrane, and analysis of total membrane fraction compared to whole 
cell lysates were considered to be the extent of this determination.
SDS-PAGE and Western blotting was carried out on equal protein 
quantities of membrane and whole cell samples from cells infected with E4.2. 
Western blots of whole cell lysate samples of the E4.2 infected cells, show the 
E4.2 protein product (50kDa) to be either undetectable, or only detectable on 
prolonged exposure of the immunofluorescent blot to film . However, 
membrane preparations made of cells identically infected, very clearly and 
consistently show the E4.2 protein band. This can be seen in figure 4.2. This 
seems to be clear indication of membrane localisation of this protein.
Differential centrifugation (2.2.3.1) in order to determine the 
percentage of the GLUT1 protein that is expressed at the cell surface was 
carried out. Although the blots were veiy poor and unclear, calculations 
indicated that between 70% and 115% of the E4.2 protein was present in the 
16,000 g ^  centrifugation. This, with the previous data, apparently confirms 
that a majority of the E4.2-expressed GLUT1 protein is localised to the 
cytoplasmic membrane.
4.1.2 DETERMINATION OF OPTIMAL PROTEIN EXPRESSION
The Western blots carried out for the initial identification of the 
desired proteins from cells infected with the recombinant viruses all used cell 
lysates made at 72 hpi, since it would be expected that if  protein would be 
detectable at all, it would be seen by this point in the infection cycle. That is, 
each of the recombinant proteins are expressed under the control of the 
polyhedrin promoter, which generally dictates that relatively large quantities o f 
protein would be present at this stage in an infection. However, since 
recombinant protein expression is part of a viral infection which eventually 
kills the cells involved, a full time course of expression was undertaken.
122
1 2 3 4 5 6 7 8  9 10
V 4- 106 kDa 
^  80 kDa





Figure 4.2 Western blotting of Sf9 cell lysates (lanes 2,3,4 and 5) and 
membrane preparations (6,7,8 and 9) of cells infected with AcMNPV:LacZ; the 
recombinant baculovirus R12; recombinant baculovirus E4.2, and mock 
infected Sf9 cells respectively. For E4.2, cells were infected with 1.13 pfii/cell 
virus, and all lysates or membranes were made at 48 hpi. Small samples were 
taken for protein estimation, and 20pg protien per sample was loaded onto the 
12% SDS-PAG. RBC membranes were run in lanes 1 and 10. The Western 
blot was carried out using the anti-C-terminal peptide antibody.
A time course analysis, as described in section 2.4.5 was undertaken 
for the infection of Sf9 cells with the E4.2 recombinant virus. As summarised 
in table 4.2, samples of infected cells were taken at regular time points, 
between 0 hours, and 168 hours post infection. A series of analyses were made 
at each timepoint.
Visual analysis was made of cells at each time point. As expected, 
there was a gradual decline in the cells’ healthy appearance, as the infections 
proceeded. At 36 hpi, the cell growth was obviously retarded, and confluence 
was at about 50% (the uninfected cells control condition showed a density of 
around 80%), though these cells themselves were showing no apparent signs of
TIM E POST INFECTION 
(hours)
M AIN VISUAL FEATURES




36 40 to 50% confluence. Appear healthy
48 -20%  of cells beginning to appear sick
56 Significant evidence of cell death
60 >60% cells appear sick. -10%  dead (floating)
72
96
120 >50% cells floating (dead) <5% appear healthy
168 Most cells dead or dying. No evidence of 
healthy cells
Table 4.2 Visual analysis of time course of infection with E4.2
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deterioration (crenellation of the outer membranes being the most visual 
indication of cell deterioration). By 48 hpi, an estimated 20% of the cells had 
begun to take on the characteristic appearance of infected cells. By 72 hpi 
more than 60% of the cells had this appearance, and an estimated 10% had 
become detached from the plastic surface, presumed dead. By 120 hpi, only 
very few cells (<5%) had a healthy appearance, and by 168 hpi, at least 50% of 
the cells were dead, with no evidence of healthy cells remaining.
Cells were harvested and lysates made, and immediately frozen at each 
point, for analysis on completion of the course. Figure 4.3 is the Western blot 
analysis of whole cell lysates over the time course. A standard volume, 
corresponding to a mean estimated total protein concentration of 20mg per 
sample was used (although protein concentrations varied per sample, see fig 
4.4, using a standard volume gives an indication of the total amount of GLUT1 
protein expressed in a culture dish, rather than relative to the total cell protein). 
This analysis shows that no GLUT1 protein is detectable before 24 hpi, and 
that from around 48 hpi onwards, no particularly noticeable differences in 
quantity can be visually detected.
Figure 4.5 is a Western blot showing membrane samples taken at each 
timepoint. Again, a constant volume was loaded per sample, corresponding to 
a mean of 20mg per sample (o f membrane protein). It is clear, on comparing 
this to figure 4.3, that there is more immunoreactive material present in 20mg 
of membrane protein than is present in 20mg of whole cell protein, suggesting 
targeting of this protein to the membrane fractions of the cell. Again, no 
material is visually detectable before 24 hpi, but samples taken at 48, 54 and 60 
hpi appear to contain more immunoreactive material than either earlier or later 
samples. From this, it appears that an optimum expression is occurring at 
around these times. Since visual analysis of the cells indicates that they are still
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Figure 4.3 Western blotting of the time course of expression of GLUT1 
protein produced by the infection of SF9 cells with the recombinant 
baculovirus E4.2. Cells were infected with a mean of 1.13 pfu/cell. Cell 
lysates were taken at a range of time points from 0 hpi to 168 hpi (see legend). 
The 12% SDS-PAG was loaded with a standard volume of sample 
corresponding to a mean of 20p.g total cell protein. The Western blotting was 
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Figure 4.4 Protein estimations of the quantities of protein per 35mm culture 
dish of Sf9 cells throughout the course of an infection with the recombinant 
baculovirus E4.2. Total cellular protein (o), and membrane protein quantities 
(+) were both measured.
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Figure 4.5 Western blotting of membrane samples during the time course of 
expression of GLUT1 protein produced by the infection of SF9 cells with the 
recombinant baculovirus E4.2. Cells were infected with a mean o f 1.13 
pfii/cell. Membrane preparations, as described in section 2.4.1 were made at a 
range of time points from 0 hpi to 168 hpi. The 12% SDS-PAG was loaded 
with a standard volume of sample corresponding to a mean of 20p,g total cell 
protein. The Western blotting was carried out using the anti-C-terminal peptide 
antibody.
relatively healthy during this period, subsequent experiments were carried out 
at either 48 hpi or 62 hpi on this basis.
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4.2 N-TERMINAL HALF PROTEIN
Figure 3.13, in chapter 3, shows the expression of several 
immunoreactive species by recombinant virus N l, when probed using an 
antibody directed to the N-terminal half of GLUT1. Figure 4.6 illustrates 
expression of these species more clearly. The protein migrating at around 
3 lkDa is of the expected size for the N-terminal half protein from the GT78 
construct. It is clear from this Western blot that this protein migrates as a 
doublet, an observation that has been consistently seen on clear Western blots, 
(this is particularly clear in figure 4.6). In addition to this observation, is the 
consistent presence of a band at about 52kDa (migrating slightly more slowly 
than the E4.2 expressed whole GLUT1). Faster migrating species sometimes 
detected in higher percentage acrylamide gels are considered likely to be 
degradation products of the higher molecular weight species.
4.2.1 QUANTITATION OF N 1 PROTEIN PRODUCT IN  INSECT CELLS
Using known concentrations of RBC membranes (therefore known 
GLUT1 content) as standards, quantitative immunoblotting using the anti N - 
terminal half anti peptide antibody was used to estimate the relative quantity of 
immunoreactive GLUT1 species being expressed by cells infected with the N l 
virus. Figure 4.6 shows a Western blot used in this quantitation. As is 
apparent from the blot, there are more immunoreactive species than the 
expected "N-terminal half’ band. Therefore, three figures can be calculated 
from such an analysis. The quantities of immunoreactive GLUT1 material 
migrating at the "N-terminal half' monomer molecular weight, material 
migrating at approximately twice that weight (the putative N -N  dimer size), 
and the total amount of immunoreactive material, including both of these and 
the higher molecular weight material. Since a monomeric unit is the intended 
species to be expressed, the first figure is perhaps the most important.
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4-27.5 kDa
Figure 4.6 Western blot showing samples of Sf9 cells infected with 
recombinant baculovirus N 1, using anti-N-terminal half anti- peptide antibody. 
Lanes 1 and 2 represent cells infected with virus E4.2, and lanes 7,8 and 9 
represent varying quantities of RBC membranes (2, 5 and 10pg protein 
respectively). Sf9 cell samples infected with virus N 1 were prepared as for 
normal membrane preparations, but centrifuged at 16,000gmax(lanes 3 and 5). 
The samples shown in lanes 4 and 6 were prepared as for normal membrane 
preparations, using centrifugation at 100,000gmax.
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From Whole Cell Lysates
N-terminal half monomer 95.7 pmol/mg
N-terminal putative dimer 30.65 pmol/mg
Total N-terminal immunoreactive 
material 126.35 pmol/mg
From Membrane Preparation
N-terminal half monomer 115 pmol/mg
N-terminal putative dimer 91.68 pmol/mg
Total N-terminal immunoreactive 
material 206.86 pmol/mg
Table 4.3 Quantitation of N l GLUT1 protein
As is clear from figure 4.6, the Western transfer was apparently not 
entirely even. This is frequently a problem with this technique, particularly 
when quantitations are being made from the blot. Apparently (also apparent 
from the figures in table 4.3) the ’’dimer" band is in a badly transferred area, 
particularly on the "whole cell lysates" sample lane. It is deduced from this, 
therefore, that the figure of 206 pmol/mg membrane protein is probably the 
more reliable figure. It is clear from a comparison of whole cell lysates 
against an equivalent quantity of membrane protein that a majority of the 
protein being expressed is located at the cell surface.
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Differential centrifugation of Nl-infected cells was carried out, and the 
expressed protein detected using the anti N-terminal half GLUT1 antibody.
The figures shown in table 4.4 are for the relative quantities of N-terminal half 
"monomer" protein, "dimer" protein, and the total quantities of immunoreactive 
protein product (not including any lower molecular weight putative degradation 
products), from centrifugation at 16,000 gmax (plasma membranes) as a 
percentage of product from centrifugation at 100,000 gmax (total cellular 
membranes).
Immunoreactive Species Percentage at plasma membrane
N-terminal monomer 112%
N-terminal dimer 67.6%
Total N-terminal protein 81.4%
Table 4.4 Cellular localisation of N-terminal protein (virus N 1)
These results were found to be reproducible in that all, or at least a 
great majority of the "monomeric" protein is apparently found to be located at 
the cell surface, but a significant proportion (approximately 20 to 30%) of 
higher molecular weight species is apparently localised to intracellular 
membranes.
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4.3 C-TERMINAL HALF PROTEIN.
The expression of protein products from R12 infected cells is 
demonstrated in the Western blot shown in figure 3.18, and in the figures of 
section 4.3, probed with the anti GLUT1 C-terminal half antibody. The protein 
of expected mobility from the construct design is that species seen at an Mj. of 
about 25kDa. As with the expressed N-terminal half (see section 4.2.1), this 
band is often, though not as clearly, seen as a doublet. The observation of a 
band appearing at around Mj. 50kDa was consistently made in early analyses of 
the products of this virus, and was the basis of the direction of the second half 
of the project. This is discussed in chapter six. As with the products of the 
E4.2 virus and the N l virus, higher molecular weight species are also almost 
always observed. Figure 6.4 shows these clearly as discrete bands (also visible 
in figure 4.9).
4.3.1 QUANTITATION OF R12 PROTEIN PRODUCT IN  INSECT
CELLS.
C-terminal half protein expressed by cells infected with the R12 virus 
was quantified by Western blotting with the anti C-terminal half GLUT 1 
antibody. Note that, as in section 4.2.2, quantities of GLUT1 immunoreactive 
material in the form of monomeric C-terminal protein, proposed dimeric form, 
and total immunoreactive material including higher molecular weight material, 
have been calculated.
134
From Whole Cell Lysates
C-terminal half monomer 100 pmol/mg
C-terminal putative dimer 117 pmol/mg
Total C-terminal immunoreactive 
material 220 pmol/mg
From Membrane Preparation
C-terminal half monomer 81 pmol/mg
C-terminal putative dimer 128 pmol/mg
Total C-terminal immunoreactive 
material 221 pmol/mg
Table 4.5 Quantitation of R12 GLUT 1 protein
As with the expression of the E4.2 GLUT 1-antibody immunoreactive 
protein products (section 4.1.1), the issue of band intensity and the spread of 
molecular weights over which a signal is detectable may be important. 
Although there are three principal immunoreactive species detected in cells 
infected with the R 12 virus, each band is sharp relative to the single 
immunoreactive GLUT1 species measured in erythrocyte membranes. It is 
therefore possible that the figures presented in table 4.5 are under-estimates of 
the expression levels that have been achieved. A visual analysis of almost any 
Western blot showing both R12 GLUT1 protein and erythrocyte GLUT1
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protein indicates relatively comparable band intensities for the erythrocyte 
GLUT1 and both the monomeric and putative dimeric forms of R12 protein.
In cells infected with the R12 baculovirus, both the R12 protein band 
(~ 25kDa) and the 50kDa band that are always found in R12 infected cells, are 
consistently very notably stronger in the membrane samples, than in the whole 
cell samples. That is , there appears to be more of the expressed protein 
present as a proportion of the cell membrane protein, than as a proportion of 
whole cell protein. Since this is clear and reproducible, it seems to be an 
indication of membrane insertion of the expressed R12 protein, (see figure 4.7). 
In order to formally determine the cellular localisation of C-terminal half 
GLUT1 protein (R12 virus), differential centrifugation was carried out. R12 
infected cells were harvested at 48 hpi and the membrane preparation protocol 
was followed to just prior to centrifugation (2.2.3.1). The sample was then 
halved, and one half subjected to centrifugation at 16,000 g ^  (plasma 
membranes), the other 100,000 g ^  (total membranes). The results of a 
representative differential centrifugation experiment are shown in table 4.6.




Total C-terminal GLUT1 protein 117% I
Table 4.6 Differential centrifugation of R12 infected cells.
It is clear from table 4.6 that most of the R12-expressed C-terminal 
GLUT1 protein is expressed at the plasma membrane of the insect cells. It is 
interesting to note that, where only around 90% of the C-terminal monomer
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1 2 3 4 5
<-49.5 kDa
»  • *
<-27.5 kDa
Figure 4.7 Western blotting of Sf9 cell lysates (lanes 3 and 5) and membrane 
preparations (lanes 2 and 4) of cells infected with the recombinant baculovirus 
R 12. Cells were infected with 1.66 pfu/cell, and lysates or membranes were 
made at 48 hpi. Small samples were taken for protein estimation, and 15pg 
protein per sample was loaded onto the 10% SDS-PAG. The Western blot was 
carried out using the anti-C-terminal peptide antibody. Lanes 1 represents red 
blood cell samples used in the quantitation.
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protein is apparently present at the cytoplasmic membrane in cells infected only 
with the R12 virus, when cells are dually infected with the R12 virus and the 
N 1 virus, the figure calculated for the percentage of "R12 monomer" present in 
the plasma membrane is 133%.
4.3.3 DETERMINATION OF OPTIMAL PROTEIN EXPRESSION
In order to determine the best possible balance between expression 
levels and cell deterioration, a full time course was carried out on cells infected 
with the R12 virus. Table 4.7 gives a summary of the timepoints used, with 
brief descriptions of the appearance of the cells at landmark timepoints. The 
progression of the infection followed an expected course, with cells gradually 
showing deterioration from about 48 hpi onwards, to an estimated 10% of cells 
still alive at 120 hpi. Cells infected with AcNPV:LacZ (LZ) DNA followed a 
similar course, demonstrating the recombinant virus infection to be fairly 
typical. Mock infected cells observed over the same period showed normal 
growth, to confluence at between 72 and 96 hpi, with the first signs of over- 
confluence (cells becoming "sick" in appearance, and floating off the plastic 
surface) at the last timepoint, 120 hpi.(summarised in table 4.7). Figure 4.8 is a 
graph of the total amounts of protein in the R12 infected cells (estimated using 
the BCA method, see 2.2.3.9), and demonstrates the early growth of the 
monolayer, which appears to slow rapidly, followed by a reduction in protein 
as the cells begin to die. (This is not intended to give any indication about the 
quantities of GLUT1 protein being expressed).
Figure 4.9 is a Western blot (using the anti C-terminal half G lutl 
antibody) o f time course samples. An estimated 20mg per sample was used, 
and this blot therefore demonstrates visually the quantities of GLUT1 protein 
present relative to the quantity of total protein, at each time point. It is clear 
from this that GLUT1 C-terminal half protein is not detectable before the 24 
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Figure 4.8 Protein estimations of the total amount of protein per 35mm 
culture dish of Sf9 cells throughout the course of an infection with the 
recombinant baculovirus R12.
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Figure 4.9 Western blotting of the time course of expression of anti-GLUTl 
C-terminal peptide antibody immunoreactive protein produced by the infection 
of Sf9 cells with the recombinant baculovirus R12. Cells were infected with a 
mean of 1.67 pfu/cell. Cell lysates were taken at a range o f time points from 0 
hpi to 120 hpi. Protein estimations were made of each sample, and the 10% 
SDS-PAG was loaded with a standard 20pg protein per sample.
TIME POST INFECTION MAIN VISUAL FEATURES Control "LZ" infected cells Control ’’mock" infected cells
(HOURS'* R12 infected cells




24 cells possibly less dense than 
mock infected cells -20 to 
30% confluent
-20 to 30% confluent -20  to 30% confluent
36
42
48 -30  to 40% confluent Some 
cells beginning to appear sick, 
reduced growth rate very 
apparent
-50  to 60% confluent. Some 
cells beginning to appear sick
-80%  confluent. A ll cells 
appear healthy.
60
72 30 to 40% confluent. -50%  
cells floating, of the remainder, 
-  40 to 60% appear sick
-80%  confluent. -20%  
floating, -40%  appear sick
>90% confluent. -2%  cells 
floating, but majority of 
remainder still appear healthy
96 -40  to 50% cells floating. O f 
remainder, only occasional 
cells seem healthy. Most 
notable feature being very low 
total cell numbers
>30% of cells floating, of the 
remainder, only -15%  appear 
healthy
-90%  confluent. -2%  cells 
floating. A few cells beginning 
to show signs of deterioration
120 -10%  confluence. >50% cells 
floating. No evidence of 
healthy cells. Cell mass on 
centrifugation -50%  of mock 
infected cells.
-50%  confluent. -  30% cells 
floating. -10%  of remaining 
cells still appear healthy
>90% confluent. -10%  cells 
floating. Monolayer appears 
typically "old"
Table 4.7 Visual record of the time course of Sf9 cell baculovirus infection.
production after about sixty hours, and that, as a proportion of the total amount 
of protein remaining, GLUT1 is not reduced as the cells begin to die.
Figure 4.10 is a Western blot where a standard volume of material has 
been used per sample (30pi, corresponding to a mean of 30pg), and therefore 
demonstrates the overall quantities of GLUT1 material at each timepoint, 
relative to the number of cells infected (i.e. rather than as a proportion of the 
total cell protein). From this, there is no discernible signal of GLUT1 protein 
until 36 hpi, and reflects the observation that the cells are still growing at this 
stage. There also appears to be an ultimate reduction in quantity at the later 
stages of the infection, presumably reflecting the observed cell death. From 
this, an optimum expression level of between 48 and 72 hpi can be determined.
In order to gain a clearer view of expression in relation to infection 
state, a further analysis of these samples was made. Quantitative 
immunoblotting was carried out on gels loaded with a constant volume (20pl, 
corresponding to an estimated 20pg) of each sample. Figure 4.11 is the Western 
blot, and figure 4.12 shows the calculated relative quantities of both the C- 
terminal half monomer species, and the "dimer” band (as measured in cpm of 
measured radioactivity content of isolated bands on the blot.). From this, 60 
hpi appears to be a clear optimum expression time for this protein. However, 
in view of the fact that the cells are in a fairly advanced stage of infection, and 
are beginning to deteriorate significantly by this stage, 48 hpi was taken to be a 
better time to use cells for further experiments, since the cells are still relatively 
healthy, but producing plenty of protein. The relative expression of the R12 
putative dimer band is also shown on this graph.
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Figure 4.10 Western blotting of the time course of expression of anti-GLUTl 
C-terminal peptide antibody immunoreactive protein produced by the infection 
of Sf9 cells with the recombinant baculovirus R12. Cells were infected with a 
mean of 1.66 pfu/cell. Cell lysates were taken at a range of time points from 0 
to 120 hpi. The 10% SDS-PAG was loaded with a standard volume of sample 
corresponding to a mean of 30pg total cell protein.
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Figure 4.11 Quantitative Western blotting (see section 3.4.4) of the time 
course of expression of anti-GLUT 1 C-terminal peptide antibody 
immunoreactive protein produced by the infection of Sf9 cells with the 
recombinant baculovirus R12. Cells were infected with a mean of 1.66 
pfu/cell. Cell lysates were taken at a range of time points from 0 hpi to 120 
hpi. The 10% SDS-PAG was loaded with a standard volume of sample 
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Figure 4.12 Relative quantities of Sf9cell/R12-expressed GLUT1 antibody 
immunoreactive protein over the course of a viral infection. The samples were 
prepared as described in section 2.2.3.5, and quantitated by quantitative 
immunoblotting (section 2.2.3.4, see figure 4.11). Time course of expression 




In summary, Western blotting, using the two anti-GLUTl antibodies, 
has identified the successful expression of GLUT1 protein in the form of the 
whole protein, the N-terminal half, and the C-terminal half (Western blotting 
profiles of each of the products can be seen in sections 4.1, 4.2 and 4.3). 
Comparisons of the main products can be made from figure 4.13. Their 
insertion into the membrane appears to be successful, even in the C-terminal 
half of the protein, which may not necessarily be expected to have any insertion 
signal sequence. The expression levels attained for each protein are within an 
order of magnitude of native expression of GLUT1 in human erythrocytes.
The expressed full-length protein has a greater mobility on SDS-PAGE 
than its red blood cell counterpart, which may reflect its glycosylation state 
when expressed in insect cells, as being incomplete as regards the transporter in 
erythrocytes. This is discussed in full in chapter seven.
The sizes of the DNA constructs for the N - and C-terminal halves are 
very similar, at 740 and 810 bp respectively; corresponding to 246 and 267 
amino acids of translated protein. Considering only the polypeptide chain, the 
products would be expected to vary in weight by no more than two and a half 
kDa, both being between 25 and 27.5 kDa. As this would predict, the C- 
terminal product of the R12 virus runs at a mobility of ~25kDa. The N - 
terminal protein, however, has a mobility o f about 3 lkDa, and this is likely to 
reflect some degree of glycosylation, at the single GLUT1 glycosylation site, 
Asn 45. That this product migrates as a doublet supports this, by suggesting a 
degree of heterology of the glycosylation.
The appearance of the "dimer" bands for the two half-GLUTl proteins, 
and the observation of higher molecular weight species of all products, are 
discussed in chapters six and seven.
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I f  a comparison is made of the quantitation figures for each of the 
protein products, from whole cell lysates and membrane preparations, it is very 
clear that there is very little difference between the two. That these figures are 
so similar is obviously indicative of localisation of the proteins in the 
membranes of the cell. The very close similarity of these figures may be 
indicative of a cellular change occurring in response to the expression of 
membrane-associated proteins. That is, in order to accommodate the large 
quantities of membrane protein present, more membrane, presumably all 
components, may be manufactured by the cell. In order to investigate this 
simply, a series of very carefully carried out protein estimations were made on 
a series of cells.
Cells, in 35mm dishes were infected (as described in chapter 2) with 
either a ’’mock" infection, "LZ" baculovirus (the product of which is 
cytoplasmically targeted); or one of the three recombinant baculoviruses, E4.2, 
N l, or R12. After 48 hours the cells were scraped from the dishes (as 
described in section 2.2.3.1). The sample volume was measured, and a large 
sample was taken for protein estimation. The remainder was prepared as 
membranes using the usual procedure. A large sample of the membrane 
preparation samples was taken for protein estimation. Large samples were also 
taken of the membrane preparation supernatant, for protein estimation. The 
results are presented as percentages of total cellular protein (from the first set of 
estimation samples taken) present in the membrane (100,000 g ^  pellet) and 
non-membrane (100,000 supernatant) fractions of the insect cells. The
"total" column gives an indication of the efficiency of the protein estimations, 
and inaccuracies may also indicate loss of material during the procedure.
14a
Sample %  protein in 
membrane
% protein in non­
membrane
(total)
mock 62 42 104
LZ 57 28 85
E4.2 80 11 91
N1 128 (too low )
R12 97 2.5 99.5
Table 4.8 Relative protein quantities in cellular fractions
It is quite clear from this table, particularly from the R 12 data which 
appears to be the most accurate, that a larger proportion of the total cell protein 
is indeed being incorporated into the membranes of the cell in response to the 







Cytochalasin B, a fungal metabolite, specifically and reversibly binds 
to the internal glucose binding site of GLUT 1 (Helgerson and Carruthers,
1986). It had been used as a potent inhibitor of glucose transport in human 
erythrocytes even before the binding protein had been characterised or 
identified (Tavema and Langdon, 1973 and Lin and Spudich 1974). Three 
cytochalasin B binding sites were identified in erythrocytes, but it was found 
that only one type was glucose sensitive, and that this represents over 60% of 
the total cytochalasin B binding sites. This one type was also found to be the 
only one of the three that does not also bind cytochalasin E (Jung et al, 1980). 
Tavema and Langdon (1973) suggested that the protein to which cytochalasin 
B binds, and the glucose transporter may be the same protein. In 1974, Lin and 
Spudich found that the ability of a sugar to inhibit the binding of cytochalasin 
B to erythrocytes was related to their affinity for the sugar transport system.
This was supported by Kasahara and Hinkle (1977), and by Hinkle et al (1979)
, who reconstituted erythrocyte proteins into liposomes. Significant transport 
function and significant cytochalasin B binding were both found in this system.
The only protein found to be sufficiently abundant to account for either of these 
findings was a protein appearing as a broad band around 55 kDa molecular 
weight on SDS-PAGE. Many later workers have shown cytochalasin B to bind 
the glucose transport protein, and the specific localisation of its binding has 
been closely determined.
Red blood cells are impermeant to cytochalasin B. It is thought to bind a 
at the internal glucose binding site, and so it is used as a competitive inhibitor 
of glucose binding at, or very near to, the internal site. It is therefore a 
competitive inhibitor of glucose efflux, and a non-competitive inhibitor of
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glucose influx across the plasma membrane. The molecular structure of 







Figure 5.1 Cytochalasin B
However, its use as an affinity ligand was initially limited by the 
reversible nature of its binding. In 1981 and 1982, Carter-Su et al, and 
Shanahan independently discovered that cytochalasin B is a natural 
photoaffinity ligand, becoming a highly reactive molecule upon exposure to 
high intensity ultraviolet irradiation. The nature of the covalent labelling o f the 
glucose transporter with cytochalasin B is now thought to be by the 
photoactivation of the transporter protein (Cairns et al, 1987). The use of [3H] 
cytochalasin B to covalently label the glucose transporter, GLUT 1, of human 
erythrocytes or erythrocyte membranes is now an established method.
Labelling is inhibited by the presence of D-glucose (Carter-Su et al recorded an 
average reduction of binding of the major binding peak of 72% +/- 5% in the 
presence of 500mM D-glucose). GLUT 1 in red blood cells is covalently 
labelled with tritiated cytochalasin B as a broad peak over the molecular weight 
range 45 to 65 kDa, peaking at around 55 kDa, (Carter-Su et al, 1981) which is 
the range covered by the transporter when analysed by Western blotting with a 
specific antibody. Cytochalasin B labelling of erythrocyte membranes was
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carried out, and is shown in Figure 5.2. Western blotting of erythrocyte 
membranes, using a specific anti-GLUT 1 antibody is shown in figure 3.4.
The aim of cytochalasin B labelling experiments on the transporter 
proteins expressed in insect cells is to determine the presence of a 
conformationally functional cytochalasin B binding site, and to determine 
whether any cytochalasin B labelling that does occur is displaceable by 
glucose. That is, to determine the presence of a functional cytoplasmic-side 
glucose binding site, in these expressed proteins.
5.1.2. CYTOCHALASIN B LABELLING EXPERIMENTS ON 
EXPRESSED FULL-LENGTH PROTEIN (E4.2)
It would be anticipated that the full length protein, having been 
demonstrated to be membrane associated, would be in an appropriate 
conformation, and therefore possess functionally intact glucose binding sites. 
From its observed molecular weight, the expressed glucose transporter would 
be expected to demonstrate a corresponding cytochalasin B labelling profile. 
That is, the peak would be expected to be slightly narrower than that observed 
of GLUT 1 in red blood cells (RBC), and at a Mj. of -50  kDa, rather than the 
55 to 65 kDa of RBC.
Labelled cells were immunoprecipitated with the anti GLUT 1 
antiserum in order to improve the specificity and clarity of the results.
A number of labelling experiments were carried out on uninfected Sf9 
cells, and cells infected with "wildtype" (AcNPV:LacZ) baculovirus, to 
determine whether any indigenous insect hexose transporter would be labelled 
with this ligand. Cytochalasin B inhibition of glucose transport has recently 
been demonstrated in Drosophila melanogaster Kc cells (Wang and Wang, 
1993). However, they also demonstrated that, by using full- length cDNA 
clones of the mammalian transporters, homologous DNA could not be found in 
these cells despite the cytochalasin B inhibition results. Figure 5.3 shows
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Figure 5.2 Cytochalasin B labelling of erythrocyte membrane GLUT1. 
Membranes were incubated with cytochalasin B in the presence (o) and 
absence (+) o f 200mM D-glucose, and irradiated using a Rayonett 
photoreactor. The solubilised membranes were immunoprecipitated using the 
anti- C-terminal GLUT1 antiserum (see 2.2.3.6 and 2.2.3.7). The labelling 
peak at -55 kDa represents the cytochalasin B labelled GLUT1 protein.
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profiles for cells infected with the wildtype virus (encoding polyhedrin), and 
the "wildtype” AcMNPV:LacZ (as used in co-transfections), and demonstrates 
that Sf 9 cells infected with baculovirus (ie. not baculovirus encoding glucose 
transporter protein) do not naturally express proteins that are both labelled with 
cytochalasin B and immunoreactive with the anti GLUT 1 antiserum.
Figure 5.4 shows [3H]-cytochalasin B labelling of Sf9 cell membranes 
expressing the E4.2 full length glucose transport protein. This quite clearly 
demonstrates that all of the predictions were accurate. The labelling peak is 
clear, and at a molecular weight of -50 kDa. On the addition of D-glucose to 
the same experimental condition, the peak is almost entirely eliminated, 
demonstrating the inhibition of labelling by glucose.
Figure 5.5 represents concomitantly labelled RBC membranes and 
E4.2- infected Sf9 cell membranes. This illustrates the molecular weight 
difference of the cytochalasin B labelling species between the two, which 
appears to be the same as the difference observed in Western blotting with the 
anti- GLUT 1 antibody used in the immunoprecipitation.
Figure 5.5 also clearly illustrates a height difference between the RBC 
and insect cell expressed GLUT 1 labelling peaks. Although expression levels 
for the protein expressed in Sf9 cells had not been determined before these 
experiments, approximately matched transporter quantities had been used in 
both conditions (as determined visually by the intensity o f immunoreactivity 
on Western blotting). Differences in immunoreactive GLUT 1 presence would 
therefore seem unlikely to account entirely for the difference in cytochalasin B 
(and therefore glucose) binding, and the difference is therefore more likely to 
be due to either a difference in binding affinity, or reflective of the fact that 
there may be immunogenic but non-functional transporters being expressed as 
well as functional ones. This is discussed in chapter 7.
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Figure 5.3 Cytochalasin B labelling of membranes of Sf9 cells infected with 
"wildtype" baculovirus (AcMNPV) (o); and cells infected witb AcMNPV:LacZ 
type "wildtype" baculovirus (+). Membranes were prepared (as section 
2.2.3.1), labelled with cytochalasin B (2.2.3.7), and immunoprecipitated using 
the anti-C-terminal GLUT1 antiserum (2.2.3.7). Immunoprecipitated samples 
were subjected to a 12% SDS-PAGE. No distinct labelling peaks are 
discernible for either sample.
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Figure 5.4 Cytochalasin B labelling of membranes of Sf9 cells infected with 
recombinant baculovirus E4.2, encoding the full-length GLUT1 protein, in the 
presence (o) and absence (+) of 200mM D-glucose. Labelled membranes 
(2.2.3.7) were solubilised, and immunoprecipitated using the anti C-terminal 
GLUT1 antibody (2.2.3.6). The major labelling peak migrated at a molecular 
weight of -50  kDa; and is shown to be inhibited by the presence of D-glucose.
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Figure 5.5 Cytochalasin B labelling of eiythrocyte GLUT1 compared to 
Sf9/E4.2 expressed GLUT1. Cell membranes were labelled with cytochalasin 
B (as described in 2.2.3.7) and immunoprecipitated using the anti C-terminal 
GLUT1 antibody. The RBC (+) and E4.2 (o) conditions were carried out 
simultaneously and subjected to SDS-PAGE on a 12% acrylamide gel. The 
mobility difference on SDS-PAGE between the two GLUT1 proteins is clear.
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5.13 CYTOCHALASIN B LABELLING EXPERIMENTS ON N-
TERMINAL HALF PROTEIN (N\ )
There has never been any suggestion for the localisation of the 
cytoplasmic glucose binding site at any point on the N-terminal half of the 
GLUT 1 glucose transport protein. Indeed, there is evidence to demonstrate 
that cytochalasin B labelling is NOT associated with the N-terminal half of the 
protein (Cairns et al, 1987; Davies et al, 1987; Karim et al, 1987). However, 
since the whole transporter expressed in Sf9 cells has been demonstrated to 
bind cytochalasin B, the demonstration o f non-labelling of the similarly 
expressed independent N-terminal half was considered to be important.
Figure 5.6 shows labelling profiles for N1-infected cells expressing the 
N-terminal half protein. These membrane samples were immunoprecipitated 
using the anti N-terminal GLUT 1 antiserum ( Western blots using this 
antibody to detect the expression of RBC GLUT 1, E4.2 protein, and N1 
protein can be seen in figure 3.12 in chapter 3).
This clearly shows that no labelling can be detected. Since no labelling 
was detectable, the addition of glucose to the experimental condition was not 
performed.
5.1.4 CYTOCHALASIN B LABELLING EXPERIMENTS ON THE C- 
TERMINAL HALF PROTEIN
There is a large body of evidence placing the location of the 
cytoplasmic-side glucose binding site on the C-terminal portion of the 
transporter protein. For example, Davies et al (1987) and Holman and Rees 
(1987) showed that tryptic digests of GLUT 1 protein yield two major 
fragments, one of around 18 kDa, and a glycosylated fragment of around 22 
kDa. Labelling the glucose transporter with cytochalasin B before digestion 
showed that the cytochalasin B binds to the 18 kDa fragment. Amino acid
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Figure 5.6 Cytochalasin B labelling of membranes of Sf9 cells infected with 
recombinant baculovirus N 1. 48 hpi membranes were incubated with 
cytochalasin B (2.2.3.7), solubilised, and immunoprecipitated using the anti N - 
terminal GLUT1 antiserum. Samples were incubated with cytochalasin B in 
the absence of glucose. No radioactive labelling peak is detected on SDS- 
PAGE on a 12% acrylamide gel.
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sequence analysis and the use of specific anti- peptide antibodies showed that 
this fragment represents most of the C-terminal half of the molecule. More 
specifically, the use of a range of proteolytic and chemical fragmentation 
techniques resulted in the mapping of the cytochalasin binding site to the 
cytoplasmic loop area between transmembrane segments 10 and 11. Clark and 
Holman (1990) demonstrated that the 18 kDa tryptic fragment could be labelled 
with cytochalasin B after tryptic digestion, demonstrating that not only does the 
cytochalasin B binding site exist on this fragment, but that its conformation 
following cleavage remains intact. This verifies the hypothesis that the 
cytochalasin B binding site is present on this half of the molecule. Closer 
identification of the binding area has located it between residues 347 and 456, 
probably between TM  9 and TM  10 (Cairns et al, 1987). Karim et al (1987) 
however, have stated that the internal ligand binding site is near to residue trp 
388. These two statements are not necessarily contradictory to each other, 
since the three dimensional structure of the protein may be such that both are 
fully accurate.
The independent expression of the C-terminal putative six 
transmembrane helixes and associated non- membrane regions would 
potentially be important support for the localisation of the internal glucose 
binding site as being within the C-terminal half. Moreover, it would be an 
important test for the hypotheses of Karim et al (1987) that the N-terminal half 
is probably not required for the binding of ligands; and Mueckler et al (1985) 
that both glucose binding sites and the transmembrane transport channel exist 
between TM  7 and TM  10, and that the C-terminal half o f the molecule could 
therefore function alone. Cytochalasin B labelling of this fragment would also 
further identify it as glucose transport protein, beyond the evidence of DNA  
restriction analysis and Western blotting.
However, figure 5.7, as representative of many similar experiments, 
clearly demonstrates that the independently expressed C-terminal half of the
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Figure 5.7 Cytochalasin B labelling of the C-terminal GLUT1 half encoded 
by the R 12 recombinant baculovirus, as expressed in Sf9 cell membranes. 
Membranes were photolabelled and immunoprecipitated using the anti-C- 
terminal GLUT1 antibody (2.2.3.6 and 2.2.3.7), in tbe presence (o) and absence 
(+) o f 200mM D-glucose. No labelling is detected following SDS-PAGE on a 
12% acrylamide gel.
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GLUT 1 glucose transport protein is not detectably labelled by [3H]- 
cytochalasin B. In many cases when carrying out the labelling experiments on 
the cells expressing R12, the lowest molecular weight standard (lysosyme) at
14.4 kDa could not be visualised (on a 12% polyacrylamide gel), possibly due 
to insufficient loading. Because of this, it could be supposed that a labelling 
peak at a molecular weight of 25 kDa may have migrated beyond the end of the 
gel. In order to demonstrate unequivocally that no labelling had occurred at 
lower molecular weights, the labelled and immunoprecipitated samples were 
subjected to electrophoresis on a 15% polyacrylamide gel, including increased 
loading of molecular weight standards. These results, shown in figure 5.8, 
clearly demonstrate that, when expressed in the absence of the N-terminal six 
transmembrane regions of the protein, the C-terminal portion does not appear to 
posses a functional cytoplasmic-side glucose binding site. In insect cells at 
least, the C-terminal half of GLUT 1 can apparently not function alone.
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Figure 5.8 15% polyacrylamide gel analysis o f immunoprecipitated
cytochalasin B labelled membrane samples o f Sf9 cells infected with the 





In 1982 Holman and Rees described the use of glucose analogues as 
inhibitors of sugar transport from the external surface of adipocytes. The use 
of side- specific agents for the inhibition of the glucose transporters was very 
important in the determination of the mode of action for transport. The 
development of a specific photolabel for the external site of erythrocyte glucose 
transporters was therefore important (Holman and Rees, 1987). ASA-BMPA is 
an azidosalicoyl derivative of bis (D-mannose). Its use resulted in important 
support for the conformational change hypothesis of glucose transport (by 
demonstrating that cytochalasin B and ASA-BMPA could not simultaneously 
occupy the same molecule, therefore suggesting that only one binding site is 
available at a time, per molecule). As a photolabel, it was also possible, by the 
use of enzymic fractionation, to determine the site of binding. Holman and 
Rees, 1987, placed the external binding site to be near to residue tryptophan 
363. ATB-BMPA, another bis-mannose derivative (2-N -4-( 1 -azi-2,2,2- 
trifluoroethyl)-benzoyl-l,3- bis(D-mannos-4-yloxyl)-2-propylamine), has been 
found to label the transporter more efficiently than ASA-BMPA (Holman,







Figure 5.9 Structure of ATB-BMPA.
In the same way that a cytochalasin B labelling experiment works, the 
ATB-BMPA labelling profile of RBC is a broad peak between 55 and 65 kDa 
molecular weight, corresponding to the molecular size of the transporter. As 
with cytochalasin B, the labelling is almost completely displaceable by D- 
glucose. ATB-BMPA labelling of human erythrocytes is shown in figure 5.10. 
The labelling peak corresponds to the molecular weight of the GLUT 1 
transporter, at between about 50 and 65 kDa.
5.2.2 ATB-BMPA LABELLING EXPERIMENTS ON EXPRESSED FULL- 
LENGTH PROTEIN
Uninfected Sf9 cells, and cells infected with the "wildtype" baculovirus 
were tested for ATB-BMPA labelling, to determine whether the cells’ native 
hexose transporter(s) would be labelled by this ligand, and immunoprecipitated 
with the anti-GLUT 1 antiserum. Since no cytochalasin B labelled species was 
immunoprecipitated with the anti- GLUT 1 antibody, no immunoprecipitated 
labelled species was expected to be detected using ATB-BMPA. Neither were 
found to bind this ligand and be immunoprecipitated.
If  the full-length transporter expressed in Sf9 cells had a functional 
external glucose binding site the ATB-BMPA labelling experiment would be
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Figure 5.10. ATB-BMPA labelling of erythrocyte membranes. Membranes 
were incubated with ATB-BMPA with (o) and without glucose (+), and 
irradiated. Solubilised samples were immunoprecipitated using the anti -C- 
terminal GLUT1 antibody, and subjected to SDS-PAGE on a 10% acrylamide 
gel. Vertical slices were made of the gel lanes, and the radioactivity pH) 
content of each slice measured. The labelling peak corresponds to a molecular 
weight of between 55 and 65 kDa.
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expected to show a labelling peak at -50  kDa, the size of the expressed 
transporter.
Figure 5.11 shows that ATB-BMPA labels the E4.2 full length 
transporter protein with a clear peak at around 50 kDa. This peak is fully 
displaced by the presence of 200mM D-glucose. -50  kDa corresponds to the 
observed molecular weight of the E4.2 GLUT1 transporter protein as 
demonstrated by Western blotting using the anti-GLUTl- C-terminal antibody.
In order to determine whether the E4.2/Sf9 expressed GLUT1 
molecules were expressed largely at the surface of the cell, or whether a 
significant proportion of them were intracellularly localised, cells were 
incubated with 0.025% digitonin for eight minutes prior to a normal labelling 
experiment. The results of this are illustrated in figure 5.1 lb, as compared to 
figure 5.11a. This appears to indicate that either a great majority of the E4.2 
GLUT1 molecules are expressed on the surface of the cell, or that any 
intracellular E4.2 GLUT1 molecule are not in an appropriate conformation for 
the binding of the ATB-BMPA ligand.
As was found with cytochalasin B labelling, when the labelling profiles 
of GLUT1 in RBC membranes and the insect cell membrane expressed E4.2 
GLUT1 (labelling concomitantly performed) are compared (figure 5.12), two 
principal differences are observed. Firstly, there is the expected difference in 
the molecular weight at which the ligand labels. The transporter expressed in 
the insect cells is apparently smaller than that of RBCs, and corresponds to the 
size difference observed by Western blotting. However, using roughly matched 
samples (as in the cytochalasin B experiments, the samples were approximately 
matched by visual assessment of immunogenic protein content at the 
appropriate weight, from Western blots), the RBC sample shows much more 
labelling with ATB-BMPA than the E4.2 sample. From this experiment, it is 
not possible to determine whether this difference is due to a reduced binding 
affinity when the protein is expressed in insect cells, or whether a substantial
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Figure 5.11 A. ATB-BMPA labelling of Sf9 cells infected with recombinant 
baculovirus E4.2 (cells taken at 48 hpi). The cells were incubated with ATB- 
BMPA, and irradiated for 45 seconds (as described in section 2.2.3.8). The 
cells were solubilised, immunoprecipitated for two hours using the anti- C- 
terminal GLUT1 antibody, and subjected to SDS-PAGE on a 12% acrylamide 
gel. The radioactivity of the gel slices made was measured. Incubations were 
made in the presence (o), and absence (+) of 200mM D-glucose. This clearly 
shows that the -50  kDa binding peak is displaced by D-glucose.
B. ATB-BMPA labelling of digitonin permeabilised Sf9 cells infected with 
recombinant baculovirus E4.2. Cells were incubated with 0.025% digitonin for 
eight minutes before incubation with the photolabel. The digitonin was not 
removed before the labelling. The cells were solubilised, immunoprecipitated 
for two hours using the anti- C-terminal GLUT1 antibody, and subjected to 
SDS-PAGE on a 12% acrylamide gel. The radioactivity o f the gel slices made 
was measured. Incubations were made in the presence (o), and absence (+) of 
200mM D-glucose. There is clearly no appreciable difference in the height of 
the labelling peak between whole cells and permeabilised cells.
Radioactivity (cpm/slice/mg protein)
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Figure 5.12. Comparison of anti C-terminal GLUT1 antiserum 
immunoprecipitates of ATB-BMPA labelling o f erythrocyte membranes (+) and 
baculovirus E4.2 infected Sf9 cell membranes (o). Sf9 cells and RBC 
membranes were photolabelled, immunoprecipitated (using the anti C-terminal 
GLUT1 antibody) and subjected to SDS-PAGE on a 12% acrylamide gel (as 
described in chapter 2) simultaneously. This figure illustrates the different 
mobilities of the photolabelled species of RBC and E4.2 infected Sf9 cells.
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number of the expressed proteins are detectable by the anti GLUT1 antisera, 
but do not have functionally appropriate external glucose binding sites.
5.2.3 ATB-BMPA LABELLING EXPERIMENTS ON N-TERMINAL 
HALF PROTEIN
Since it is generally accepted that neither of the glucose transporter’s 
binding sites are located anywhere on the N-terminal half of the molecule, no 
labelling of cells infected with the N-terminal GLUT 1 expressing N 1 
baculovirus was expected with this ligand.
Figure 5.13 demonstrates the consistent finding that on the usual 
exposure to ATB-BMPA, and following immunoprecipitation with the anti N- 
terminal anti GLUT1 antiserum, no labelling at any molecular weight could be 
detected in cells expressing the N1 protein. Figure 5.14 is presented as 
confirmation that the anti N-terminal antiserum successfully 
immunoprecipitates the ATB-BMPA labelled E4.2 transporter protein.
5.2.4. ATB-BMPA LABELLING EXPERIMENTS ON C-TERMINAL 
HALF PROTEIN
The labelling studies of Clark and Holman (1990) of tryptic digests of 
the erythrocyte glucose transporter demonstrated that cytochalasin B bound to 
the 18 kDa fragment which corresponds to a large portion of the C-terminal 
half o f the molecule (but excluding the cytoplasmic C-terminal tail, and without 
most of the putative central cytoplasmic loop). Cytochalasin B was found to 
bind before digestion, to be detected to be associated with this fragment. It 
would also bind to this fragment following digestion. However, if  the glucose 
transporter was labelled with ATB-BMPA before trypsin treatment, the 
digestion was prevented. This was considered to be indicative of 
conformational change, that when the transporter is in the outward- facing 
conformation (i.e. binding an external- site specific ligand) the trypsin digest
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Figure 5.13 ATB-BMPA labelling of Sf9 cells infected with recombinant 
baculovirus N l. Labelled samples (section 2.2.3.8) were immunoprecipitated 
(2.2.3.6) using the anti N-terminal half GLUT1 antiserum, and subjected to 
SDS-PAGE on a 12% polyacrylamide gel. Samples were incubated in the 
absence of glucose. The radioactivity content of the gel slices made was 
measured. No distinct labelling species is detectable.
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Figure 5.14 ATB-BMPA labelling of Sf9 cells expressing the E4.2-encoded 
GLUT1 protein (cells taken at 48 hpi). The cells were incubated with ATB- 
BMPA, and irradiated for 45 seconds (as described in section 2.2.3.8). The 
cells were solubilised, and immunoprecipitated for two hours using the anti- N - 
terminal half GLUT1 antibody, before being subjected to SDS-PAGE on a 
12% acrylamide gel. This demonstrates immunoprecipitation of the E4.2/SP9 
ATB-BMPA-labelled species by the anti N-terminal GLUT1 antibody.
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site was not available to the trypsin molecule. On pre- digestion with trypsin, 
ATB-BMPA could not be shown to bind. This was considered to be an 
indication that the 18 kDa C-terminal fragment was perhaps locked into an 
internal- facing conformation, allowing only the binding of ligands specific to 
the internal binding site. However, the external binding site has been shown to 
exist on the C-terminal half of the molecule (Karim et al, 1987; Hashirimoto et 
al, 1992).
Despite the observations by Clark and Holman (1990) that the 18 kDa 
C-terminal fragment was apparently locked into an inward- facing 
conformation, the C-terminal half expressed in the Sf 9 cells is a quite different, 
and larger polypeptide. Since the external binding site is considered to exist on 
this half of the molecule it was considered that labelling might be observed. 
Based on the observation of apparent "dimer" structures as seen by 
approximately 50 kDa anti-GLUT 1 antibody immunoreactive bands on 
Western blotting (see chapters 3 and 4), it was considered that if  an association 
of the C-terminal polypeptides is the case, than perhaps this may have some 
bearing on either the structural or functional status of the molecules. That is, 
labelling was anticipated to be detected at either a molecular weight of around 
25 kDa, or at the weight of the higher molecular weight species observed on 
Western blotting.
The failure of the ligand to bind at any molecular weight of protein 
expressed by R12 baculovirus infected cells was consistently shown, and is 
demonstrated in figure 5.15. This shows that the C-terminal half of the protein, 
when expressed alone in this way, does not possess a functional external 
glucose binding site. However, since the C-terminal half was also 
demonstrated to fail to bind cytochalasin B, this could not support the 
prediction that a C-terminal half molecule may be locked into an inward- facing 
conformation.
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Figure 5.15 ATB-BMPA labelling of Sf9 cells infected with recombinant 
baculovirus R12. Cells were incubated with ATB-BMPA, immunoprecipitated 
using the anti C-terminal GLUT1 antibody, and subjected to SDS-PAGE on a 
12 %  acrylamide gel, according to sections 2.2.3.2, 2.2.3.6 and 2.2.3.8 of 
chapter two. No anti-GLUTl antibody reactive ATB-BMPA-labelled peak was 




Glucose transport measurements of cells infected with recombinant 
baculovirus E4.2 (expressing the full-length GLUT1 protein) were exhaustively 
tried, by way of uptake assays of tritiated 2-deoxy-D-glucose. The basic 
method used is described in section 2.2.3.10 of Materials and Methods. It had 
been previously found that the endogenous sugar transporter of the Sf9 cells 
was capable of 2-deoxy-D-glucose transport, but that this transport could be 
inhibited by the presence of 400 mM fructose (A.E. Clark; unpublished).
Since GLUT1 ligand binding and glucose transport are not inhibited by 
fructose, fructose was added to all of the experimental conditions in order to 
minimise any background transport activity occurring by the insect cells’ own 
transporters. As is clear from figure 5.16, the measurement of non-fructose 
inhibitable 2-deoxy-D-glucose uptake was not possible in cells infected with 
baculovirus. The findings were consistent in that there was no noticeable 
difference in the results o f transport assays carried out on cells infected with 
AcMNPV-lacZ (w ild type) virus and cells infected with either E4.2 (whole 
GLUT 1 transporter) or R12 (C-terminal half molecule). Despite fructose 
inhibition, some degree of 2-deoxy-D-glucose uptake was measurable in 
"mock" infected Sf9 cells (see fig.5.16). This is lost when cells are infected 
with baculovirus. On a number o f occasions (without consistent 
reproducibility), uptake was apparently measured in cells infected with virus 
E4.2. However, the levels apparently measured were not higher than those 
measured for "mock" infected Sf9 cells . Since this was not reproducible, the 
occasional apparent transport measurement may therefore be the result o f an 
inadequate infection.
In one transport assay, both the fructose inhibitable glucose transport, 
and the non-inhibited glucose transport levels measured (calculated per 106 
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Figure 5.16 2-deoxy-D-glucose transport assay (see section 2.2.3.10) of Sf9 
cells infected/mock infected, and assayed at 48 hpi. Cells were mock infected 
(+), infected with AcMNPV.LacZ (o), or infected with either recombinant 
baculovirus E4.2 (□ ), or R12 (x). A ll assay conditions included 400mM 
fructose.
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in either cells infected with the wildtype baculovirus, or mock infected cells 
(see figures given in table 5.1). A ll figures shown in table 5.1 represent 
transport of 2-deoxy-D-glucose at two minutes transport, having taken away the 
figures measured for cells incubated with both fructose and glucose during the 
assay.
Infection of cells fructose- non-inhibited fructose
inhibitable D- D-elucose inhibitable
elucose transport transport transport as a %
(fmol/106cells) (finol/106cells) of total.
mock 0.4 2.8 14%
”LZ" 0.2 1.9 10%
E4.2 0.8 5.7 14%
Table 5.1 2-deoxy-D-glucose transport in infected and uninfected Sf9 
cells.
As is clear from table 5, although the transport measurements were 
apparently higher for the E4.2 infected cells, the reduction in transport 
measured by the addition of fructose, as a proportion, was not different 
between the two conditions. That is, although the measurements were higher, 
the increased transport measured was not due to the actions of a non-fructose 
inhibitable system. Although this result is interesting, in that it appears to 
demonstrate that the GLUT1 encoded by the E4.2 virus is not functional, the 
result was never reproduced, and the result shown in figure 5.16 is more typical 
of the results of glucose transport assays on these cells.
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It was therefore considered to be highly likely that the measurement of 
hexose uptake was to be impossible. At 48 hpi, when expression of the 
GLUT1 protein was good, the cells were already in a state of considerable 
deterioration, as a consequence of the viral infection. It was considered that the 
damage sustained by the majority of the cells by this stage in the infection was 
such that the cells had become "leaky" as their membrane integrity was 
becoming compromised. The measurement of hexose transport at an earlier 
point o f the viral infection would mean the measurement from veiy many fewer 
transporters (for example, the quantity of GLUT 1-antibody immunoreactive 
material at 24 hours is less than four-fold lower than at 48 hours (by visual 
assessment of Western blots; see the E4.2 time course, chapter 4 section 4.1.2; 
and based on the relative quantification carried out on the R12 protein, which 
showed a very similar expression pattern).
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5.4 SUMMARY
The results of this chapter have demonstrated that the GLUT 1 protein 
expressed in insect cells is successfully labelled by the ligands cytochalasin B 
and ATB-BMPA. The labelling in both cases is glucose displaceable, which 
demonstrates the presence and ability of both glucose binding sites to bind 
glucose. This indicates that the insect cell-expressed GLUT 1 glucose 
transporter has functional external glucose binding sites and functional internal 
glucose binding sites, when expressed as a full-length protein. However, the 
results also indicate that the labelling of both ligands appears to be significantly 
lower than labelling of the GLUT 1 protein in the native erythrocyte 
environment. This is considered to be either due to a reduced affinity in the 
protein when expressed in insect cells; or possibly that only a proportion of the 
GLUT 1 molecules bind the ligands. This finding is consistent with that from 
similar experiments carried out by Y i et al (1992), who also expressed GLUT 1 
(human) in Sf 9 cells, using the baculovirus expression system. Although their 
expressed protein showed apparent differences to the Sf 9/ baculovirus 
expressed GLUT 1 protein described here when analysed by Western blotting 
(discussed in chapter 7), their protein was also found to bind cytochalasin B. 
Their findings, as those described here, were that the apparent concentration of 
active cytochalasin B binding sites was much lower than the quantity of 
immunoreactive protein present. No other study has to date provided labelling 
or binding data for external binding site ligands for glucose transport proteins 
expressed in this way.
These results apparently indicate that the functional (i.e. w ill bind the 
ligand ATB-BMPA) E4.2/Sf9 expressed GLUT1 molecules are largely present 
on the surface of the Sf9 cells. However, the results of the digitonin- 
permeabilisation experiments were not clearly reproducible, so this result is not
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considered to be conclusive evidence that the functional molecules are largely 
cell-surface localised.
These results concluded that the functional status of the full-length 
GLUT1 glucose transporter by hexose transport could not be determined using 
this system. Y i et al (1992) also found that on their expression of GLUT1, no 
hexose transport measurements were possible. The assessment of functional 
status of their GLUT1 protein was determined by cytochalasin B binding.
They also concluded that measurements could not be made because the cells 
had become "leaky" at the time of optimal (or even reasonable) glucose 
transporter expression.
Woon et al (1991)however, on their expression of GLUT4 protein, 
apparently found that measurement of hexose transport was possible. They 
found that the increase in GLUT 4 expression measured over 78 hours of 
infection, was accompanied by an increase in 2-deoxy-D-glucose uptake by the 
cells. This transport was found to be inhibitable by forskolin (as would be 
expected of GLUT 4), with an apparently different affinity than that of the 
endogenous transporters, for which they recorded a significant background rate 
of transport. Why transport measurements were demonstrated to be possible 
for the GLUT 4 (Woon et al) isoform but not for GLUT 1 (described here, and 
by Y i et al, 1992) is not known.
Results presented here have shown that, expressed independently of 
one another, neither of the two glucose transporter halves bind either o f the 
ligands. This indicates that, despite possessing the secondary structural 
positions of both the external and the cytoplasmic side glucose binding sites, 
the C-terminal half of GLUT 1 expressed alone in this way does not have 
functional glucose binding sites. That is, the suggestion of Karim et al (1987) 
that the residual N-terminal half region of the molecule (as a tryptic digest in 
their work, and therefore still present in the membrane ) is not required for 
ligand binding is not supported. The hypothesis made by M ueckleretal
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(1985) that a fragment containing only the transmembrane regions TM 7 to TM  
10, with associated links, would be fully functional, is shown here (for a larger 






One of the original aims of the project was to express the C-terminal 
half of GLUT 1, in insect cells, as though it were a protein in its own right.
The hypothesis was that both glucose binding sites were resident on this part of 
the molecule. As has been described in chapters 2 and 5 , this is a hypothesis 
based on, and supported by, a broad body of evidence. As has been described 
in chapter 5 however, this hypothesis could not be supported by the work 
described in chapter 5.
However, on the basis of a number of factors, the aim of the project 
was later modified. The C-terminal half protein expressed independently of 
any N-terminal half protein or whole GLUT 1 protein, could not be shown to 
bind the ligands. Yet the body of evidence for the localisation of the binding 
sites appears to contradict this. It was concluded that the binding sites may 
indeed be present on this part o f the molecule, but that part of the N-terminal 
half of the molecule must be necessary to permit the binding to occur. In a 
paper by Karim et al (1987), the authors speculatively conclude that the C- 
terminal half o f the molecule could function alone, on the basis of proteinase 
digestion of, and ligand binding to the GLUT 1 protein. However, the authors 
also offer the alternative conclusion that proteolysis with trypsin only "nicks” 
the transporter, and that the two major fragments observed may actually be held 
together as a functional unit during ligand binding and labelling. Therefore, 
evidence in which the transporter is fragmented, but where no fragment is 
isolated, cannot rule out the possibility of N-terminal involvement in ligand 
binding.
It was consistently observed, on Western blotting experiments of the 
R12 C-terminal protein, that the 25 kDa expected - size protein was not the 
only species to be detected by the anti GLUT 1 antibody. Figure 6.1 illustrates 
the second major species to be detected. This species has an Mj. of around 50
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Figure 6.1 Western blot o f a 12% SDS-PAGE, using anti C-terminal GLUT1 
antibody. Lanes 1 and 2 show red blood cell membrane GLUT1 protein.
Lanes 3 and 5 show anti-GLUTl antibody immunoreactive material in Sf9 cell 
membranes, at 48 hpi, with recombinant baculovirus R12. Lane 4 shows 
immunoreactive material o f Sf9 cell membranes similarly infected with 
recombinant baculovirus E4.2. Note the presence of an immunoreactive 
species of apparently -5 0  kDa in R12 infected membranes (lanes 3 and 5) in 
addition to the C-terminal half ~25 kDa size protein.
kDa; approximately twice that of the C-terminal 25 kDa. As figure 6.1 shows, 
the mobility is slightly greater than the mobility of the E4.2 GLUT 1 protein. 
Western blots have also often revealed immunoreactive species at higher 
molecular weights, but the 50 kDa band is consistently shown and always gives 
a strong signal. It was concluded that this may represent a dimeric form of the 
C-terminal half protein. Western blots of E4.2 (full-length GLUT 1 protein) 
often also reveal higher molecular weight immunoreactive species. It is widely 
believed that GLUT 1 may function in dimers or higher order multimers (E.g. 
Cuppoletti and Jung, 1981, Leib and Stein, 1971, Hebert and Carruthers, 1991). 
On the expression of the GLUT 4 glucose transporter in insect cells using the 
baculovirus expression system, Woon et al (1991) found a similar phenomenon 
occurring on Western blots of their protein. That is, from a monomeric GLUT 
4 molecule with an apparent Mr of 38 kDa, a higher molecular weight 
immunoreactive species was also apparent, at an Mj. of 84 kDa. Their 
conclusion was also that this form was "presumably” a dimeric form of their 
transporter molecule.
These observations were the basis for the theory upon which the 
experiments of this chapter were founded. The theory was also based on the 
work of Bibi and Kaback, 1990, Kaback et al, 1990, and Kaback, 1991. They 
studied the lac permease protein of E. coli. This protein is responsible for the 
transport of b-galactoside against its concentration gradient, by harnessing the 
energy from the electrochemical hydrogen ion gradient, in a coupled 
translocation system. Like GLUT 1, this membrane protein has a putative 12 
membrane spanning domains, and is more than 80% helical in structure. At 
417 amino acids, its length also is similar to that of GLUT 1. The gene (lac Y ) 
was divided into two approximately equal halves, and the two halves (each 
representing a six transmembrane domain polypeptide) were individually sub­
cloned. On the independent expression of the C terminal half, no protein could 
be detected. On the independent expression of the N-terminal half, protein
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could not be consistently detected. Their conclusion was that, as incomplete 
parts of a whole protein, the individual halves were being proteolysed by the 
cells. On the simultaneous expression of both polypeptides however, both 
fragments could be detected by immunoblotting and radiolabelling. In addition 
to this, no increase in lactose transport was detectable in cells harbouring 
plasmids containing only one of the halves. Lactose transport, at a rate of 
around 30% of normal was detected in cells expressing both proteins. Their 
conclusions from these findings were that an association was occurring in the 
membranes, between the separate but complementary polypeptides, which 
prevented or reduced the proteolysis of both, and resulted in a catalytically 
active complex. However, the observation of any "dimer" or "whole lac 
permease" bands on Western blotting, was not reported.
An equivalent co-expression approach has also since been 
demonstrated to return function in truncated muscarinic receptors (Maggio et 
al, 1993). O f a putative seven membrane spanning domain structure, the N - 
terminal four, including a long connecting loop usually between TM4 and 
TM5 were expressed in COS-7 cells. The remaining C-terminal "tail" 
including the final two transmembrane regions were also expressed using these 
cells. When the two constructs were simultaneously, but under different 
genetic control, expressed in COS-7 cells, ligand binding, not detected in the 
single expressions, was recorded. The ligand binding was found to have 
properties similar to the wildtype receptor.
The theory on which the work of this chapter was based, is as follows. 
Figure 6.2 describes this theory diagramatically. If, as has been suggested from 
the Western blotting results, associations are formed between the C-terminal 
half molecules, to form 12- membrane spanning domain units (as has been 
suggested to occur between the two different halves of the lac permease 
protein), and perhaps higher order multimeric units; perhaps N-terminal
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Expression of C-terminal half alone
expressed monomers nonfunctional dimers
Expression of N-terminal half alone
expressed monomers nonfunctional dimers
Co-Expression of the separate halves...
expressed C monomersexpressed N monomers
functional N-C dimers
Figure 6.2 Diagramatic representation of the dual infection theory
halves, expressed in the same way, may form similar associations with one 
another.
I f  then, in cells infected with the C-terminal encoding virus (R12) C-C 
associations are formed, and in cells infected with virus encoding the N - 
terminal half (N 1 ), N -N  associations are formed; perhaps if  cells are infected 
with both R12 and N 1 viruses, there may be N-C associations formed. I f  the 
two independently expressed proteins are in the correct conformation and 
orientation, perhaps then, such an association may form a functional glucose 
transporter, in the same way that lactose transport was detected when the two 
halves of the lac permease protein were individually encoded (Kaback et al,
1990). A functional conformation could be determined, in the same way that 
function was determined in the GLUT 1 protein expressed whole, using the 
specific photo ligands (as described in chapter 5).
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6 .2 THE N-TERMINAL HALF PROTEIN
This theory was approached by the production of a virus encoding the 
N-terminal half of the protein. The details and results of its independent 
expression can be seen in chapters three, four and five. The results of the 
labelling studies were not unexpected. No labelling was detected. There is no 
body of evidence to suggest that the labelling sites might exist on this part of 
the transporter molecule.
However, the "dimer" band which was hypothesised as the first part of 
the theory was detected, in addition to the "monomer" band of the expected M r 
It's detection on Western blots of cells infected with the N-terminal 
recombinant virus was found to be consistent, and higher molecular weight 
species were also often detected. Figure 6.3 shows this "dimer" band clearly. 
At around 53 kDa, it is apparently approximately twice the size of the 27 kDa 
N-terminal monomer protein. It shows a slightly lesser mobility than the E4.2 
protein.
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Figure 6.3 Western blot of 12% SDS-PAGE - using the anti N-terminal half 
peptide antibody. Lanes 1 to 4 show red blood cell membrane GLUT1. Lanes 
5 to 8 show 48 hpi membrane preparations of Sf9 cells infeceted with 
recombinant bacuovirus JE4.2. Lanes 9 and 11 show 48 hpi whole cell lysates, 
and lanes 10 and 12 show membrane preparations of Sf9 cells infected with 
recombinant baculovirus N 1. Note the presence, in these lanes, in addition to 
the -27  kDa band of N-terminal half GLUT1 protein, of an immunoreactive 





6.3 SIMULTANEOUS INFECTION OF CELLS WITH
VIRUSES ENCODING BOTH GLUT 1- HALF PROTEINS.
After having determined the Western blotting and labelling profiles of 
cells singly infected with either of the two transporter half encoding viruses, 
the way was paved to determine these profiles of cells infected with both 
viruses simultaneously.
Where singly infected, cells were infected with an average of 1.6 p.f.u. 
per cell (virus titres determined by plaque assay), in order to ensure the 
simultaneous infection of a large majority of the cells in the culture; doubly 
infected cells were infected with an average of 1.6 p.f.u. per cell of each virus, 
in order to infect as many cells as possible with both viruses.
6.3.1 WESTERN BLOTTING
On Western blotting of cells infected with both viruses, detected using 
the anti C-terminal GLUT 1 antibody, the usual immunoreactive profile of R12 
was found. That is, the R12 C-terminal monomer and dimer bands appeared, 
as well as higher molecular weight material. On blotting with the anti-N- 
terminal half GLUT 1 antibody, the usual profile of N1 was found. 
Simultaneous detection with both antibodies simply revealed an amalgamation 
of the two Western blotting profiles of the singly infected cells. A  clear size 
difference exists between the "dimer" bands of the R12 protein and the N1 
protein,(R12 dimer having slightly greater, and N1 dimer having slightly lesser 
mobility than E4.2 protein) but no intermediately migrating species was found. 
That is, Western blotting failed to reveal a band that was predicted by the 
theory as representing an N-C dimeric association. Figures 6.4, 6.5 and 6.6 
show lysates and membranes of dually infected cells, the GLUT 1 species 
being detected by the anti- C-terminal GLUT 1 antibody, the anti-N-terminal 
half GLUT 1 antibody, and both antibodies (respectively).
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Figure 6.4 Western blot using anti C-terminal peptide GLUT1 antibody. 
Lane 4 shows red blood cell membranes. Lanes 1, 2 and 3 show Sf9 cell 
lysates, taken at 48 hpi following infection with; recombinant baculovirus R 12 
(lane 1), recombinant baculovirus N1 (lane 2); and cells simultaneously 
infected with both viruses R12 and N l, with a pfu of -  1.6 per virus. 
Equivalent quantities of total protein were loaded in each Sf9 sample lane.
O
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Figure 6.5 Western blot detected using the anti N-terminal half anti-peptide 
antibody. Sf9 cells were infected with recombinant or "wildtype" baculovirus, 
at an average of 1.6 pfu/cell. Lysates were made at 48 hpi, and run on a 12% 
polyacrylamide gel. Lane 1 shows cells infected with AcMNPV-LacZ; lane 2 
shows cells infected with E4.2, lane 3 shows cells infected with R12, lane 4 
shows cells infected with N 1; and lane 5 shows cells infected with R12 and N 1 
simultaneously.
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Figure 6.6 Western blot of an SDS-PAG, using anti C-terminal and anti N- 
terminal half GLUT1 antibodies simultaneously. Lane 1 shows Sf9 cell 
lysates, taken at 48 hpi, following infection with baculovirus E4.2; Lane 2 
shows cells similarly infected with baculovirus R12. Lane 4 shows cells 
infected with virus N l, and lane 3 show cells dually infected with R12 and N l. 
Lane 5 shows red blood cell membranes GLUT1.
6.3.2 ATB-BMPA LABELLING STUDIES
Following the theory, N-terminal halves and C-terminal halves should 
associate by some means, on a one to one basis, in the way which appears to 
occur in the association of N-terminal halves and N-terminal halves, and C- 
terminal halves with C-terminal halves. Since no labelling species can be 
detected in cells expressing only C-terminal half monomers and possible 
multimers, the hypothesis suggests that although the binding sites are situated 
on this part of the molecule, perhaps part of the N-terminal half of the molecule 
is essential for some aspect of the binding. Therefore, the hypothesis would 
predict that, if  formed, the amalgamated N-C dimer species might be labelled 
with the side - specific ligands.
Cells were infected, in 35mm dishes, as described in chapter 2 , with 
an avg. infection of 1.6 pfu per cell each of viruses N l and R12. After 48 
hours, a normal labelling experiment was carried out using the photolabel 
ATB-BMPA. Since the predicted labelling species was expected to be 
relatively low in abundance, compared to the E4.2 protein, and even the C and 
N-terminal half molecules, three times the usual quantity of label was used 
(300jiC i), in order to ensure that if  a labelling species was present, it would be 
detected. The experiment was conducted as described in section 2.4.8.
The results are shown in figure 6.7. As is clear from this, a species of 
protein from the dually infected cells has been labelled with the photoprobe. 
Labelling at this molecular weight (-25  kDa) is not detected in cells expressing 
the E4.2 protein, the C-terminal protein alone, the N-terminal protein alone, 
cells infected with an "irrelevant” P-galactosidase-encoding virus, or cells 
"mock" infected with T C I00 medium only (see chapter 5). However, the 
hypothesised labelling species was at about 50 kDa ( the expected weight o f an 
N-C dimer species). The actual labelled species that was detected has an 
equivalent M r of around 25 kDa.. This is more clearly illustrated in figure 6.8,
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Figure 6.7 ATB-BMPA labelling of Sf9 cells simultaneously infected with 
recombinant baculoviruses R12 and N l. Cells were taken at 48hpi, and 
incubated with ATB-BMPA in the presence (o) and absence (+) of 200mM D- 
glucose. Cells were irradiated for 45 seconds, and immunoprecipitated using 
the anti GLUT1 C-terminal peptide antibody. Samples were subjected to SDS- 
PAGE on a 12% acrylamide gel. A labelling peak at ~ 25 kDa is clear.
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Figure 6.8 ATB-BMPA labelling of dual-infected cells (simultaneous 
infection with viruses N l and R12) (+) concomitantly with cells infected with 
virus E4.2 (o). Labelled cells were immunoprecipitated with the anti GLUT1 
C-terminal peptide antibody, and subjected to SDS-PAGE on a 12% acrylamide 
gel. This illustrates the difference in mobility of the labelling peaks from the 
two conditions.
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which shows the result of an ATB-BMPA labelling of dual infected cells, with 
a simultaneously performed ATB-BMPA labelling experiment using cells 
infected with the E4.2 virus. It is clear from its mobility that the species that is 
labelled by the ATB-BMPA ligand is approximately half the size of the 
predicted labelling species. The apparent weight of the labelled species 
corresponds to the molecular weight of the R12 C-terminal monomer species.
This experiment was repeated, and the labelling at this molecular 
weight (~ 25 kDa) was found to be reproducible. As is apparent from figure 
6.7, less label is found to be associated with the dual-infected cells than cells 
infected with E4.2. From a series of comparative experiments, it was found 
that, on average (mean) the dual-infected cells label to about 33% of the cells 
expressing the full-length protein whole.
Figure 6.9 shows ATB-BMPA labelling of Sf9 cells infected with E4.2, 
or simultaneously with N 1 and R12; where samples were immunoprecipitated 
with the anti-N-terminal half GLUT 1 antibody. This demonstrates that the anti 
N-terminal half antibody successfully recognises the E4.2 encoded GLUT 1 
protein in an immunoprecipitation. This also demonstrates that the labelled 
species detected in dually infected cells using the anti-C-terminal GLUT 1 
antibody is not immunoprecipitated by the anti-N-terminal half GLUT 1 
antibody. That is, the label appears to be associated with the C-terminal half 
polypeptide, but not with the N-terminal half polypeptide.
6.3.3. CYTOCHALASIN B LABELLING STUDIES
A similar experiment was conducted using the cytochalasin B 
photolabel (as described in chapter 5 and chapter 2 section 2.2.3.7). Again, the 
experiment was conducted in the same way as for the three recombinant 
proteins expressed singly, with the modification of the use of three times the 
usual quantity of label (48pCi). Figure 6.10 shows the result of such a 
labelling experiment. There is a clearly defined labelled species at an Mr
199










1610 12 14 18 202 6 80 4
Gel Slice No.
Figure 6.9 ATB-BMPA labelling of dual-infected cells (simultaneous 
infection with viruses N l and R12)(o) concomitantly with cells infected with 
virus E4.2 (+). Labelled cells were immunoprecipitated with the anti N - 
terminal GLUT1 antibody, and subjected to SDS-PAGE on a 12% acrylamide 
gel. Although the E4.2 ATB-BMPA labelled species is immunoprecipitated by 
the anti N-terminal antibody, the dual-infected cells have no labelled species 
that can be immunoprecipitated using that antibody.
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Figure 6.10. Cytochalasin B labelling of cells simultaneously infected with 
recombinant baculoviruses N l and R12. Cells, at 48hpi, were incubated with 
cytochalasin B in the presence (o) and absence (+) of 200 mM glucose, 
irradiated (as described in 2.2.3.7), and immunoprecipitated using the anti 
GLUT1 C-terminal peptide antibody. Samples were subjected to SDS-PAGE 
on a 12% acrylamide gel. A labelled species of ~ 25 kDa can be seen.
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corresponding to around 25 kDa. On repeating this experiment, this result was 
found to be reproducible.
On carrying out a series of comparative labelling experiments between 
cells expressing the full-length GLUT1 protein (virus E4.2), and cells 
separately expressing the two halves of the GLUT1 protein (viruses N l and 
R12), it was found that the labelling of the GLUT1 protien in the dual-infected 
cells was about 55% (actual mean 57.7%) that of the whole GLUT1 protein.
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6.4 DISCUSSION
The tentative conclusion from these results is that, expressed as a 
separate protein, the C-terminal half of GLUT 1 can be labelled with ligands 
specific for both the external and the internal glucose binding sites, if  N - 
terminal protein is present in the cell. Therefore, the general hypothesis 
outlined in section 6.1 appears to be partially supported. The N-N association 
predicted in the first part of the theory was apparently detected by Western 
blotting. The simultaneous expression of independently expressed C-terminal 
protein and N-terminal protein does result in the binding o f ligand by a protein 
species expressed in the cells as a result of the infection. However, the 
predicted association of N  and C-terminal half proteins could not be detected 
by Western blotting. However, since the molecular weights o f the N-N, C-C, 
and predicted N-C association species would be expected to differ by only a 
few kDa, the appearence of the N-C species may be masked in Western blotting 
by the detection of the N-N or C-C species (depending on which antibody is 
used in the detection). Also, the size of the protein species predicted to become 
labelled was the size of the C-terminal monomer, and not the predicted 
hypothetical N-C dimer species.
Therefore, where Kaback et al (1990) succeeded in producing a 
functional association of two independently encoded halves of a bacterial 
transporter protein, without the direct detection of the association per se; these 
results show the successful functional association of the two independently 
encoded halves of a mammalian transport protein, without the direct detection 
of an association species.
Since ligands specific to both the internal and the external glucose 
binding sites have been shown to bind to the C-terminal R12 protein, there 
seems to be two possible explanations for the conformational state of the C- 
terminal half protein, or for the N-C association species. Firstly, there may be
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two forms of the N-C association, corresponding to transporter protein locked 
into external- facing form, and some transporters/halves existing in the internal- 
facing conformation. Alternatively, the association allows the conformational 
change in the C-terminal half that is necessary for the alternating availability of 
the two sites for ligand binding. This model would represent a fully functional 
glucose transport protein.
That the labelling of the C-terminal half in dual-infected cells does not 
label to the same extent as the full-length GLUT1 protein may be due to a 
number of points. I f  the N-C dimer association theory is correct, then, on the 
basis that that N-C, N -N  and C-C associations are present in approximately 
equal proportions, and based on the observation that monomers of both N - 
terminal and C-terminal species are still the most highly immunoreactive 
species in dual-infected cells; the N-C species represents only a fraction of the 
availabel GLUT1 C-termini in the cells. Even on the basis that there is only a 
slight apparent reduction in expression of each species in the dual-infected cells 
as compared to cells infected only with one virus (judged visually from 
Western blotting), the level of labelling (at 33% and -55%  for the two ligands) 
is good. On this basis, it would appear that all of the associations give rise to a 
functional (ie. can be labelled) molecule, which is capable of binding both 






7.1 EXPRESSION OF FUNCTIONAL GLUCOSE
TRANSPORTERS IN Sf9 CELLS
The work described in this thesis has demonstrated that by using a 
recombinant baculovirus, the mammalian GLUT 1 glucose transporter can be 
functionally expressed in Sf9 insect cells. It has been demonstrated that the 
insect cells do not innately express any protein species that cross react with the 
specific anti GLUT 1 antibodies used to detect the baculovirus encoded GLUT 
1 proteins. The expression of the full- length protein yields a predominant and 
broad band on Western blotting following SDS-PAGE at an average Mj. of 
~50kDa, with smeary high molecular weight immunoreactive products (at ~
100 kDa, often some higher) being consistently observed at a lower abundance. 
Optimal expression of the full- length protein product is at around 60 to 72 hpi. 
However, sufficient quantities of protein for experimentation and analysis were 
expressed by 48 h p i, and because of significant cell damage observed at 60 to 
72 hpi, this time-point was used for further experiments. The expressed protein 
was demonstrated to be appropriately inserted into membrane, and using side- 
specific photoreactive ligands, was found to have both internal and external 
glucose binding sites intact. The expression level of the full length protein was 
found to be around 150 to 200 pmols GLUT1 protein/mg membrane protein. 
Although this does not represent a very high level, as is achieved by many 
proteins expressed using the baculovirus expression system, the amounts 
present were easily detectable using Western blotting, consistent with levels of 
other membrane proteins expressed in this system, and fully adequate for any in 
situ analyses.
In 1991, Woon et al successfully expressed GLUT 4 in Sf9 cells in a 
similar way to the GLUT1 expression described here. The protein was found 
to be appropriately membrane associated, and the use of a specific antibody to 
a GLUT 4 extracellular epitope demonstrated that a significant proportion of
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the protein was intracellularly located, as is usual for GLUT 4 in its native 
environments (e.g. in rat adipocytes GLUT 4 is associated with the low density 
microsomal fraction on subcellular fractionation). Their use of antibodies to an 
external epitope of the molecule on whole cells also apparently confirmed the 
appropriate orientation of the molecule within the membrane. Like the GLUT 
1 expression described here, Western blotting of Sf9 cells expressing GLUT 4 
showed that expression could be detected with specific antibodies by 24 hpi, 
and reached a maximum expression at around 72 hpi. This was followed by a 
gradual reduction o f expression levels as the viral infection progressed beyond 
72 hours. The levels of expression for the GLUT 4 protein, as determined by 
quantitative immunoblotting were found to be 1.2 nmol/mg membrane protein. 
This expression level is apparently significantly higher than the levels of 
GLUT1 expression described in this thesis.
In 1992, Y i et al expressed GLUT 1 in Sf9 cells using the baculovirus 
expression system. In common with results presented here, and with the 
expression of GLUT 4 by Woon et al., Y i et al (1992) demonstrated that their 
GLUT 1 protein was membrane associated. Since there is as yet no reliable 
subcellular fractionation protocol for insect cells, and in the absence of 
reliable specific GLUT 1 extracellular epitope antibodies, we were unable to 
unequivocally determine whether our GLUT 1 protein expressed in insect cells 
was associated with the plasma membrane, intracellular membranes, or a 
combination of both. Y i et al, however, using confocal immunofluorescence 
microscopy, and the production of serial confocal optical sections, were able to 
demonstrate that GLUT 1 protein was found to be located both at the cell 
surface, and associated with intracellular membranous structures. A time 
course of expression showed that the GLUT1 protein expression recorded by 
that group reached a maximal level at 120 hpi., following a steady increase over 
the five days followed. This is in contrast to the work described here, where 
optimal expression was found at around 60 hpi, following a steady increase
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from the first appearance of the protein (at 18 to 24 hpi). Following this 
optimal expression, the levels of detectable GLUT1 protein began to level off, 
and even to decrease, more closely following the pattern of GLUT 4 
expression described by Woon et al (1991). These differences may be due to 
different multiplicities of infection used by each group (ave. 1.6 pfu/cell for 
GLUT1 protein described here; ave. 10 for the GLUT 4 of Woon et al, and 5 to 
10 for the GLUT 1 of Y i et al.), and the effects of moi and cell growth phase 
as described in section 1.3.3.
The binding of ligands specific to both the internal, and the external 
glucose binding sites was demonstrated. However, as is discussed in section 
5.1.2, the extent of labelling (with either ligand) did not appear to match the 
expression levels obtained. That is, although equivalent quantities of RBC 
GLUT1 and Sf9/baculovirus GLUT1 (determined visually from Western 
blotting) were used for ligand labelling experiments, the labelling of the insect­
cell expressed GLUT1 was apparently only about one third of that of the 
erythrocyte. Since immunoreactive protein content of the two conditions had 
been approximately matched, the differences in GLUT1 protein presence 
cannot account for the differences in labelling that are observed. The 
differences must therefore be due to either a difference in binding affinity, or 
reflective of the fact that there may be immunogenic but non-functional 
transporters being expressed as well as functional ones.
This phenomenon was also observed by Y i et al (1992), where the 
calculated observed difference was approximately 5.5 fold. The authors 
suggested that the difference was due to only a proportion of the expressed 
transporters being capable of ligand binding. A similar phenomenon was 
observed by Germann et al (1990) on the expression of the human multidrug 
transporter.
The proposed presence of a mixture of functional, and non-functional 
GLUT 1 molecules in the insect cell membranes may be the result of different
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levels of glycosylation being achieved. That the GLUT1 bands observed on 
Western blotting are consistently smeary is consistent with the presence of 
heterologous glycosylation. Heterologous glycosylation is usual for GLUT1, 
and is observed in the native erythrocyte form, though at a higher average 
molecular weight than the range observed in the SfWbaculovirus system. This 
average molecular weight difference is very likely to be due to a reduced 
overall level of glycosylation of the insect cell - expressed GLUT1.
As is described in section 1.3.3.1, it is very rare for a glycoprotein 
expressed using the baculovirus system, to be folly appropriately glycosylated. 
Insect cells are generally considered to be deficient in the enzymes required for 
the "decoration” of "trimmed" high-mannose type oligosaccharides. The 
heterologous glycosylation of many mammalian glycoproteins is a mixture of 
"trimmed" and "trimmed and decorated" oligosaccharides. Although the 
presence of more simple oligosaccharides; either high-mannose type, or a 
mixture of high-mannose and trimmed oligosaccharides has apparently no 
effect on the biological function of a number of glycoproteins expressed in 
insect cells (section 1.3.3.1), there are notable exceptions (also outlined in 
1.3.3.1). Although there are apparently no cases of completely non-functional 
glycoproteins being expressed in this way, reduced function, considered to be 
perhaps due to the reduction in glycosylation, has been recorded: for example, 
the human multidrug transporter (Germann et al 1990), and the extracellular 
domain of human nerve growth factor (Vissavajjhala and Ross, 1990).
The expression of GLUT1 by Y i et al (1992), showed that the protein 
had an apparent molecular weight of around 45 kDa. In contrast with the 
GLUT1 band described here, a smeary band of around 50 kDa, their band was 
fairly sharp. Endoglycosidase F treatment yielded a protein of slightly 
increased electrophoretic mobility, which was barely different from the 
deglycosylated erythrocyte GLUT1 (at -46  kDa). This demonstrated that their 
GLUT1 protein was glycosylated only to a limited extent of the native
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erythrocyte form. The relative absence of smearing of the GLUT1 band 
suggested that their GLUT1 protein was relatively homologously glycosylated. 
That the GLUT1 protein expression described here is of higher apparent 
molecular weight, and an immunoreactive band apparently more smeary, than 
that described by Y i et al, may be indicative of an expression in which a 
heterologous range of glycosylation (perhaps high-mannose type, and trimmed 
oligosaccharides) is achieved. However, the glycosylation state of GLUT1 
expression described here, was not experimentally determined. Treatment with 
endoglycosidases, and analysis by Western blotting would be necessary in 
order to reach any conclusions about the actual state of glycosylation of the 
expressed protein. The differences in molecular weight and range observed 
between the GLUT1 protein expressed in the same way but by two different 
groups may only be technical. That is, a different range of molecular weight 
standard markers was used by each group, and slight variations in technique of 
sample and gel preparation are likely to be the case. These technical 
differences may be sufficient to account for the apparent molecular differences. 
In order to unequivocally conclude that there are differences in the levels of 
glycosylation and in the molecular weight of the GLUT1 protein between the 
different groups (both using the AcMNPV/Sf9 baculovirus system), they would 
have to be compared directly. In the absence of such a study, of the GLUT 1 
protein expressed here, it can be said that some level of glycosylation is 
apparent (treatment with endoglycosidases in concert shows that the core 
polypeptide of erythrocyte GLUT1 has an Mj. of ~ 38,000 kDa, Haspel et al, 
1985), and that that glycosylation is not to the extent of the native erythrocyte 
GLUT1. The expression of GLUT 4 by Woon et al (1991) showed that this 
molecule too, had a reduced glycosylation status when expressed in insect cells.
Studies of the importance of glycosylation of the glucose transporter 
proteins have suggested that the alteration of the asparagine- linked 
glycosylation can effect the rate of transcription of transporter DNA, but does
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not affect glucose uptake (Haspel et al, 1988, on studying GLUT 1 expressed in 
N-acetylglucosaminyltransferase 1- deficient CHO cells. (Asano et al,
1992,1993). These studies suggested that alterations in the glycosylation of the 
transporter may affect the formation of a structure with a high affinity for 
glucose, or the targeting of the protein to the membrane compartments 
appropriate to its isoform. The apparent observation (here, and by Y i et al, 
1992) that only a proportion of the expressed GLUT1 molecules are capable of 
ligand binding at the glucose binding sites, (or that the binding is o f a reduced 
affinity compared to native GLUT 1), is consistent with these suggestions.
The evidence for the effects of altered, particularly reduced, 
glycosylation on the biological function of a glycoprotein is largely based on 
the evidence of proteins being expressed in systems deficient of one or more of 
the enzymes required for full glycosylation. It is therefore largely 
circumstantial and rather indirect. Much more research is required in this 
important area, before definitive statements of cause and effect can be attached 
to the glycosylation status and functional status of glycoproteins.
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7.2 GLUCOSE TRANSPORT IN BACULOVIRUS-INFECTED
Sf9 CELLS.
The functional status of the GLUT1 glucose transporter expressed in Sf9 
cells was determined by the use of two transporter side-specific ligands. These 
results are described in chapter 5.
Glucose transport measurements, thought exhaustively tried, were found 
to be unsuccessful, and therefore not an appropriate method of determining 
glucose transporter function in this system. The conclusions reached by Y i et 
al (1992) on their expression of GLUT1 using the Baculovirus expression 
system were in agreement with this. That is, that by the time in an infection 
that a measurable amount of transporter protein is expressed by the cells, the 
cell membranes are beginning to suffer as a result of the viral infection, and 
become "leaky".
This phenomenon is not restricted to glucose transport proteins. For 
example, Germann et al (1990) expressed the human multidrug transporter, 
which usually functions to confer multidrug resistance to a cell. It was not 
possible to demonstrate this when the transporter was expressed in insect cells 
using the baculovirus system. They also concluded that this was due to the 
cells becoming leaky dining the course of the infection. The functional status 
of this molecule was determined by ligand binding, and found to be 
functionally similar to its authentic counterpart.
Although the binding of ligands to each glucose binding site of the 
baculovirus/insect cell GLUT1 molecule is good evidence for the functional 
status of the transporter, empirical evidence of actual transport would be 
necessary for fully definitive evidence that the molecule functions as a glucose 
transporter. This could be achieved by reconstitution experiments in which the 
Sf9/baculovirus expressed transporter is put into intact membrane systems, 
where the integrity of the original host membrane is unimportant. GLUT 1
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from erythrocytes have been reconstituted into non-native membrane 
environments (for example; Kasahara and Hinkle, 1977; Hinkle et al, 1979; 
Baldwin et al, 1980; Baldwin et al, 1981; Chin et al, 1986). Baldwin et al 
(1981) described the reconstitution of GLUT 1 into vesicles such that each 
vesicle contained an average of one GLUT1 molecule. Although they found 
that the transport activity of the reconstituted erythrocyte GLUT1 was only 
~5% of that o f intact erythrocytes under similar conditions, the activity was 
readily measurable, and was found to be due to a general reduction in activity 
of all molecules, rather than the loss of function of a proportion of them. In 
this case, the detection of transport of reconstituted insect cell-expressed 
transporters would conceivably be possible.
In view of the evidence that has been obtained, and that a vast majority 
of foreign proteins, even glycoproteins, expressed in insect cells using the 
baculovirus system are found to be biologically functional, often to the same 
level o f the protein in a native environment, it is quite likely that transport 
activity, in a reconstitution system, would be detected, and that that activity 
would match the ligand binding that has been measured. If  measurements of 
hexose transport could not be made in such a system, this would suggest that 
perhaps the apparent reduced affinity or presence of non-functional molecules 
as compared to the transporter in the erythrocyte environment, may actually 
indicate the expression of two forms of transporter. That is, one form that is 
locked into an inward-facing conformation, and one form that is locked into an 
extracellular-facing conformation; with no conformational change possible 
between the two. Given the circumstantial evidence that most other proteins 
expressed using the baculovirus expression system are found to be biologically 
functional, and that a degree of function has been demonstrated for the GLUT1 
protein, by way of the ligand binding; it is perhaps more likely that hexose 
transport would be measurable in a reconstituted membrane system.
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7.3 FUNCTIONAL ARRANGEMENT OF GLUCOSE
TRANSPORTER MOLECULES.
7.3.1. ASSOCIATION OF TRANSPORTER MOLECULES
At the onset of this project, it was intended that the C-terminal half of 
the GLUT1 protein would be expressed in Sf9 cells independently. In the light 
of all of the evidence pointing to the C-tenninal half as the "functional end" of 
the transporter, is was hypothesised that it might function as a transporter when 
expressed alone. Chronologically fairly early, it was clearly demonstrated that 
the C-terminal half expressed alone was not able to bind ligands at either the 
internal, or the external glucose binding sites. Chapter six describes the theory 
behind the production of an N-terminal half-encoding baculovirus, and its co­
expression with the C-terminal half to produce a functional unit. The reasons 
why it was considered that this might work, and the description of a similar 
experiment conducted in E.coli bacterial cells (Bibi et al, 1990; Kaback et al, 
1990) are also fully discussed in chapter six.
One of the bases for the development of the dual expression hypothesis 
was the observation of higher molecular weight material on Western blots of 
the independently expressed C-terminal half protein. Higher molecular weight 
species were also found on many Western blots of the full-length transporter.
It is quite evident from the literature that the appearance of apparent 
multimeric forms of a number of proteins has been reported. The observation 
of higher molecular weight species on Western blotting of the expression of 
GLUT 4 in baculovirus was also made (Woon et al, 1991).
A good example of the detection of a multimeric form of a protein on 
SDS-PAGE is that of the Sf9/baculovirus expression system expressed 
serotonin receptor, o f Ng et al (1993). On Western blotting, the monomeric 
form, at -42 kDa was the most prominent. The proposed dimer band at -95
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kDa was less prominent. Both bands were found to be immunoprecipitated by 
a specific antibody for the serotonin receptor. However, where, on the 
expression of glucose transporters using the baculovirus system no functional 
status could be attributed to the higher molecular weight species, Ng et al 
(1993) found that photolabelling with a serotonin receptor specific ligand 
labelled species at both molecular weights, Although apparent dimers have 
been described for a number of proteins, this example positively confirms 
(beyond immunological reactivity) the identity of the higher molecular weight 
species as actually being a multimeric form of the protein in question.
As is described in chapter one (section 1.1.5 in particular) it has been 
suggested that the functional unit o f the GLUT1 molecule is as a multimer; 
either a dimer, or a tetramer. There is much evidence to support this view. If  
there is a close interaction between GLUT1 molecules, then it may seem 
feasible that the highly hydrophobic nature of the overall GLUT1 protein, along 
with whatever forces are involved in the maintenance of multimeric units, may 
cause aggregation on SDS-PAGE such that the multimers would appear on the 
gels. Hebert and Carruthers (1992) have suggested that the maintenance of the 
proposed homotetrameric structure may be stabilised by intramolecular 
disulphide bonds, which are preserved particularly in the absence of a reductant 
by the hydrophobic nature of the GLUT1 protein (samples for SDS-PAGE 
described in this thesis were solubilised in a 6M urea sample buffer without p- 
mercaptoethanol, and were not boiled before loading onto the gels). They 
propose that there are up to two intramolecular disulphide bonds per monomer 
pair, and that the establishment of the native structure is established prior to 
translocation to the plasma membrane. They propose that the intra-subunit 
disulphide bonding promotes the co-operative subunit interactions that stabilise 
transporter structure and function.
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Associations between different molecules have been reported from dual 
expression studies of proteins using the baculovirus system. The Simian Virus 
40 large T-antigen was dually expressed with mouse p53 protein in Sf21 cells 
(O'Reilly and M iller (1988). During infection with Simian Virus 40; the large 
T-antigen normally associates with the host cell p53 protein. Such an 
association is also recorded when both are simultaneously expressed in insect 
cells. Another example is the expression, from two different recombinant 
baculoviruses, of two Influenza viral polymerase proteins results in the 
formation of a functionally intact association, as would occur in a host cell 
when both proteins are encoded by the Influenza virus (St. Angelo et al, 1987). 
Therefore, the insect cells apparently permit interactions between proteins as 
would occur in their authentic environment.
I f  intra-molecular disulphide bonding between GLUT1 molecules so 
readily occurs, and that there is more than one such bond per molecule, as 
suggested by Hebert and Carruthers (1992), then the appearance o f dimers of 
the C-terminal half is not unreasonable. If  an appropriate conformation of the 
C-terminal monomers is achieved within the membrane, then it may be 
reasonable to assume that the mechanisms of molecular recognition responsible 
for the formation of intra-subunit disulphide bonds within the intact molecule 
should also apply to the association of C-terminal monomers. I f  the suggestion 
that there are at least two such bonds responsible for the association o f intact 
GLUT1 molecules is correct, then it is possible that at least one associates the 
C-terminal half of one molecule to the C-terminal half of another; and that 
another associates the respective N-terminal halves. Since we have 
demonstrated the existence, on Western blotting of cells infected with virus 
encoding only the N-terminal half of GLUT1, of apparent N-terminal dimers, 
then some kind of intra-molecular association is clearly taking place.
Pessino et al (1991), as discussed in chapter one, have presented 
evidence that GLUT1 functions in oligomeric formations. They describe the
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expression of GLUT 1:GLUT 4 chimeric molecules, in cells endogenously 
expressing GLUT1, and the successful immunoprecipitation of native GLUT1 
molecules using specific GLUT4 antibodies. By the nature of the construction 
of the chimeric molecules, they concluded that a major determinant of 
oligomerisation of GLUT 1 is located within the first 199 residues. The work 
described in this thesis apparently contradicts this, if  the higher molecular 
weight species of the half molecules expressed separately are to be believed to 
be dimers. However, although Pessino et al (1991) suggest a major determinant 
to be located within the first 199 residues, they do not suggest that there is not 
also a determinant located within the remainder of the molecule.
The work of Popot and Engleman (1990) on protein folding and 
oligomerisation uses the bacteriorhodopsin molecule as a model. They discuss 
the nature of forces and bonds responsible for holding membrane proteins in 
the correct conformation. The bacteriorhodopsin molecule can be cleaved into 
two parts (a five transmembrane portion, and a two transmembrane-domain 
spanning portion) by a single cleavage. The two fragments can be completely 
denatured, and re-folded in separate vesicles. Upon fusion of the two types of 
vesicle, the two fragments successfully re-form an appropriate conformation for 
the binding of retinal. That is, the native structure is apparently completely re­
formed, and a covalent link between the two fragments is not required for the 
molecule to refold properly.
The findings of Popot and Engleman (1990) might suggest that the 
association of the independently expressed portions of the glucose transporter 
may be due to their adoption of conformations that are sufficiently similar to 
their structures in the entire GLUT 1 protein, that recognition and correct 
association occur purely on this basis.
The successful, albeit non-functional, independent expression of the two 
halves of the GLUT1 glucose transporter serves to support part of a theory 
constructed by Mueckler and Lodish (1986). They proposed that the GLUT 1
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glucose transporter, having no cleavable signal sequences, has at least two 
signal sequences responsible for the direction to, and insertion into the 
membrane. They propose that such a signal exists at least once in the N - 
terminal half, and at least once in the C-terminal half of the molecule. They 
propose that these signals target the polypeptide to the membrane, and initiate 
insertion into the membrane co-translationally; each sequence initiating the 
insertion of the polypeptide area immediately adjacent to it, as soon as it itself 
has been translated. That both the N-terminal polypeptide and the C-terminal 
polypeptide expressed in the insect cells are both found to be membrane 
associated, and that together they associate to form a functional unit, confirms 
that there is at least one independently functional membrane-insertion signal 
sequence in each half of the molecule.
Molecular modelling and mapping studies suggest that GLUT1 may 
exist as a bilobular structure, consisting of two closely packed bundles of six 
helices, corresponding to the N-terminal and the C-terminal halves of the 
molecule (Hodgson et al, 1992). The flexibility o f the long central cytoplasmic 
loop between TM  6 and TM 7 allows the packing in these two distinct domains, 
and the relatively short linker regions between the other transmembrane 
segments suggest a close packing of helical bundles in each of the two halves. 
The dual expression studies described in this thesis support this view. It is 
demonstrated that although it is the C-terminal half o f the molecule to which 
the ligands bind, the presence of the N-terminal half of the molecule is 
required in order for the binding to take place.
It is suggested that the N-terminal half, or part of it, provides a packing 
surface for the C-terminal half, such that this part of the molecule can adopt an 
appropriate conformation for the binding of ligands. From studies of the role of 
glycosylation of the glucose transporter molecule already discussed, it has been 
strongly suggested that glycosylation, which is found only associated with Asn 
45 of the N-terminal half, may be important in the maintenance of a functional
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conform ation. Based on this, the glycosylation of the N-terminal half may 
perform a key function in the formation of a ligand binding conformation of the 
C-terminal half.
In order to more closely define the relationship between the C- and N - 
terminal halves of the molecule, a series of constructs could be made which 
consist o f selected areas of the N-terminal half only. Viruses from these 
constructs could then be co-expressed in insect cells with the C-tenninal half 
virus R12. A fu ll six-membrane spanning domain N-terminal construct with a 
single amino acid substitution at Asn 45 to produce a non-glycosylated form 
may be one of the simplest, to test the hypothesis that the glycosylation of the 
molecule is important in the formation of a functional conformation. The 
production of a series of constructs having sequential deletions of the 
membrane spanning helices may also be useful. However, not all protein 
products may be viable, or may not be correctly targeted, due to the absence of 
signal sequences etc. The analysis of membrane association of such constructs 
may be helpful in determining the localisation of the signal sequences involved 
in the membrane insertion of the N-terminal half. The close analysis of 
whether "dimer" bands are present on Western blotting of cells singly infected 
with the sequentially truncated N-terminal constructs may also provide 
indications about the localisation of intra-molecular interactions within this half 
of GLUT 1.
Figure 7.1 shows a cartoon of the three-dimensional molecular 
modelling of the GLUT 1 molecule based on the two dimensional model, and 
considerations such as the lengths of the putative helix-connecting loops 
(Hodgson et al, 1992; Gould and Holman, 1993). This structure (also 
discussed in section 1.1.3.1) is a bilobular arrangement of two six- 
transmembrane-helix bundles, corresponding to the N- and C-terminal halves. 
This model was constructed before the commencement of the work described in 
this thesis.
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Figure 7.1 Cartoon representation of the proposed three-dimensional 
structural arrangement of GLUT1, showing the proposed bilobular structure of 
the two six-transmembrane domain spanning halves. The N-terminal half is 
shown in orange, and the C-terminal half in red.
The large central loop, and the very short nature of the remaining a- 
helix connecting loops may be indicative of a bilobular tertiary structure. The 
length and sequence of many of the connecting loops, especially at the 
cytoplasmic surface, are highly conserved, at seven to 15 residues, and are 
generally shorter at the cytoplasmic surface. This suggests a very close packing 
of the six helixes of each domain, rather than a single bundle of twelve helixes. 
The slightly shorter loops on the cytoplasmic surface suggest a closer 
association of the helixes at this side of the molecule. A structure of this 
nature has been observed in the twelve -membrane- spanning domain protein of
E.coli, lactose permease, by low resolution electron microscopy ( Li and Tooth, 
1987). A molecular model of the two domain packing of GLUT1 is illustrated 
in figure 1.2
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7.4 THE FUTURE OF GLUT 1 AND THE BACULOVIRUS
EXPRESSION SYSTEM.
The further elucidation of the packing arrangement of GLUT 1 with 
respect to its two halves has been discussed in section 7.3, and is likely to be 
the primary route to be followed with respect to the expression of GLUT 1 in 
insect cells using the baculovirus expression system.
Although the expression levels of the three GLUT 1 protein products 
were not as high as have been reported for many proteins expressed using the 
baculovirus system, the levels achieved were not low in comparison with other 
membrane associated glycoproteins. On consideration of this, and the 
relatively low virus titres achieved (in comparison to other reported 
recombinant baculoviruses), the expression levels achieved are good. With the 
use of a simple purification technique for the transporter, it may be possible to 
produce sufficient quantities of GLUT 1 expressed in baculovirus to allow 
further examination of the protein structure, such as crystallisation trials with a 
view to X-ray crystallography.
The insertion of a short section of DNA encoding five or six histidine 
residues, into the central loop region of GLUT 1 would not be expected to have 
an effect on either the structure or function of the molecule. The expression of 
a protein with a polyhistidine section allows a one-step purification method to 
be carried out. A metal ion affinity column, where (for example) nickel ions 
are immobilised on a solid support allows the purification of proteins bearing a 
polyhistidine motif. I f  the protein could be satisfactorily eluted from the 
column and purified to a non-denatured state, this could prove to be a suitable 
substrate for structural analysis. This work is currently in progress in Dr 
Holman's laboratory.
Since the C-terminal half of GLUT 1 expressed alone has been 
demonstrated to be correctly inserted into the membrane, and, in the presence
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of the N-terminal half, able to take up an appropriate conformation for the 
binding of ligands, this too may be a suitable substrate for three dimensional 
structure determination. The use of a specially created baculovirus transfer 
vector such as "pBlueBacHis" (Invitrogen, R &  D Systems Europe Ltd., 
Abingdon, 0X14 3YS) allows, by subcloning of the desired gene or fragment, 
the addition of a polyhistidine tail to the N-terminus of the expressed protein. 
This could be purified using a metal ion column, as described. Although there 
is some question about the conformational state of the structure of the C- 
terminal half in isolation, the purification and renaturation of this molecule may 
be more successful than the larger full-length GLUT 1 molecule.
For whatever particular purpose the baculovirus system expressed 
GLUT 1 protein and fragments may be used, this project has demonstrated the 
potential for this system for the expression of glucose transport protein. The 
demonstration that the C-terminal half, known to bear the ligand binding 
domains of the transporter, requires the N-terminal half in order to adopt the 
correct conformation for ligand binding, may only be the first step in a series of 
important findings about glucose transporter structure and function.
The construction of new GLUT 1 fragment-encoding baculoviruses may 
provide much more information about the structure-function relationship of the 
GLUT 1 glucose transporter; and the purification of large quantities of 
transporter protein may be possible, to enable three-dimensional structure 
determination of the molecule.
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APPENDIX I PST I DIGESTED LAMBDA DNA SIZING
Molecular size (bp) Approximate positioning
of bands on a 1% agarose 
gel.
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